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i. Abstract 
The use of mass spectrometry imaging (MSI) for the analysis of 3D tissue 
models of human skin has been shown to provide an elegant label-free 
methodology for the study of both drug absorption and drug biotransformation. 
The main aim of the work presented in this thesis was to develop methodology 
for quantitative assessment of percutaneous absorption using matrix assisted 
laser desorption ionisation mass spectrometry imaging (MALDI-MSI). 
Quantitative assessment of the absorption of an antifungal agent, terbinafine 
hydrochloride, into the epidermal region of a commercial full thickness living 
skin equivalent model (Labskin) was used as a model system. 
Different approaches to generate robust and sensitive quantitative mass 
spectrometry imaging (QMSI) data were developed and compared. The 
combination of microspotting of analytical and internal standards, matrix 
sublimation, and recently developed software for quantitative mass 
spectrometry imaging provided a high-resolution method for the determination 
of terbinafine hydrochloride in Labskin. A quantitative assessment of the effect 
of adding a penetration enhancer (dimethyl isosorbide (DMI)) to the delivery 
vehicle was also performed, and data was compared to LC–MS/MS 
measurements of isolated epidermal tissue extracts. Comparison of means and 
standard deviations indicated no significant difference between the values 
obtained by the two methods. 
In this thesis the localisation of hydrocortisone hydrochloride in ex-vivo skin was 
also investigated. Hydrocortisone exhibits a low ionisation efficiency that makes 
its detection challenging with mass spectrometry techniques. An in-solution and 
on-tissue chemical derivatisation reaction using the Girard reagent T, a 
hydrazine based reagent, significantly increased the sensitivity and detection of 
the respective hydrocortisone-derivative using MALDI-MSI. 
In an additional study, MALDI-MSI was used to assess the metabolic activity in 
Labskin by employing the approach of "substrate-based mass spectrometry 
imaging" (SBMSI). Preliminary MALDI-MSI data detected the activity of the 
carboxylesterase 1 enzyme in the epidermal layer of skin. The MALDI-MSI data 
was supported by preliminary LC-MS/MS analysis. To investigate the 
reproducibility of the results future investigations are required. 
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v. Abbreviations 
α-CHCA: alpha-cyano-4-hydroxycinnamic acid 
µg: microgram 
μL: microliter  
µm: micrometer  
2D: two dimensional  
3D: three dimensional  
3Rs: Replacement, Reduction and Refinement  
9-AA: 9-aminoacridine 
AC: acetyl-l-carnitine  
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ADE: acoustic droplet ejection  
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CEM: chain ejection model 
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CPE: chemical penetration enhancer  
CRM: charge reduction model  
CYP: cytochrome 
d: deuterated  
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DAN: diaminonaphthalene  
DC: direct current  
DESI: desorption electrospray ionisation  
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DMI: dimethyl isosorbide  
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ESI: electrospray ionisation  
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FT-ICR: fourier transform-ion cyclotron resonance 
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g: gram  
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HC: hydrocortisone  
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Chapter 1:Introduction  
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1.1 Mass spectrometry  
Mass spectrometry (MS) is an analytical technique capable of molecular 
analysis by ionisation of chemical species and subsequent sorting of the ions by 
their mass to charge ratio (m/z). The principal elements of a mass spectrometer 
instrument include the: 
 Ionisation source, where molecules within the sample are ionised.  
 Mass analyser, where ions are separated by their mass to charge ratio. 
 Detector, for the measurement of ion relative abundance, resulting then 
in a mass spectrum. 
 Data system, which includes computer and software, for the acquisition 
and processing of data derived from MS. 
Commercially available mass spectrometers offer different configurations of 
ionisation sources, mass analysers and detectors.  
A simple diagram of a mass spectrometer is illustrated below (Figure 1.1).  
 
Figure 1.1 Basic components of a mass spectrometer, including; a sample inlet, 
an ionisation source, a mass analyser, a detector and a data system (displaying 
the mass spectrum). 
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1.2 Ionisation source 
Multiple ionisation sources are associated with mass spectrometry and their 
different characteristics are mainly related to the exploitable mass range and 
the energies involved in the ionisation process. The ionisation sources used in 
the present study are electrospray ionisation (ESI) and matrix assisted laser 
desorption ionisation (MALDI); they are referred to as "soft" ionisation 
techniques as they cause little or no fragmentation.   
 
1.2.1 Electrospray ionisation (ESI) 
Electrospray ionisation (ESI) was  presented  in the late 1960's by Dole and co-
workers (Dole et al., 1968), and later combined with a quadrupole mass 
analyser by Yamashita and Fenn (Yamashita and Fenn, 1984).  
 
ESI is an atmospheric pressure ionisation technique produced by injecting an 
analyte solution through a capillary, to which a high voltage is applied, into a 
desolvation chamber. The voltage (~ 3-6 kV), which is applied between the 
capillary and the sampling cone, leads to the formation of a droplet containing 
an excess of charges (positive or negative) at the tip of the capillary. As a 
consequence of the strong electric field the shape of the droplet changes to a 
Taylor cone, from which an aerosol of highly charged droplets is released 
(Kebarle and Verkcerk, 2009; Hoffmann and Stroobant, 2007). 
 
In the desolvation chamber, the volume of the droplets reduces due to the 
evaporation of the solvent under the influence of a stream of drying gas/heat. 
The shrinking of droplet volume leads to an increase of the repulsive force 
between the charges at the surface until reaching the Rayleigh instability limit, 
the point at which the surface tension matches Coulombic repulsion. When the 
Rayleigh limit is exceeded, the droplet undergoes Coulombic explosion, 
releasing smaller droplets, which undergo further desolvation and coulombic 
explosion until the formation of gaseous phase analyte ions occurs (Figure 1.2). 
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Figure 1.2 Representation of an electrospray ionisation source. A Taylor cone 
is formed at the tip of the capillary, from which a spray of charged droplets is 
expelled due to an applied voltage. 
The advantage of this method is that it requires very little sample preparation 
and it is able to generate multiply charged ions. Because the analyser in mass 
spectrometry arrays the ions based on their mass to charge ratio, the ability of 
electrospray to produce multiply charged ions extends the mass range of 
analysis up to kDa-MDa orders of magnitude, which makes it possible to 
observe intact proteins and their associated polypeptide fragments (Ho et al., 
2003; Pitt, 2009). Molecules for ESI are already ionised in solution prior to them 
being transferred to the gas phase, therefore non-polar molecules are not very 
ionisable by ESI. 
 
Three main mechanisms have been proposed for the process that leads up to 
the emission of the ions from the charged droplets; these include: the ion 
evaporation model (IEM); the charge reduction model (CRM) and the chain 
ejection model (CEM). The IEM model was proposed by Iribarne and Thomas 
and it is more likely to occur during analysis of small molecular weight 
compounds (Iribarne and Thomson, 1976). This model suggests that pre-
formed solution ions are expelled from nanodroplets, which have reduced their 
volume by evaporation until the field strength at the surface of the droplet is 
large enough to assist the desorption of the ions into the gas phase (Nguyen 
and Fenn, 2007). The CRM model was proposed by Dole et al. and it is more 
likely to occur during analysis of large molecular weight compounds (Dole et al., 
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1968). The CRM model proposes that nanodroplets, containing a single analyte, 
fully evaporate and the residual charge is transferred to the analyte (Fernandez 
de la Mora, 2000). The latest mechanism is the CEM, which was firstly 
described by Ahadi et al. and it is more likely to occur during analysis of 
unfolded, disordered proteins (Ahadi and Konermann, 2012). This model 
suggests that an unfolded protein migrates to the surface of the droplet due to 
the exposure of hydrophobic residues and one chain terminus get partially 
ejected from the droplet into the gas phase. This is followed by further ejection 
of the rest of the protein, which will result in highly charged ions (Konermann et 
al., 2013; Metwally, Duez and Konermann, 2018). A schematic illustration of the 
main mechanisms responsible of ion formation by ESI is provided in Figure 1.3.
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Figure 1.3 Schematic representation of the three proposed mechanisms of ESI. In the IEM small ions are emitted from droplets which 
shrink until the field strength at the surface is large enough for ions to be expelled. In the CRM a droplet containing a single analyte 
evaporates with the residual charge being transferred to the analyte. In the CEM a disordered polymer is partially ejected from the droplet 
where protons attach to the exposed portion, followed by further extrusion and ultimate ejection of the rest of the protein.
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1.2.2 Matrix assisted laser desorption ionisation (MALDI) 
Matrix assisted laser desorption ionisation (MALDI) was developed in the late 
1980’s by Karas, Hillenkamp and co-workers (Karas, Bachmann and 
Hillenkamp, 1985).  MALDI generates intact gas-phase ions from non-volatile 
and thermally labile compounds. Initially, it was established as a widespread 
and powerful source for the detection of macromolecules and biomolecules, 
such as proteins and polysaccharides (Hoffmann and Stroobant, 2007). 
However, the application areas have quickly extended and, nowadays, this 
technique also finds a place into many laboratory’s workflow for the analysis of 
small molecules such as pharmaceuticals, lipids, metabolites and peptides 
(Amstalden van Hove, Smith and Heeren, 2010) . 
MALDI uses a laser to induce ionisation of an analyte, which is mixed with a 
matrix, typically a molecule with conjugated double bonds. The matrix is a key 
component of the method, since it acts by absorbing most of the laser energy 
and promoting analyte ionisation. Although either ultraviolet (UV) or infrared (IR) 
lasers can be used as light sources, the majority of MALDI sources contain UV 
lasers, which include nitrogen laser at a wavelength of 337 nm, and 
neodymium-doped yttrium aluminium garnet (Nd:YAG) laser at a wavelength of 
355 nm. 
In MALDI mass spectrometry profiling (MSP) experiments, an analyte is first co-
crystallised with the matrix, which is usually in high excess. The mixture 
(analyte embedded in the matrix) is dried and placed under vacuum conditions 
inside a MALDI source, where it is irradiated by intense laser pulses. 
Subsequently, high energy excitation of matrix molecules causes rapid heating 
and ablation of crystals which expand into the gas phase. Ionisation events 
could happen under vacuum at any time during this process (Hoffmann and 
Stroobant, 2007). 
A schematic overview of the MALDI technique is shown in Figure 1.4. 
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Figure 1.4 A schematic diagram of the matrix assisted laser desorption 
ionisation process. The laser fires at the crystals (analyte-matrix) causing the 
desorption and ionisation of the gas phase ions, which are then directed into a 
mass analyser. 
 
However, MALDI source can operate also at atmospheric pressure (AP-MALDI) 
(Laiko, Moyer and Cotter, 2000; Li et al., 2014). The principles behind the 
sample preparation and ionisation are the same for both vacuum and AP-
MALDI, however in the latter case, the ions are generated under normal 
atmospheric pressure conditions and their movement into a high vacuum 
analyser is pneumatically assisted by a stream of dry nitrogen (Laiko, Baldwin 
and Burlingame, 2000; Hoffmann and Stroobant, 2007). The main advantages 
of AP-MALDI over conventional vacuum MALDI are associated with the 
preservation of sample integrity, as well as the higher experimental practicality, 
indeed AP-MALDI can be easily combined with mass spectrometer equipped 
with atmospheric pressure interface (API) and interchanged with other AP 
sources (Hoffmann and Stroobant, 2007).  
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1.2.2.1 MALDI ionisation 
The mechanisms behind the ionisation process in MALDI are not entirely 
understood yet. However, it is commonly accepted that the ionisation process is 
separated into two steps: a primary ionisation process during or shortly after the 
laser pulse and a secondary ionisation process in the expanding plume of 
desorbed material (Knochenmuss, 2006). Generation of the first ions represents 
the most disputed part of the ionisation mechanism. Several processes have 
been proposed, and those considered the most probable are: the Lucky 
Survivor model (Jaskolla and Karas, 2011), the coupled photophysical and 
chemical dynamics (CPCD) model (Knochenmuss, 2013, 2016) and the thermal 
proton transfer model (Chu et al., 2014; Lu et al., 2015). 
The Lucky Survivor model proposes that analyte molecules are embedded into 
the matrix as charged species (Hillenkamp and Peter-Katalinić, 2007). After the 
ablation upon laser irradiation, clusters of different sizes, containing matrix, 
analytes and ionic species incorporated in the matrix crystals, are generated. 
An extensive neutralisation of most of the ions by their counter ions is thought to 
occur in the plume; only ions that escape the neutralisation can be detected, 
hence they are called "lucky survivors". This model offers an explanation of the 
presence of the predominantly singly charged ions observed in MALDI spectra, 
since they have the greatest chance of "surviving" (Karas, Glückmann and 
Schäfer, 2000; Karas and Krüger, 2003; Jaskolla and Karas, 2011). In the 
CPCD model, the photoexcitation of the matrix is principally involved in the 
ionisation process.  First, upon laser irradiation, excitation of matrix molecules 
takes place, which raise to the first electronically excited state (S1). This is 
followed by an energy pooling event defined as redistribution of the total energy 
of two neighbouring excited matrix molecules leading to a matrix molecule at a 
higher excited state (Sn), while the other molecule returns to the ground state 
(S0). A subsequent pooling event between one matrix molecule in a highly 
electronic excited state (Sn) with another in the first electronic excited state (S1) 
results in the formation of matrix ions. These ions will undergo a set of reactions 
to generate the final ions (secondary process) (Knochenmuss, 2013, 2016). A 
diagram of the steps that occur in the CPCD model is illustrated in Figure 1.5. 
 
42 
 
 
Figure 1.5 Schematisation of the two energy pooling events, which are the key 
of the coupled chemical and physical dynamics (CPCD) model: A) S1 + S1 
pooling to S0 and Sn. B) S1 + S0 pooling to S0 and ion. 
 
In the thermal proton transfer model it is important to estimate the ion-to-neutral 
ratio of matrix and analyte molecules for the MALDI mechanism. The laser 
energy absorbed by matrix molecules is converted in thermal energy leading to 
an increase in temperature. The creation of a polar fluid, then, causes a 
reduction of the ionisation energy of the matrix with consequent formation of 
free protons. These protons diffuse through the polar fluid and they are trapped 
by the analyte molecules, causing ionisation of the analyte molecules (Lu et al., 
2015). 
The ions formed during the primary ionisation will react with neutral molecules 
present in the expanding plume of desorbed material, causing the formation of 
the ions which will be detected by the mass spectrometer. The secondary 
ionisation mechanisms include: proton, cation or electron transfer 
(Knochenmuss and Zenobi, 2003). Proton transfer is the main secondary 
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reaction in MALDI and it takes place between protonated matrix and neutral 
analytes, as shown below: 
MH+ + A M + AH+ 
 
1.3 MALDI mass spectrometry imaging (MALDI-MSI) 
MALDI mass spectrometry imaging (MALDI-MSI) is a relatively new and 
powerful technique able to study intact biological samples providing ion 
distribution maps of many non-labelled endogenous and exogenous species 
simultaneously. This is a distinct advantage in comparison to conventional 
techniques, such as immunohistochemistry and radiolabelling. The absence of 
labels or chemical probes makes this technique a fast and relatively 
inexpensive technique, which can be used to perform de novo discoveries. 
MALDI-MSI was first illustrated by Spengler et al. (Spengler, Hubert and 
Kaufmann, 1994), while the first full publication was reported by Caprioli and 
coworkers in 1997 (Caprioli, Farmer and Gile, 1997). In this work, the authors 
described the development of the MALDI-MSI technique to localise peptides 
and proteins in biological tissue.  
Over the past two decades, MALDI-MSI has become established as a powerful 
method extensively employed in many applications (Anderson et al., 2010; 
Francese and Clench, 2010; Solon et al., 2010; Ryan, Spraggins and Caprioli, 
2019) and its use to study skin absorption was one of the first applications of 
MSI in pharmaceutical analysis to be reported (Bunch, Clench and Richards, 
2004).  
In a typical MALDI-MSI experiment, prior to analysis, an effective sample 
preparation step is required, which includes: tissue sampling; tissue sectioning 
and matrix application (Shimma and Sugiura, 2014). An overview of the 
workflow for the MALDI-MSI analysis of a tissue section is illustrated in Figure 
1.6. 
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Figure 1.6 Schematic overview of a MALDI MSI experiment. Figure adapted 
from (Schwamborn and Caprioli, 2010). 
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Matrix deposition technique represents a crucial step in the MSI workflow and 
can significantly impact MSI results in terms of analyte extraction and spatial 
localisation (Smith et al., 2017). Several matrix deposition devices, used to 
generate data in this thesis, will be described later.  
The MALDI-MS images presented in this thesis were acquired using the 
microprobe approach. In this mode, upon co-crystallisation of the matrix with the 
analytes, the laser is fired at the coated sample, at a series of programmed 
raster points in an array of two dimensional positions, creating a full mass 
spectrum at each x,y coordinate. Once the experiment has concluded, the 
results from individual mass spectra are reconstructed into an image revealing 
the localisation and the abundance of ions within the sample (Luxembourg et 
al., 2004). With the microprobe approach, the resolution of the image depends 
on the laser spot size as well as on the sample stage movement increment; and 
the throughput time increases significantly with increased resolution. An 
alternative mode is the microscope mode. In this approach, the laser fires the 
sample with a large beam (usually 200 µm) and the derived ions maintain their 
spatial coordinates throughout travel until they reach a position sensitive 
detector (Luxembourg et al., 2004). In microscope mode the spatial resolution is 
influenced by the quality of the ion optics and the resolving power of the 
detector (Luxembourg et al., 2004; Klerk et al., 2009). Figure 1.7 shows a 
representation of both microprobe and microscope modes for MALDI imaging 
experiments. 
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Figure 1.7 Representation of the two modes used for MALDI-MSI experiments: 
A) microprobe mode, where a high focus laser is rastered across distinct 
regions of the sample, and B) microscope mode, where the laser focus is wide 
and the location of ions is picked up using a position sensitive detector. Image 
from (Luxembourg et al., 2004). 
 
Although the microscope technique offers advantages in terms of high-spatial 
resolution (down to few μm) and high-speed of analysis (Luxembourg et al., 
2006; Lee et al., 2012), at present microprobe mode represents the dominant 
mode for obtaining MALDI-MSI data. This is due to several drawbacks of the 
microscope mode that hamper its implementation. These include: the risk of a 
partial sampling of the sample, if the latter is bigger than the entire area of the 
microscope field of view; the limited m/z range and sensitivity; and its 
compatibility with only analysers that enable ions to preserve the original spatial 
information (i.e. TOF) (Lee et al., 2012; Gessel, Norris and Caprioli, 2014). In 
light of these considerations, the employment of microscope mode is currently 
inappropriate for the image of complex biological sample and, hence, efforts to 
overcome the limitations are necessary.    
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1.3.1 Matrix deposition techniques  
1.3.1.1 Manual spotting  
Manual spotting is the easiest and most practical matrix application technique. 
This technique includes the deposition of microliter (µL) volumes of matrix using 
a hand-held pipette. The main disadvantage of this technique is the significant 
irregularity and inhomogeneity of matrix-analyte crystals, responsible, 
subsequently, for an intense spot-to-spot irreproducibility. The spot 
inhomogeneity also results in the analyte signal changing when the laser is fired 
in different points of an individual spot; the points in which higher analyte 
sensitivity is detected are known as "sweet spots" (Dai, Whittal and Li, 1996; 
Fujita and Fujino, 2013). 
Different approaches for the deposition of matrix using manual spotting have 
been investigated, such as dried droplet (Karas and Hillenkamp, 1988), 
crushed-crystals (Xiang, Beavis and Ens, 1994) and sandwich (Kussmann et 
al., 1997). The most commonly used method is the dried droplet method, which 
consists either of pre-mixing the analyte with the matrix or directly depositing 
the matrix onto the sample surface prior to introduction into the mass 
spectrometer for analysis (Figure 1.8). 
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Figure 1.8 The 'dried droplet' methods. The analyte can be pre-mixed with the 
matrix (A) or the matrix can be applied onto the analyte surface (B). 
 
Considering the poor reproducibility in sample preparation, manual spotting is   
not used for MALDI-MSI experiments, but it finds application in MALDI-MSP in 
order to assess the best matrix and polarity to use for a specific analysis.  
 
1.3.1.2 Acoustic droplet ejection 
Acoustic droplet ejection (ADE) is a technology able to deposit submicroliter 
volumes (170 picoliter per droplet) of matrix solution onto a sample. In ADE, 
radio frequency power is converted to ultrasonic energy through a piezoelectric 
transducer; the ultrasonic energy is spread though the reagent reservoir 
causing the ejection of small droplets from the fluid surface (Pickett et al., 2006)  
A schematic illustration of the ADE mechanism is illustrated in Figure 1.9. 
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Figure 1.9 Schematic representation of an acoustic droplet ejector, consisting 
of a reagent reservoir and acoustic ejector.  
 
The main advantages of this method are the reproducibility of droplet sizes, the 
high extraction capabilities and no risk of clogging due to the absence of 
nozzles (Aerni, Cornett and Caprioli, 2006). The main disadvantages are 
represented by the fixed distance between the droplets (200 μm), which limits 
the spatial resolution in MALDI-MSI experiments (Kaletaş et al., 2009). This 
represents a limiting factor when the acoustic ejector is used as a matrix 
deposition device, in fact, although several spotting patterns could be overlaid 
to minimise the distance between the droplets, the entire coverage of a given 
area is difficult to achieve. 
A commercial acoustic spotter, the Portrait® 630 (Labcyte Inc. California, USA), 
has been employed in this thesis for the work reported in Chapter 3 and 
Chapter 4. 
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1.3.1.3 Sprayers 
Spraying technology allows the deposition of the matrix onto the sample in the 
form of small aerosol droplets. This technique offers the advantage of obtaining 
a uniform matrix coating and it can be accomplished in two ways: manual 
(pneumatic spray) or automatic. An example of a manual pressurised airbrush 
is shown below in Figure 1.10. 
 
 
Figure 1.10 The Iwata Eclipse manual sprayer (www.iwata-airbrush.com). 
 
With manual spraying the reproducibility of experiments is not guaranteed due 
to the difficulty of controlling variables, such as the distance between the 
sprayer and the sample, the speed of the spraying and the amount of matrix 
deposited. These issues can be overcome by using an automatic sprayer which 
permits parameters to be kept constant in multiple experiments with the aid of 
software. 
In the work presented in this thesis, the Sunchrom Suncollect automated 
sprayer has been used (KR Analytical, Sandbach, UK) (Figure 1.11). This 
instrument is equipped with a syringe driver, for controlled matrix delivery, and a 
compressed nitrogen gas line surrounding the needle, enabling ejection of the 
matrix solution as a fine mist. The matrix can be applied at a specific flow rate 
and pressure within a predefined area. Unlike the spotting technique, spraying 
has the advantage of covering the entire sample with matrix, unless clogging 
occurs.  
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Figure 1.11 The SunCollect automated sprayer (www.sunchrom.de). 
 
 
1.3.1.4 Sublimation  
Sublimation is the transition of a solid directly into a gaseous phase. Among the 
matrix application techniques investigated, sublimation is the most recently 
applied to MALDI-MSI.  A detailed description of this technique was illustrated in 
the work by Hankin et al., which reported for the first time the sublimation of 
matrix onto brain tissue sections for the detection of lipids using MALDI-MSI 
(Hankin, Barkley and Murphy, 2007). 
A typical sublimation apparatus is shown in Figure 1.12. This device consists of 
a bottom and top section (condenser part). The matrix is inserted in the bottom 
section, whereas the slide with the sample is fixed on the underside of the top 
section; the two parts are then assembled and tightly sealed. At this point, 
under reduced pressure and heat, the matrix starts to sublime and it is 
deposited onto the sample surface since the condenser is filled with cold water 
(<15° C). 
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Figure 1.12 Representation of the sublimation process. 
 
In Chapter 2 the main advantages of this technique over the spraying technique 
are discussed and sublimation has been chosen as method of choice for the 
deposition of the matrix in the work reported in this thesis. In this regard, a 
commercially available sublimation apparatus available from Sigma-Aldrich, 
(Gillingham, U.K.) has been used. 
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1.4 Mass analysers 
The mass analyser is the component of a mass spectrometer responsible for 
separating ions based on their mass to charge ratio (m/z). Currently, there are 
several mass analysers commercially available that differentiate for the upper 
mass limit and the resolution.  
Common commercially available mass analysers include: time of flight (TOF), 
quadrupole (Q), linear ion trap (LIT), quadrupole ion trap (QIT), fourier 
transform-ion cyclotron resonance (FT-ICR) and Orbitrap. 
 
1.4.1 Time of flight (TOF) 
The concept of a time of flight (TOF) mass analyser was initially introduced by 
W.E. Stephens (Wolff and Stephens, 1953). The TOF analyser operates by 
separating ions according to their velocity when they drift in a free-field region, 
called a flight tube (Hoffmann and Stroobant, 2007). Firstly, ions generated in 
the source are subjected to an applied voltage, responsible for giving the same 
kinetic energy to all ions, which are then accelerated into the TOF tube. The 
velocity and therefore the time that ions take to travel the tube is a function of 
their m/z. The m/z of ions can be determined by measuring the time necessary 
for ions to go through the length of the tube to the detector as reported in 
Equation 1.1; ions with lower m/z will be faster to reach the detector than those 
with higher m/z.  
Equation 1.1 
𝒕𝟐 =
𝒎
𝒛
 (
𝑳𝟐
𝟐𝒆𝑽𝒔
) 
Where t is the time required to cover the distance L before reaching the 
detector; m = mass of ions; z = number of charges; e = charge of an electron; 
Vs = acceleration potential. 
A representation of a linear TOF is illustrated in Figure 1.13. 
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Figure 1.13 Representation of a linear time of flight mass spectrometer. 
 
One of the major limitations of linear TOF instruments is the low mass 
resolution. This aspect is essentially due to the spatial and kinetic energy 
spread amongst the ion packets generated by the laser-based ion sources.  
One approach to increase the resolution is by using a reflectron, or ion mirror 
(Figure 1.14). The reflectron was proposed by Mamyrin and coworkers in 1973 
(Mamyrin et al., 1973) and it consists of a cylinder made up of a series of ring 
electrodes and grids that are subjected to a gradient voltage. When the ions 
enter the electrical field, they are deflected back along the flight tube; the ions 
with higher energy will penetrate further into the reflectron field than those with 
lower energy, which penetrate the field less. In this way, the spread of kinetic 
energy of ions with the same m/z is corrected and ions will arrive at the detector 
at the same time (Hoffmann and Stroobant, 2007). 
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Figure 1.14 Representation of a reflectron time of flight mass spectrometer. 
 
TOF is a pulsed ion analyser, and, hence, its coupling with continuous 
ionisation sources (i.e. ESI) is arduous. A way to overcome this issue is by 
generation of ion packets from the continuous ion stream. The strategy used is 
by setting the TOF analyser orthogonally to the axial path of ions derived from 
the source. Ions are transmitted in a 'pusher' region where ion packets are 
excised and are accelerated into the orthogonal TOF by a pulsed voltage. The 
insertion of an orthogonal reflectron TOF analyser after a horizontal path of ion 
beam confers a V-geometry of the ion trajectory (Hoffmann and Stroobant, 
2007; Greaves and Roboz, 2013) (Figure 1.15). 
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Figure 1.15 Representation of an orthogonal reflectron time of flight analyser. 
Ions derived from the source are accelerated into the orthogonal TOF by a 
pulsed voltage, travelling in a V-shaped trajectory. 
 
By increasing the length of the analyser path it is possible to increase the mass 
resolution. In this regard, an additional reflectron TOF can be introduced in the 
analyser, describing a W-geometry for the ions trajectory (Figure 1.16). It is 
important to consider that, although the increment of flight path allows a high-
resolution, it also increases the chance of ion loss, at the cost of the sensitivity 
(Fliegel et al., 2006; Greaves and Roboz, 2013; Chernushevich et al., 2017) 
(Figure 1.16). 
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Figure 1.16 Comparison of an orthogonal reflectron time of flight analyser with 
V-geometry and W-geometry. In the W-geometry two TOF analysers are 
combined, this allows the ions to travel within a longer flight path and hence, 
increases the mass resolution.  
 
1.4.2 Quadrupole  
A quadrupole mass analyser consists of four parallel metal rods arranged in 
opposite pairs, to which direct current (DC) and alternating radio frequency (RF) 
voltages are applied. In particular, one pair of rods has an applied potential of 
(U+Vcos(ωt)) and the other pair a potential of -(U+Vcos(ωt)). The separation of 
the ions in accordance with their mass to charge ratio (m/z) is based on their 
stability within the oscillating electric field applied to the rods: ions with stable 
trajectory (bounded oscillation) will be able to pass through the rods and reach 
the detector, whereas ions with an unstable trajectory (unbounded oscillation) 
will strike the rods, neutralising them (Figure 1.17). The quadrupole, as an 
analyser, can operate in two modes, in "full scan" or in "selected ion 
monitoring". In the first case, by changing RF and DC voltages, while 
maintaining the ratio of these two voltages constant, the analyser performs a 
sequential scan of ions with different mass to charge ratios. In the second case, 
the quadrupole is fixed at a specific voltage in order to allow only ions with a 
specific m/z to reach the detector. The quadrupole is used in this mode for 
58 
 
tandem mass spectrometry (MS/MS) experiments, allowing selection of a 
specific ion of interest prior to fragmentation. 
 
 
Figure 1.17 Representation of a quadrupole mass analyser; the red ions with 
stable trajectory (bounded oscillation) are able to pass through the quadrupole 
whilst the blue ions with unstable trajectory (unbounded oscillation) collide with 
the metal rods. 
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1.5 Multi-analyser systems 
1.5.1 Tandem MS/MS Instruments  
1.5.1.1 TOF/TOF 
Tandem time-of-flight (TOF/TOF) is a tandem mass spectrometry method that 
uses two TOF analysers in sequence. In the currently available instruments, the 
more common configuration is the combination of a linear TOF as a first 
analyser with a reflectron TOF, as a second analyser (Medzihradszky et al., 
2000; Cotter et al., 2005). An electronic gate, called a timed ion selector (TIS) 
allows an ion of interest, separated from the first TOF, to pass through and 
enter a collision chamber, where the parent ion will undergo dissociation by 
induced collision with an unreactive gas (nitrogen or argon) (Figure 1.18). 
 
 
Figure 1.18 A schematic diagram of a tandem time of flight mass analyser; the 
precursor ions selected by the TIS enter into the collision cell, where they 
undergo collisionally induced dissociation. Once generated, the product ions are 
extracted and reaccelerated into the second TOF (Cotter et al., 2005). 
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In this thesis, the tandem TOF instrument used is the Autoflex III manufactured 
by Bruker Daltonics (Germany), which employs LIFT technology.  
In the LIFT configuration, to perform MS/MS experiments ions generated in the 
source are accelerated to 8 keV and enter the collision chamber. The precursor 
ion and its product ions, together indicated as an "ion family", have the same 
velocity and reach the TIS gate at the same time. The TIS gate enables only the 
"ion family" of interest to pass through and enter the LIFT cell, a free field region 
whose the potential is raised by 19 keV while the ions are in residence, adding 
acceleration energy when they are extracted into the second TOF (Cotter et al., 
2005).  
A schematic representation of a LIFT-TOF/TOF mass spectrometer is illustrated 
in Figure 1.19.  
 
Figure 1.19 A schematic diagram of a tandem time of flight mass analyser 
using LIFT technology; the precursor with the product ions are selected by the 
TIS gate and enter the LIFT cell, from where they are extracted and 
reaccelerated into the second TOF (Cotter et al., 2005).  
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1.5.2 Hybrid mass spectrometers  
1.5.2.1 Quadrupole Time-of-Flight (QTOF) 
Mass spectrometers that combine different mass analysers are commonly 
termed “hybrid” mass spectrometers. Quadrupole time of flight (QTOF or 
QqTOF) instruments are robust and versatile configurations usually combined 
with ESI and MALDI sources. In the common QTOF instruments, an additional 
quadrupole Q0, operated in RF-only mode, is inserted, therefore the instrument 
consists of three quadrupoles Q0, Q1 and Q2 combined with an orthogonal TOF 
mass analyser (Chernushevich, Loboda and Thomson, 2001). The first 
quadrupole Q0 acts as ion guide rather than a mass analyser, enabling the 
transmission of all ions within a specific mass range (Greaves and Roboz, 
2013). 
To obtain full-scan MS data, the three quadrupoles are operated in RF-only 
mode (i.e. as transmission devices) and all ions are transferred into the TOF 
analyser for detection. When using a QTOF for obtaining MS/MS data, the first 
quadrupole Q0 functions as transmission device, the second Q1 as a mass filter 
to select a specific ion of interest, the third Q2 acts as a collision cell, into which 
a collision gas (argon or nitrogen) is introduced (Figure 1.20). The product ions 
then travel into the TOF analyser and are detected (Oberacher and Pitterl, 
2009).  
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Figure 1.20 Representation of a hybrid quadrupole time of flight mass analyser. 
 
In the commercial instrument Synapt G2 HDMS (Waters Corp., UK) (used in 
this thesis) the first quadrupole, used for transmission, is replaced by a 
hexapole and the analytical capabilities of the instrument are increased by 
introducing a 'triwave' region into the QTOF system (Figure 1.21).  
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Figure 1.21 Synapt G2 HDMS mass spectrometer adapted with a MALDI source (Waters Corporation, Manchester, UK). 
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The triwave consists of a travelling wave ion mobility separator (TWIMS), 
preceded and followed by the trap and transfer travelling wave ion guides 
(TWIG's), respectively. IMS is a powerful technique, which enables the 
separation of ions based on their size/charge ratios, as well as their shape 
(cross-sectional area), as they move through an inert gas due to the influence of 
an electric field (Kanu et al., 2008). 
The drift tube of a TWIMS cell is made up of a series of stacked ring ion guides 
(SRIG), organised so that opposite RF voltages are applied on adjacent rings, 
forming a confining barrier surrounding the ions. The superimposition of a DC 
voltage on the RF of adjacent electrodes in a repeating pattern generated a 
series of potential hills (travelling waves). These enable ions to propel over the 
top of the travelling waves as they traverse the cell in the presence of the carrier 
gas buffer (Giles et al., 2004; Pringle et al., 2007). Ions with lower mobility will 
interact more with gas particles and will roll over the wave more times than 
higher mobility ions (Figure 1.22).  
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Figure 1.22 A) Representation of the IMS cell of the Synapt G2 HDMS 
instrument, showing a series of stacked ring ion guides (SRIG) carrying 
opposite RF voltages on adjacent rings to form a confining barrier surrounding 
the ions. B) Representation of the propulsion of ions over the top of the 
travelling wave pulse in the presence of the carrier gas buffer. 
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1.6 Skin structure 
The skin is the largest organ of the human body and represents a natural barrier 
to the environment. It restricts the inward and outward movement of 
substances, i.e. water and electrolytes, and at the same time, ensures 
protection against toxic agents, microorganisms, mechanical insults and 
ultraviolet radiation (Bensouilah and Buck, 2006). 
The skin is commonly subdivided in two structural layers: the epidermis and the 
dermis. The dermis is attached underneath to the hypodermis or subcutaneous 
layer, containing adipose and areolar connective tissue (Tortora and Nielsen, 
2011) (Figure 1.23). 
 
 
Figure 1.23 Structure of skin. Image adapted from (Tortora and Nielsen, 2011).  
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95% of the epidermis is comprised of keratinocyte cells (Xu, Timares and 
Elmets, 2013). Keratinocytes are derived from basal cells, which go through a 
constant process of differentiation and migrate through several suprabasal 
layers (the spinous layer, granular layer, lucidum layer and corneum layer) 
losing their nucleus and becoming more and more compacted in size before 
being finally shed from the surface by the process of desquamation (Sandilands 
et al., 2009).  
The stratum basale consists in a single layer of cuboidal-shaped keratinocyte 
cells, anchored to the basement membrane by epithelia multiprotein complexes, 
called hemidesmosomes-junctions. This layer is also called the germinativum 
layer for the presence of stem cells that undergo mitosis and generate new 
keratinocytes (Borradori and Sonnenberg, 1999). Melanocytes, Langerhans 
cells and Merkel cells can also be present (Parsons, 2002; Tortora and Nielsen, 
2011). 
The spinous layer, also called the prickle-cell layer, is made up of 8-10 layers of 
keratinocytes, which join together through desmosomes. Among the 
keratinocytes, in this layer Langerhans cells and melanocytes may also be 
found (Parsons, 2002; Tortora and Nielsen, 2011). 
In the higher layer, the granular layer, the keratinocytes assume a more 
flattened shape. Here, it is possible to find from three to five layers of 
keratinocyte cells that start to undergo apoptosis. The cells contain granules of 
keratohyalin protein; responsible for binding keratin intermediate filaments into 
keratin (Tortora and Nielsen, 2011; Nafisi and Maibach, 2018). 
The lucidum layer contains about five layers of translucent, flat and dead cells 
that accumulate eleidin, a protein derived from keratohyalin. This layer is 
commonly present in the skin of the palm, soles and fingertips (Tortora and 
Nielsen, 2011; Yousef and Sharma, 2017) 
The stratum corneum, the outermost layer of the epidermis, represents an 
essential mechanical barrier responsible for limiting the penetration of external 
substances as well as limiting water loss. It is made up of 25 to 30 layers of flat 
corneocytes, the finally differentiated keratinocytes, comprised mostly of keratin. 
The corneocytes fix one to another through adhesive intercellular structure 
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called corneodesmosomes, degradation of which seems to be directly 
correlated to the desquamation process (Ishida-Yamamoto and Igawa, 2015) 
(Figure 1.24). 
 
 
Figure 1.24 Representation of the structure of the epidermis. Starting from the 
basal layer, the keratinocytes migrate into layers: spinous, granular, lucidum 
and corneum. Image adapted from (Tortora and Nielsen, 2011). 
 
The dermis is composed mainly of connective tissue, blood vessels, hair shafts, 
sweat glands and nerves; it supports and feeds the epidermis. The main cells 
present in the dermis are fibroblasts, macrophages and adipocytes. The dermis 
is divided into two areas: a papillary layer and a reticular layer (Freinkel and 
Woodley, 2001).  
The papillary layer is the uppermost layer of the dermis, consisting mainly of 
loose connective tissue. From here small extensions of the dermis, called 
"dermal papillae", protrude inside the epidermis, increasing the surface area 
between epidermis and dermis (Hardy, 1992). The dermal papillae nourish the 
avascular epidermis through the capillaries and are directly associated with hair 
follicles growing. Furthermore, the papillary layer can also include free nerve 
endings and touch receptors, called Meissner corpuscles (Tortora and Nielsen, 
2011; Stocum, 2012; Borojevic, 2013). In contrast to the papillary layer, the 
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reticular dermis, the bottom layer of the dermis, is constituted primarily by dense 
irregular connective tissue. It provides elasticity and overall strength to the skin. 
Furthermore, this layer contains also hair follicles, sebaceous as well as sweat 
glands (Tortora and Nielsen, 2011). 
 
1.7 Barrier properties in the skin 
The stratum corneum (SC) represents the principal skin barrier and this function 
is essentially due to the lipid composition and organisation within it (Grubauer et 
al., 1989; Bouwstra et al., 1999; Wertz, 2018). In the SC each corneocyte is 
surrounded by an envelope of cross-linked proteins with which a layer of lipids 
(lipid envelope) are covalently bound, forming the cornified envelope structure 
(Abraham and Downing, 1990; Nemes and Steinert, 1999; Candi, Schmidt and 
Melino, 2005). Between corneocytes, instead, a matrix of lipids arranged into a 
multi-lamellae structure is present. This represents around 20% of the SC 
volume and includes mainly ceramides, cholesterol, cholesterol esters, fatty 
acids, and a small fraction of cholesterol sulphate (Madison et al., 1987; 
Bouwstra et al., 2003). In a few regions of the stratum corneum, the intercellular 
lipid matrix is absent and the interaction of lipid envelopes of adjacent 
corneocytes can occur, increasing the cohesion of the stratum corneum (Wertz 
et al., 1989).  
Michaels and colleagues first proposed the "brick and mortar" model to describe 
the structure of the SC (Michaels, Chandrasekaran and Shaw, 1975). With this 
model, the skin barrier is defined as a two compartment system; corneocytes as 
the bricks and the tightly packed intercellular lipids as the mortar (Nemes and 
Steinert, 1999; Norlén, 2001). A schematic representation of the "bricks and 
mortar" model is offered in Figure 1.25. 
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Figure 1.25 Schematic representation of the "bricks and mortar" model for the 
stratum corneum. 
 
1.8 Percutaneous absorption  
The stratum corneum represents the principal obstacle for the percutaneous 
absorption of therapeutic agents, wherever designed for topical or transdermal 
delivery (Schaefer et al., 1980). With topical drug delivery it is intended that a 
pharmaceutical agent is applied directly onto the skin surface for a localised 
action; whereas with transdermal drug delivery it is intended that a 
pharmaceutical agent enters into the circulation in order to execute its action; 
hence transdermal formulation must be able to pass through all the layers of the 
epidermis and dermis (Osborne, 2008; Murthy and Shivakumar, 2010). 
Percutaneous delivery represents a valid alternative to conventional oral and 
parenteral delivery; it in fact offers the advantage of bypassing the hepatic "first 
pass effect", controlling drug delivery over a longer period of time, acting directly 
on target (e.i. in case of skin pathologies), and increasing patient compliance 
(Kanikkannan et al., 2000; Brown et al., 2006; Pathan and Setty, 2009).  
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It has been established that there is a direct correlation between stratum 
corneum reservoir function (its ability to accumulate topically applied molecules) 
and percutaneous absorption (Rougier et al., 1983; Teichmann et al., 2005). 
The absorption through the stratum corneum is a passive diffusion process, 
which occurs in three possible ways (Haque and Talukder, 2018): 
 intercellular diffusion through the lipid matrix; 
 intracellular diffusion through both the corneocytes and the lipid matrix; 
 transappendageal diffusion along the sweat pores and follicles.  
A schematic representation of the main permeation routes across the stratum 
corneum is shown in Figure 1.26. 
 
 
Figure 1.26 Representation of the pathways responsible for the penetration of 
substances through the stratum corneum. Figure taken from (Haque and 
Talukder, 2018). 
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The passive diffusion of a drug through the stratum corneum can be described 
by  Fick's first law of diffusion, as shown below (Lane, 2013; Ita, 2015) . 
Equation 1.2 
𝐽𝑠𝑠 =
𝐴𝐷𝐾𝐶𝑣
ℎ
 
where: Jss is the steady-state flux of the drug, A is the surface area, D is the 
diffusion coefficient of the drug in the membrane, K is the vehicle/membrane 
coefficient of partition, Cv is the drug concentration in the vehicle and h is the 
membrane thickness. 
From this equation it is evident that the flux is directly proportional to the 
gradient of concentration and inversely proportional to the thickness of the 
stratum corneum. However, it does not consider other factors (biological, 
biopharmaceutical and physio-chemical) that could influence the percutaneous 
absorption too, as summarised in Table 1.1 (Leite-Silva et al., 2012). 
 
 
Table 1.1 Factors that influence the percutaneous absorption. 
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1.8.1 Chemical penetration enhancers (CPEs)  
A method commonly employed for enhancing permeation of drugs is based on 
the inclusion of additives within the formulation. These additives called chemical 
penetration enhancers (CPEs) increase drug flux by provoking reversible 
alterations to the skin constituents (Walker and Smith, 1996; Sindhu et al., 
2017). 
CPEs should satisfy the following properties, (although accomplishing all is 
unlikely) (Williams and Barry, 2012; Sindhu et al., 2017): 
 chemical stability and absence of toxicity; 
 pharmacological inactivity; 
 compatibility with the drug and excipients; 
 absence of irritant and allergenic activity; 
 absence of odour and colour; 
 cost-effectiveness; 
 rapidity in onset and action. 
 
The CPEs can mainly act in three different ways: i) by disrupting SC intercellular 
lipids ii) by improving the partitioning of drug in the membrane or iii) by 
interacting with SC proteins  (Williams and Barry, 2012; Sindhu et al., 2017).  
These mechanisms were first summarised in the lipid-protein-partitioning 
theory, proposed by Barry et al. (Barry, 1991). 
 
1.8.1.1 Disruption of stratum corneum lipids 
As described in Chapter 1.7, in the SC lipids surround the corneocytes in a high 
organised multi-lamellae structure. CPEs can interact either with the head 
groups or the hydrophobic tails of the lipids (Marjukka Suhonen, A. Bouwstra 
and Urtti, 1999). In the first case, CPEs can break hydrogen-bonding between 
ceramide head groups and become new H bond acceptor or donator (Jain, 
Thomas and Panchagnula, 2002; Dragicevic and Maibach, 2015). Amphiphilic 
compounds, instead, are able to enter between the hydrophobic tails of the 
bilayer, disrupting the structure and favouring the lateral fluidisation of lipids 
(Vavrova and Hrabalek, 2005). Some CPEs can act by inducing phase 
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separation in the lamellae (i.e oleic acid) (Ongpipattanakul et al., 1991) or via 
lipid extraction (i.e dimethylsulfoxide, ethanol) (Bommannan, Potts and Guy, 
1990; Anigbogu et al., 1995; Dragicevic and Maibach, 2015). In all cases, a 
perturbation of the original multi-lamellae order is observed, with a decrease of 
microviscosity and an increase in diffusion of substances as a consequence 
(Hadgraft, 1999). 
 
1.8.1.2 Increase of the partitioning of drug  
The partitioning of the drug between the SC and the vehicle represents a key 
role for percutaneous absorption and it is expressed by the coefficient of 
partition (K) (Rougier et al., 1990). For lipophilic substances with log K > 3, the 
preferential absorption pathway is the intercellular route, whereas for hydrophilic 
penetrants with log K < 1, the intracellular route represents the prominent route 
(N’Da, 2014; Marwah et al., 2016) Some CPEs are able to penetrate into the 
SC and modify its chemical properties and, hence, its solvent nature. This 
causes as a result an increase of solubility and partitioning of drug into the SC 
(Dragicevic and Maibach, 2015). 
 
1.8.1.3 Interaction with stratum corneum proteins 
The dense crosslinking of SC proteins is responsible of the insolubility of 
corneocytes, and, hence, limits drug absorption through the intracellular route 
(Marjukka Suhonen, A. Bouwstra and Urtti, 1999). The CPEs increase drug 
permeation by denaturing or modifying SC proteins conformation causing 
swelling and increase of hydration (Williams and Barry, 2012). An example of 
CPEs belonged to this category are sulfoxide enhancers, that have been shown 
to denature keratin from alpha helical to beta sheet (Oertel, 1977). 
A common classification of the CPEs is based on their chemical structure, as 
shown in Table 1.2 (Lane, 2013; Dragicevic and Maibach, 2015). 
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Table 1.2 Main classification of chemical penetration enhancers 
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1.9 Methods for evaluating percutaneous absorption 
and drug quantitation in skin 
The evaluation of quantitation of skin penetration/permeation is of essential 
importance for the analysis of dermatoxicity and pharmacological activity of 
topically applied drugs. This analysis can be carried out either in-vivo or in-vitro. 
However, considering the issues relating to costs and ethics, in-vivo studies are 
limited and, hence, in-vitro techniques are usually more popular. 
A comprehensive analysis of the many techniques used for the analysis of 
drugs in the skin was performed by Moser et al. (Moser et al., 2001) and Ruela 
et al. (Ruela et al., 2016). Three approaches - tape-stripping, diffusion cell and 
autoradiography - are described below. 
 
1.9.1 Tape stripping  
Tape stripping represents the traditional method for the analysis of drug 
concentration throughout the SC (Escobar-Chávez et al., 2008). This technique 
consists on removing the cells from the SC by applying serial adhesive tapes to 
the skin surface; from each tape the drug levels and stratum corneum thickness 
are calculated (Moser et al., 2001) (Figure 1.27). 
 
 
Figure 1.27 Representation of tape stripping method. After applying formulation 
at the skin surface of the donor (A), the cells from the stratum corneum are 
progressively removed by adhesive tapes (B). Image adapted from (Moser et 
al., 2001). 
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This technique is easy to perform, relatively non-invasive and does not require 
labelled compounds and, hence, it can be performed both in-vivo and in-vitro. 
However, it also presents several drawbacks; the amount of the SC removed is 
not constant on each strip, and decreases as more tapes are used, probably 
due to a more effective cohesiveness of the SC in the deeper layers (Alikhan 
and Maibach, 2010). In this regard, the measurement of the SC harvested from 
each tape strip must be identified e.g. by calculating the weight of the pieces of 
tape before and after stripping (Bommannan, Potts and Guy, 1990). In addition, 
the difficulty of removing completely the stratum corneum must be also 
considered. As reported by van der Molen et al. the presence of furrows in the 
skin can prevent complete cell removal (van der Molen et al., 1997). As a 
consequence of these issues, a high experimental error from tape stripping can 
be expected.  
 
1.9.2 Diffusion cell method 
A classic diffusion cell experiment is composed of two compartments, a donor 
and a receptor, separated by a mounted sample (i.e. skin), as illustrated in 
Figure 1.28. 
 
Figure 1.28 Schematic representation of a diffusion cell, containing a donor and 
a receptor compartment separated by the skin sample. Image taken from 
(Moser et al., 2001) 
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In the donor compartment the drug formulation is inserted and, then, by 
measuring periodically the drug concentration in the receptor compartment it is 
possible to evaluate the permeation rate of the drug through the skin barrier 
(Touitou, Meidan and Horwitz, 1998). Usually the analysis of drug within the 
receptor fluid is performed using high performance liquid chromatography 
(HPLC). In addition, excess analyte on top of the skin as well within the skin 
layers can be examined for further evaluations, such as total disposition and 
percentage recovery.  
 
1.9.3 Autoradiography 
Autoradiography is a photographic technique able to visualise radiolabelled 
compounds across the stratum corneum, at both the cellular and sub-cellular 
level (Caro and van Tubergen, 1962). Its application for transdermal research 
was first reported by Touitou and co-workers (Fabin and Touitou, 1991; Touitou, 
Alkabes, et al., 1994; Touitou, Levi-Schaffer, et al., 1994). In the work of Fabin 
and Touiton quantitative evaluation of drug localised in various levels of skin, 
using autoradiography was obtained with the aid of imaging software (Fabin and 
Touitou, 1991). 
Autoradiography can also be performed on the whole body, enabling the 
evaluation of dermal absorption and the involvement of other tissues in the body 
(Wester and Maibach, 2001; Griem-Krey et al., 2019). 
 
1.10 Models for analysis  
Over the years animal samples have been often used as a replacement for 
human subjects in order to generate representative information, important for 
the progress of pharmaceutical, toxicological and cosmetic skin research. 
However, studies carried out by Netzlaff et al. and Bronaugh et al. provide 
evidence that the choice of the animal is key in such studies and that the most 
appropriate animal will depend on the compound under investigation. They 
showed that differences in the skin structure of different animals, such as 
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thickness of the SC, composition of intercellular SC lipids, and density of hair 
follicles could give rise to changes in the absorption kinetics for different 
compounds. It is therefore impossible to find a perfect animal model but, most 
often, porcine skin has been selected as the model of choice (Bronaugh, 
Stewart and Congdon, 1982; Netzlaff et al., 2006; Lademann et al., 2010). The 
understanding of whether animal models can actually predict the human in-vivo 
response represents a contentious issue and difficulties in translating results 
derived from animal models to clinical studies have recently been highlighted by 
leading pharmaceutical companies (Shanks et al., 2009; Mead et al., 2016). 
The intrinsic differences between human and other species as well as the 
common failure to reproduce all of the clinical and histopathological features of 
individual subtypes can give rise to misleading results (Conn, 2013). In addition, 
under the 7th Amendement to the EU Cosmetics Directive, the use of animals to 
test cosmetic ingredients has been banned (EU 2003), therefore the cosmetics 
industry has been forced to consider alternatives.  
 
1.11 3D skin models 
The NC3Rs (National Centre for the Replacement, Reduction and Refinement 
of Animals in Scientific Research) is an UK national organisation that strives to 
find alternative models as efficient methods for non-animal testing and 
research. The principles behind the 3Rs were first described by Russell and 
Burch in 1959; these include: Replacement, the use of insentient material as an 
alternative to conscious living animals; Reduction, the use of fewer animals that 
experience distress; Refinement, the use of methods to reduce or eliminate 
animal distress (Tannenbaum and Bennett, 2015). In light of these principles, a 
variety of in-vitro three dimensional (3D) reconstructed skin models have been 
developed (Nakamura et al., 2018). 
The possibility of isolating the epidermis from the dermis in human skin and 
culturing keratinocytes in-vitro represents the starting point behind the 
development of 3D skin models (Medawar, 1941; Rheinwald and Green, 1977). 
For the development of these models, following isolation of the epidermis, 
keratinocytes are cultured at an air liquid interface, either on an acellular 
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support or on a cellular support (dermal component consisting of fibroblasts in a 
3D scaffold) (Niehues et al., 2018). The scaffolds most commonly used are 
collagen and fibrin. The scaffold plays an important role since it recapitulates 
the in-vivo dermal extracellular matrix and allows cells to communicate with 
each other and form a differentiated epidermis; this process occurs after about 
two weeks, resembling the structure of the in-vivo skin epidermis (Macneil, 
2007; Rademacher et al., 2018). Alternatively, keratinocytes can be cultured 
directly onto a human de-epidermised acellular dermis (DED) (Pruniéras, 
Régnier and Woodley, 1983; Ponec et al., 1988). However, in the work reported 
by El-Ghalbzouri and colleagues it was illustrated that the inclusion of 
fibroblasts positively affected the epidermal morphogenesis and differentiation 
(El‐Ghalbzouri et al., 2002; Tjabringa et al., 2008). In light of these 
considerations, human skin equivalent models [HSEs] can be divided into two 
main groups: reconstructed human epidermis [RHEs] - 3D differentiated 
epidermis cultures derived from human keratinocytes; and full thickness living 
skin equivalents [LSEs], constituted of both epidermis and dermis. 
A schematic representation of the 2 groups of 3D skin models is illustrated 
below in Figure 1.29. 
 
Figure 1.29 Schematic representation of A) a reconstructed human epidermis 
[RHE]. Keratinocytes are cultured on the membrane of a cell culture insert; B) 
living skin equivalent [LSE]. Keratinocytes are cultured on a dermal support, 
consisting of fibroblasts in a 3D scaffold. Figure taken from (Rademacher et al., 
2018). 
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To date, a range of commercially available models have become established for 
toxicological and pharmaceutical studies. These include RHEs, such as EpiSkin 
(Epskin, Lyon, France) and EpiDerm (Mattek, Ashland, USA) and LSEs, for 
example EpiDermFT (Mattek, Ashland, USA), T-skin (Episkin, Lyon, France) 
and Labskin (Innovenn (UK) Ltd, York, UK). A comprehensive review of their 
use in drug development has been published by Mathes and co-workers 
(Mathes and Ruffner, 2014; Ruffner, Graf-Hausner and Mathes, 2016). As a 
result of including the dermal component, the biological complexity increases 
moving from RHEs to LSEs, and can be further increased by adding within 
these models cell types such as melanocytes, stem cells or Langerhans cells, 
or by using novel approaches, such as organ-on-a-chip (Mathes and Ruffner, 
2014; Niehues et al., 2018). This last approach offers the possibility to culture 
different types of cells on a specially designed microchip, in which cells interact 
with a dynamic micro or nano fluidic flow in order to reproduce the in-vivo 
microenvironment (Wang et al., 2015). The fabrication of the first chip, on which 
skin cells were directly cultured and differentiated on, was presented by Lee et 
al. (Lee et al., 2017). The chip consisted of two compartments, separated by a 
porous membrane. On the top compartment, a chamber containing fibroblasts 
within a mixture of collagen and keratinocytes was present; whereas the bottom 
compartment contained a chamber for vascular cells and channels for the 
infusion of culture media with nutrients. Compared to engineered skin 
equivalents, RHEs and LSEs, skin-on-chip offers the advantage of including 
vascular structure into the model, as well as reproducing mechanical forces and 
dynamic flow system, representing a more physiologically appropriate skin 
model. However, the high cost and technical challenge of this model represent 
the main drawbacks that hamper its wide spread use (Abaci et al., 2017; van 
den Broek et al., 2017; Rademacher et al., 2018; Sriram et al., 2018).  
The main advantages of 3D over 2D skin models for the testing of topical 
medication have been described by Teimouri et al. (Teimouri, Yeung and Agu, 
2018). 3D cell culture models provide a better representation of native skin 
compared to monolayer 2D cell culture. More representative cell-to-cell and cell-
to-extracellular matrix interactions occur in 3D skin models, leading to a better 
understanding of the in-vivo processes. 3D skin models offer an enhancement 
in quality, since they can be cultured for a longer time before de-differentiation 
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and decline occurs, making these models more appropriate and flexible for in-
vitro analysis (Teimouri, Yeung and Agu, 2018).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
1.11.1 3D skin models and skin absorption 
Over the years tissue engineered HSEs have been established as valid models 
for in-vitro cosmetic and pharmaceutical testing, as well as for the investigation 
of skin biology mechanisms behind the generation of the epidermis, skin barrier 
repair/wound healing, skin pathologies and absorption testing  (Schäfer-Korting, 
Mahmoud, et al., 2008; Xie et al., 2010; Ali et al., 2015; De Vuyst et al., 2017; 
Lewis et al., 2018; Bataillon et al., 2019). 
The main aim of developing RHEs is to obtain models able to mimic faithfully 
the structure and architecture of in-vivo skin, such as protein expression and  
lipid organisation (Zhang and Michniak-Kohn, 2012). In the work reported by 
Ponec et al. tissue architecture, lipid organisation and permeability properties of 
three RHEs models (EpiDerm, SkinEthic, EpiSkin) were investigated (Ponec et 
al., 2000). From this study it emerged that the tissue architecture of these 3D 
models highly mirrored that in native epidermis, whereas the main differences 
were found in the lipid expression levels. The levels of polar ceramide 
subclasses were much lower or absent in RHEs models in comparison to in-
vivo skin, causing a higher permeability. In the work reported by Smeden et al. 
the lipid analysis of HSE models was performed using liquid chromatography-
mass spectrometry (LC-MS) (Van Smeden et al., 2014). The results showed 
that HSEs differed from native skin mainly in the free fatty acid (FFA) chain 
length and grade of unsaturation. In particular an increase of monounsaturated 
FFAs were present compared to native skin, in agreement with previous results 
showed by Thakoersing et al. (Thakoersing et al., 2013). The formation of 
epidermal barrier in RHEs can be improved by the introduction of supplements 
within the culture media. Several studies have shown that vitamin D, vitamin C, 
fatty acids and serum growth factor type can decisively influence the final lipid 
content in the skin (Ponec et al., 1997; Vičanová et al., 1999; Gibbs et al., 
2007). 
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However, a concern that has been expressed in the use of 3D cell culture 
models for absorption studies relates to the difference in the absorption 
properties of such models compared to human skin (Schäfer-Korting, Bock, et 
al., 2008). It was found in a large-scale validation study carried out in Germany 
that the permeation of chemicals was overestimated when using 3D models 
(Schäfer-Korting, Bock, et al., 2008). This aspect is mainly due to the deviations 
in lipid composition and organisation within these models (Bell et al., 1991; 
Mathes and Ruffner, 2014; Abd et al., 2016). 
A discussion of the philosophy of the use of tissue models is appropriate. For 
acceptance of the use of these models in demonstrating absorption what is 
required is an acknowledgment that the models are "models", not human skin. 
In order for the models to be used to predict absorption behaviour in human 
skin, what is therefore required is that their absorption behaviour be fully 
characterised for substrates with a range of physio-chemical properties so that 
conversion/scaling factor can be derived (Russo et al., 2018). 
 
1.11.2 Labskin 
In this thesis the skin model system used is a commercial 3D living skin 
equivalent model, Labskin, produced by Innovenn (York,UK). 
Labskin is a well-structured model, containing all of the layers of skin 
(epidermis, dermis and complete basement membrane). The development of 
this model consists of the following steps: 
1. Dermal equivalent: first, fibroblast cells are placed in a fibrin gel scaffold 
and left for 6 days within media specifically created for Labskin; 
2. Living skin equivalent: after 6 days, keratinocyte cells are deposited on 
top of the dermal component and left for 2 days within the media 
(submerged growth). Afterwards, the media on the surface is removed 
allowing the keratinocyte cells to differentiate into the suprabasal layers 
at an air-liquid interface. After seven days exposure at the air-liquid 
interface, the keratinocytes differentiate into the different layers of the 
epidermis; at this point, the stratum corneum is thin and therefore, the 
model mimics sensitive skin. At day 12 air-liquid interface, the stratum 
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corneum becomes thicker thus, mimicking mature skin. The company 
ships the model at day 12 air liquid interface. 
 
After 12 days at the air-liquid interface, Labskin is viable for an additional 10 - 
14 days, representing a valuable model for longer-term skin experiments. In 
addition, Labskin is the only 3D skin model presently available, able to host 
microorganisms on the surface and, hence, mimic the microflora of human skin. 
This potential is due to the properties of surface, which is relatively dry 
compared to other models and presents protective functions similar to human 
skin. Considering these aspects, it is understandable that interest in the use of 
Labskin has increased over the years as a valuable platform for microbial 
studies of cosmetics and skin products, drug delivery as well as wound care 
products (https://www.labskin.co.uk/). 
 
In light of all these benefits in addition to the easy availability of the model (no 
ethical licence required), Labskin was selected as the model of choice for the 
experiments carried out in this thesis.  
 
1.11.3 MALDI-MSI and skin  
This thesis is particularly focused on the quantitative assessment of 
percutaneous absorption of an antifungal agent, terbinafine hydrochloride, in a 
3D LSE model, Labskin, by using MALDI-MSI. In addition, the effect of the 
penetration enhancer dimethyl isosorbide (DMI) to the delivery vehicle has also 
been investigated.  
 
1.12 Terbinafine hydrochloride 
Terbinafine hydrochloride is an antifungal agent belonging to the allylamine 
class (Petranyi, Ryder and Stütz, 1984) and it acts by blocking squalene 
epoxidase (Nowosielski et al., 2011). The hydrochloride form of terbinafine has 
been included in topical formulations for the treatment of dermatophytoses, 
pityriasis versicolor, and cutaneous candidiasis (Belal, El-din and Eid, 2013) 
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(Figure 1.30). Commercial dosage cream contains 1% (w/w) of terbinafine 
hydrochloride and, in a previous study, this was used as a model formulation for 
dermatopharmacokinetics (DPK) study of terbinafine hydrochloride through in-
vivo and in-vitro tape-stripping experiments (Saeheng et al., 2013). 
 
 
Figure 1.30 Structure of terbinafine hydrochloride. 
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Chapter 2: Optimisation of the 
detection and imaging of terbinafine 
hydrochloride in a commercial 3D 
skin model using MALDI-MSI. 
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2.1 Introduction 
As discussed in Chapter 1.8 drug penetration through the skin represents a 
crucial process for targeting the active agent directly to the action site in the 
body, whilst limiting the side effects. The understanding of this process 
represents a very big scientific challenge that, if addressed, would lead to the 
significant advancement of novel topical and transdermal system delivery 
(Depieri et al., 2015; Ruela et al., 2016). Traditional techniques widely accepted 
for assessing the efficacy of drug formulations for topical and transdermal 
delivery include tape stripping and diffusion cells, as discussed in Chapter 1.9. 
However, the major disadvantage of these approaches is represented by the 
lack of spatial resolution, as they are restricted to the thickness of skin layers. 
 
To increase the spatial resolution, mass spectrometry imaging techniques have 
been introduced to assess drug penetration directly in biological sections; the 
imaging techniques employed to date include matrix assisted laser desorption 
ionisation mass spectrometry imaging (MALDI-MSI) (Prideaux et al., 2007) 
time-of-flight secondary ion mass spectrometry (TOF-SIMS) (Sjövall et al., 
2014), and desorption electrospray ionisation mass spectrometry imaging 
(DESI-MSI) (D’Alvise et al., 2014; Taudorf et al., 2015). Comprehensive reviews 
of the application of mass spectrometry imaging techniques for drug distribution 
studies have been produced by Stoeckli and Prideaux (Prideaux and Stoeckli, 
2012) and Swales et al. (Swales et al., 2019). 
 
MALDI-MSI is currently the most popular MSI technique being used to visualise 
the distribution of compounds directly in tissue sections (Jove et al., 2019; 
Strnad et al., 2019). MALDI-MSI offers large advantages; comprising high 
throughput, robustness and the ability to map ion distribution of many 
compounds without requiring the use of labels, such as isotopes or fluorescent 
tags (Schulz et al., 2019). 
 
Although over the years, several studies have described the application of 
MALDI-MSI to examine endogenous compounds in skin tissue, such as lipids 
and proteins (Hart et al., 2011; Enthaler et al., 2012, 2013), few publications 
have reported its application for the study of drug absorption. In work completed 
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by Bunch et al. MALDI-MSI was used to map the distribution of an antifungal 
agent, ketoconazole, in porcine epidermal tissue (Bunch, Clench and Richards, 
2004). More recent work by Bonnel et al. used MALDI-MSI to investigate the 
distribution profiles of four different drugs in human skin explants (Bonnel et al., 
2018). 
 
Because of the poor accessibility of ex-vivo human skin due to ethical and 
functional limitations, 3D in-vitro engineered models have been developed as 
an alternative system for drug penetration testing, as described in Chapter 1.11 
(Mathes and Ruffner, 2014; Ruffner, Graf-Hausner and Mathes, 2016).  MALDI-
MSI of 3D skin models was initiated by the Clench group, who published the 
first publication on the use of MSI with these models, demonstrating that 
MALDI-MSI could be used to analyse the drug penetration of imipramine within 
a commercially available 3D tissue model of the epidermis "Straticell" (Avery et 
al., 2011). Other studies of a similar type have been reported by Francese et al. 
(Francese et al., 2013) and Mitchell et al. (Mitchell et al., 2015, 2016). In the 
work of Francese et al. MALDI-MSI was used to map the distribution of the drug 
acetretin within a commercial living skin equivalent model, with the purpose of 
investigating the efficiency of the compound curcumin as a matrix compared to 
CHCA. MSI data of Labskin 4 hours post-treatment showed the penetration of 
acetretin into the epidermal layer (Francese et al., 2013). In further development 
of this work reported by Harvey et al., the localisation of the same drug was 
analysed using MALDI-MSI, after the creation of an LSE exhibiting psoriatic-like 
properties by treatment of the commercial product with the pro-inflammatory 
cytokine interleukin-22 (Harvey et al., 2016). In this modified model, the 
distribution of acetretin was studied at 24 hours and 48 hours post-treatment 
and the data obtained demonstrated that after 48 hours, it was possible to 
observe the drug penetration into the dermal region, whereas at 24 hours, it 
was still localised in the epidermal layer only.  
 
In MALDI-MSI experiments a basic requirement is the presence of a matrix 
(usually a small organic compound) which enables analyte desorption and 
ionisation  (Hoffmann and Stroobant, 2007). The choice of the correct matrix 
plays a pivotal role as it can highly influence the desorption/ionisation process, 
thus contributing to spectral quality, i.e., peak resolution, sensitivity, intensity 
  
89 
 
and noise (Lemaire et al., 2006). A comprehensive review into MALDI 
approaches for the analysis of low molecular weight compounds was conducted 
by Bergman et al. (Bergman, Shevchenko and Bergquist, 2014). Most 
commonly for MALDI positive mode, alpha-cyano-4-hydroxycinnamic acid (α-
CHCA), 2,5-dihydroxybenzoic acid (DHB) and sinapinic acid (SA) matrices have 
been found to be good candidates for direct analysis of both large molecules, 
i.e. peptides and proteins, and low-weight molecules (endogenous and 
exogenous). Matrices such as 9-aminoacridine (9-AA) are preferred for the 
detection of small molecules in negative mode (Baker, Han and Borchers, 
2017). Aside from the conventional matrices, novel strategies have been 
developed to overcome matrix selectivity issues, i.e. including additives to 
matrix solutions (Billeci and Stults, 1993), combining  matrix compounds (binary 
matrices) (Laugesen and Roepstorff, 2003; Guo and He, 2007) and using ionic 
matrices (Zhao et al., 2017). 
There is not an easy way to determine which matrices will work for a particular 
analyte, and a "trial and error" approach is often employed. The fastest and 
most cost-effective way for matrix sample preparation is by manual pipetting of 
analyte-matrix onto a MALDI sample target. This way could include a variety of 
possible procedures, i.e. crushed-crystals (Xiang, Beavis and Ens, 1994), 
sandwich (Kussmann et al., 1997) and dried droplet (Karas and Hillenkamp, 
1988), which represents the most common (Chapter 1.3.1.1).  
Although the dried droplet method has been widely used for MALDI-MS profiling 
(MALDI-MSP), it is usually not applicable for MALDI-MS imaging (MALDI-MSI), 
due to diffusion and segregation effects causing irregular distribution of matrix 
crystals (Luxembourg et al., 2003). 
The crystal size and homogeneity of matrix distribution onto the sample are 
strongly influenced by the matrix deposition technique, which therefore affects 
the spatial resolution of images when using MSI. Over the years multiple matrix 
deposition techniques have been established, such as micro-spotting, 
airbrushing, inject printing, spraying and sublimation (Aerni, Cornett and 
Caprioli, 2006).  
Several studies have provided evidence that sublimation is able to create 
smaller matrix crystal size diameters (1 to 3 µm) than those produced by 
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spraying methods which are typically 5 to 20 µm (Phan et al., 2016). Murphy et 
al. showed the improved quality of imaging of lipids in different tissues  
analysed by MSI when the matrix was applied by sublimation (Murphy et al., 
2011). However, owing to its solvent-free mechanism, a recrystallisation step 
after sublimation can be necessary to allow better extraction of analyte of 
interest from the sample and therefore a more intense signal (Yang and 
Caprioli, 2011). Commonly the recrystallisation step is performed by incubation 
with solvent vapour (Yang and Caprioli, 2011; Meisenbichler et al., 2019; 
Morikawa-Ichinose et al., 2019), although the literature has also reported  the 
use of sprayers for solvent application (Ferguson et al., 2013; Lauzon et al., 
2015; Dueñas, Carlucci and Lee, 2016). 
 
2.2 Aims of the chapter 
In the following chapter we aimed to develop a suitable method to detect an 
antifungal agent, terbinafine hydrochloride, in a 3D LSE, Labskin, by using 
MALDI-MSI. Firstly, optimisation work of mass spectrometry analysis to improve 
the signal of the standard terbinafine hydrochloride (TBF HCl) was performed. 
Furthermore, in this chapter, two different matrix deposition techniques, 
automated spraying and sublimation, to image the distribution of terbinafine HCl 
in Labskin, were examined and compared. Finally, the use of the penetration 
enhancer dimethyl isosorbide dimethyl ether (DMI) was investigated for 
assessing percutaneous penetration of the drug by MALDI-MSI. 
 
2.3 Materials and methods 
2.3.1  Chemicals and materials 
MALDI matrices and instrument calibrants - Alpha cyano-4-hydroxycinnamic 
acid (α-CHCA), 2,5-dihydroxybenzoic acid (DHB), 9-aminoacridine (9-AA), 
aniline, acetone, trifluoroacetic acid (TFA), phosphorus red and formic acid (FA) 
were purchased from Sigma-Aldrich (Gillingham, UK). For tissue staining 
protocols haematoxylin, eosin, xylene substitute and ethanol (EtOH) were 
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purchased from Sigma-Aldrich (Gillingham, UK). Pertex mounting medium was 
obtained from Leica Microsystems (Milton Keynes, UK). Acetonitrile (ACN) and 
methanol (MeOH) were purchased from Fisher Scientific (Loughborough, UK). 
Terbinafine hydrochloride standard and isosorbide dimethyl ether (DMI) were 
purchased from Sigma-Aldrich (Gillingham, UK). Conductive indium tin oxide 
(ITO)-coated microscope glass slides were purchased from Sigma-Aldrich 
(Gillingham, UK). 
 
2.3.2  Tissue preparation 
Living skin equivalent models (LSEs) were supplied by Innovenn (York UK). 
LSEs were delivered after 14 days of development in transport culture medium. 
At the time of delivery LSEs were transferred into new 12 deep well plates, 
suspended in fresh Labskin maintenance medium and left to incubate for 24 
hours with 5% CO2, 37°C. Labskin was treated with terbinafine hydrochloride at 
1% w/w dissolved either in acetone/olive oil (80:20 v/v) or in 100% DMI. After 
treatment, LSEs were re-incubated for 24 hours. After incubation, the samples 
were taken, snap-frozen with liquid nitrogen cooled isopentane (2-5 min) and 
stored at -80°C. For cryosectioning, LSEs were transferred into the cryostat 
(Leica 200 UV, Leica Microsystems, Milton Keynes, U.K.) and mounted onto a 
cork ring using diH2O at −25°C for 30 min to allow to thermally equilibrate. The  
tissues were cryosectioned (12 µm), thaw mounted onto ITO glass slides, and 
stored at −80°C.  
 
2.4 Optimisation of mass spectrometry imaging  
2.4.1  Mass spectrometric profiling of terbinafine 
hydrochloride 
Different matrices dissolved in several solvent mixtures were compared for best 
mass spectrometric analysis of terbinafine hydrochloride. For positive mode the 
matrices used were: either 5 mg/mL or 10 mg/mL of α-CHCA in ACN/0.5% TFA 
(7:3, v/v); 5 mg/mL of α-CHCA in ACN/0.2% TFA (1:1, v/v) + equimolar amount 
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of aniline added to the final volume; 20 mg/mL DHB in either ACN/MeOH (1:1, 
v/v) or ACN/0.2% TFA (1:1, v/v). The binary matrix was prepared by mixing in 
ratio 1:1 CHCA solution matrix (20 mg/mL in ACN/5% FA (7:3, v/v)) with DHB 
solution matrix (20 mg/mL in ACN/0.1%TFA (7:3, v/v)). For negative mode, the 
matrix used was: 15 mg/mL 9-AA in MeOH/diH2O (4:1, v/v).  
Terbinafine hydrochloride (100 μg/mL unless otherwise stated) was mixed with 
each matrix solvent composition (ratio 1:1) by using the dried droplet method. 
Then, three spots (0.5 μL) from each mixture were deposited across the length 
of the MALDI stainless steel plate and then allowed to dry at room temperature 
prior to mass spectrometric analysis. 
 
2.4.2  Mass spectrometric imaging of terbinafine in Labskin 
2.4.2.1 Matrix deposition  
2.4.2.1.1 Spraying  
All sample sections were taken from -80oC and freeze-dried under vacuum 
(0.035 mbar) for 2 hours to avoid delocalisation of the analyte and preserve the 
integrity of the tissues. The matrix (5 mg/mL α-CHCA in ACN/0.2% TFA (1:1, 
v/v) with equimolar amount of aniline added to the final volume) was deposited 
onto the treated tissue section surface using a SunCollectTM automated sprayer 
(KR Analytical, Sandbach, UK). Eleven layers of matrix were sprayed with a 
flow rate of 3 μL/min for the first layer and 3.5 μL/min for the following ten 
layers. The time taken to spray eleven layers of matrix on an area of 432 mm2 
was around 1 hour and the total amount of matrix deposited was around 1 mg 
per the entire area (432 mm2), hence 2.31 µg/mm2. 
 
2.4.2.1.2 Sublimation  
α-CHCA (300 mg) was spread evenly at the bottom of the sublimation 
apparatus (Sigma-Aldrich). ITO-coated glass slides containing treated Labskin 
tissues were attached to the flat top of the chamber using double-sided tape. 
The flat top of the chamber was then attached to the bottom using an O-ring 
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seal and the vacuum was applied. When a stable vacuum of 2.5 x 10-2 Torr was 
achieved, the top was filled with cold water (5°C) and the temperature was set 
to 180°C. The sublimation process was performed until the optimal amount of α-
CHCA (0.2 mg/cm2) was achieved. To monitor the quantity of matrix deposited, 
the glass slide with the tissue section was weighed before and after the 
sublimation process; the amount of matrix (mg) was calculated by the difference 
and divided by the area of the sublimed slide (mg/cm2). The time taken to 
complete this process was around 20 minutes.  
 
2.4.2.1.3 Recrystallisation 
For MS/MSI experiments, after sublimation an additional recrystallisation 
process was performed. A glass Petri dish (100 mm diameter x 15 mm depth) 
was used to carry out the recrystallisation on sublimated tissues. The glass 
slide was fixed to the underside of a petri dish lid using standard double-sided 
tape. The lid was then placed on the rest of the dish and put in the oven for 2 
minutes at 180°C. The petri dish was then retrieved from the oven and a 
solution of 1 mL deionised water and 50 μL trifluoroacetic acid was pipetted 
onto filter paper placed at the bottom of the petri dish. The petri dish was then 
sealed with Parafilm (Sigma Aldrich, UK) and placed in the oven for 6 minutes. 
The dish was then unsealed, and the lid returned to the oven to dry for a further 
2 minutes. 
 
2.5 Instrumentation  
2.5.1  Mass spectrometry  
All experiments were performed using an Autoflex III (Bruker Daltonik GmbH, 
Germany) equipped with a 200-Hz SmartbeamTM laser. For MALDI-MSP mass 
spectra were manually acquired in positive and negative mode in reflectron 
mode at a mass range of 50-1000 m/z. Six hundred laser shots were acquired 
for each spectrum. External mass calibration was achieved using a phosphorus 
red standard at approximately 200 ppm. 
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2.5.2  Data processing  
MALDI-MSP data were acquired using FlexControl (Bruker Daltonics, 
Germany), converted to .txt file format using FlexAnalysis (Bruker Daltonics, 
Germany) and analysed using Mmass v5 open source software (Strohalm et al., 
2010). 
 
For MALDI-MSI positive ion mode, mass spectra were acquired at a pixel size 
of either 30 µm or 10 µm from 100 m/z -1000 m/z. The laser was focused at the 
small setting (around 20 µm diameter). Four hundred laser shots were acquired 
for each pixel and the data were processed using FlexImaging 3.0 software 
(Bruker Daltonics, Germany). 
 
2.6 Histological analysis  
2.6.1  Haematoxylin and eosin staining  
LSE sections (12 µm) after MALDI-MSI were stained used Mayer's 
haematoxylin and eosin solutions. First, any presence of matrix was removed 
by washing the slides with 100% (v/v) EtOH. Sections were then rehydrated by 
submerging in 95% (v/v) and 70% (v/v) EtOH washes for 3 min and they were 
left for 1 min in deionised water before being stained in filtered Meyer's 
haematoxylin for 10 min. Tissues were washed in running tap water for 3-5 min 
and dehydrated using 70% (v/v) and 95% (v/v) EtOH solutions then immersed 
in filtered eosin 100% (v/v) for 1 min. The last dehydration step was performed 
using 95% (v/v) and 100% (v/v) EtOH solution, each for a period of 3 min. 
Finally, the slides were submerged in 2 changes of xylene substitute for 5 min 
each and mounted using Pertex mounting medium.  
Optical images were obtained using an Olympus BX60 microscope and 
analysed with Q-Capture-Pro 8.0 software (QImaging, Surrey, BC, Canada). 
  
95 
 
2.7  Results and discussion 
2.7.1  Comparison of matrices  
A wide variety of matrices are currently available for the analysis of low 
molecular weight analytes. The optimisation of the matrix choice remains a 
fundamental aspect, since it strongly depends on the analyte under 
investigation in terms of structure, solubility and physiochemical properties 
(Reyzer and Caprioli, 2007). 
In positive mode, a standard solution of terbinafine hydrochloride (100 µg/mL) 
was examined using MALDI-MSP with the two most commonly used matrices, 
CHCA and DHB, at different concentrations and solvent compositions. 
Alternatively, in negative mode, terbinafine hydrochloride (100 µg/mL) was 
analysed using 9-AA matrix. With 9-AA matrix no significant signals were 
obtained; this matrix was therefore not considered further (Figure 2.1). These 
results were expected due the basic nature of the amine group of terbinafine. All 
profiling experiments were performed using the dried droplet technique, the 
most common approach used to prepare MALDI sample spots. 
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Figure 2.1 MALDI-MS spectrum acquired in negative mode on the spot TBF 
(100 µg/mL) mixed with the matrix 9-AA. No evidence of the expected peak [M-
H]-, m/z 290.19 was observed. 
 
For positive mode, first, the effect of DHB at the same concentration (20 
mg/mL) prepared in either ACN/MeOH (1:1, v/v) or ACN/0.2% TFA (1:1, v/v), 
were compared. The presence of TFA in the solvent, an excellent proton 
donator, led to a more efficient ionisation of the analyte and consequently 
higher signal intensity, as show in the Figure 2.2A. In addition, a lower standard 
deviation in the latter case was also observed. However, the differences in error 
bars shown in the Figure 2.2A could be derived from inhomogeneity of matrix-
analyte crystals, responsible for spot to spot irreproducibility, as well as from   
the background noise of the MALDI technique (Krutchinsky and Chait, 2002; 
Wijetunge et al., 2015) The chemical noise measured at the detector, beside 
limits the sensitivity of the technique, affects the signal of the acquired spectra, 
generating a non-uniform background.  
 
Next, the performance of CHCA at two different concentrations; 5 and 10 
mg/mL dissolved in ACN/0.5% TFA (7:3, v/v) was investigated. The optimal 
concentration of matrix was found to be 5 mg/mL; since a lower signal intensity 
of terbinafine hydrochloride was detected when the higher concentration of 
CHCA was used (Figure 2.2B). As reported in the proteomic study conducted 
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by Zhang et al., this aspect may be explained by the fact that an increase in 
matrix concentration may derive an increase of matrix clusters responsible for 
the analyte signal suppression (Zhang et al., 2010). 
To increase the sensitivity of the terbinafine hydrochloride different approaches 
have been investigated, either by mixtures of matrix compounds (CHCA-DHB) 
or by adding liquid aniline to matrix preparation. 
The application of CHCA-DHB mixture was previously reported to improve the 
spot-to-spot reproducibility and signal-to-noise ratio in peptide analysis 
(Laugesen and Roepstorff, 2003; Schlosser et al., 2005). In more recent work, 
Shanta et al. reported the combination of CHCA-DHB with a mixture of 
piperidine and TFA for the visualisation and identification of phospholipids in 
brain tissue by using MALDI-MSI in both positive and negative modes (Shanta 
et al., 2011).  
Another strategy widely employed to increase the sensitivity and improve the 
ionisation of the analyte of interest involves the use of ionic liquid matrices 
(ILMs). The most common examples of ILMs consist of a combination of an acid 
normally used as MALDI matrix with an organic base, i.e pyridine, aniline, 
tributylamine in equimolar proportions (Meriaux et al., 2010). In particular, the 
addition of aniline within CHCA matrix solution has been reported as an 
excellent strategy to detect low molecular mass analytes, thanks to the 
improvement in the signal-to-noise ratio and absence of interfering peaks 
generated by conventional CHCA matrix (Calvano, Carulli and Palmisano, 
2009).  
Analysing these two different approaches, ANI-CHCA was found to be the most 
favorable for increasing the absolute intensity of terbinafine hydrochloride and 
reducing the matrix interference in the low m/z range on the spectrum (Figure 
2.2C). 
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Figure 2.2 The effect of several matrices on the signal intensity of terbinafine 
hydrochloride ([M+H]+; m/z 292.2) (n = 9). A) 20 mg/mL DHB dissolved in I) 
ACN/MeOH (1:1, v/v), II) ACN/0.2% TFA (1:1, v/v). B) CHCA dissolved in 
ACN/0.5% TFA (7:3, v/v) at concentrations: I) 5 mg/mL and II) 10 mg/mL. C) 
CHCA dissolved in different solvents at different concentrations: I) 5 mg/mL in 
ACN/0.2% TFA (1:1, v/v) with equimolar aniline, II) 20 mg/mL in ACN/5% FA 
(7:3, v/v) mixed in ratio 1:1 with 20 mg/mL DHB in ACN/0.1% TFA (7:3, v/v). 
 
(B) 
(C) 
(A) 
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The final step of the matrix optimisation study was to compare the energy 
threshold for ion production of terbinafine hydrochloride obtained when mixed 
with all different matrix compositions (Figure 2.3). 
 
 
Figure 2.3 MALDI-MS spectra of terbinafine hydrochloride standard (100 
µg/mL) obtained for different matrices. Peaks with a star represent the peak of 
the terbinafine hydrochloride in positive mode ([M+H]+; m/z 292.2). 
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Figure 2.4A shows that the employment of ANI-CHCA matrix resulted in a 
significant enhancement in spectral quality of terbinafine hydrochloride 
compared to the other matrices. Furthermore, the superiority of the ionic liquid 
matrix was highlighted also when the relative intensity of the analyte was 
investigated (intensity peak of terbinafine HCl/intensity peak of matrix), 
supporting the ability of the ionic liquid matrix (ANI-CHCA) to suppress matrix 
ion peaks (Figure 2.4B).   
Morphological aspects of matrix crystallisation resulting from sample deposition 
in different matrices by the dried droplet technique are shown in Figure 2.4C. 
With manual spotting, the crystallisation tended to be irregular and 
inhomogeneous, DHB formed needle-shaped crystals pointing to the edge of 
the rim, whereas CHCA crystals appeared smaller with low density at the center 
of the rim. A slightly higher homogeneity crystal distribution was obtained with 
the combination of two matrices (CHCA-DHB), whereas the ANI-CHCA gave a 
very typical transparent droplet base with crystal clusters across. 
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Figure 2.4 A) Absolute and B) relative intensity of terbinafine hydrochloride 
peak ([M+H]+; m/z 292.2) with several matrices (n = 9). I) 5 mg/mL CHCA in 
ACN/0.2% TFA (1:1, v/v) with equimolar aniline, II) 5 mg/mL and III) 10 mg/mL 
CHCA in ACN/0.5% TFA (7:3, v/v); 20 mg/mL DHB in: IV) ACN/MeOH (1:1, v/v) 
and V) ACN/0.2% TFA (1:1, v/v). VI) 20 mg/mL CHCA in ACN/5% FA (7:3, v/v) 
mixed in ratio 1:1 with 20 mg/mL DHB in ACN/0.1% TFA (7:3, v/v). For relative 
intensity, TBF intensity was normalised with the [CHCA+H]+ peak of m/z 190.05, 
when CHCA was used as matrix, and with the [DHB+H]+ peak of m/z 155, when 
DHB was used as matrix. When the binary matrix was used, the TBF peak was 
normalised for both VIa) [CHCA+H]+ peak and VIb) [DHB+H]+ peak.  C) Matrix 
crystal morphologies obtained by the dried droplet deposition method. 
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2.7.2 Spraying  
As the ionic liquid matrix ANI-CHCA was found to be the optimal matrix to 
enhance the intensity of the analyte of interest, terbinafine hydrochloride, it was 
decided to use this matrix for further MALDI-MS imaging investigations. First, 
the matrix ANI-CHCA was applied onto the Labskin tissue by using a 
SunCollect automated sprayer, widely used as matrix deposition device 
(Francese et al., 2013; Barré et al., 2019; Morikawa-Ichinose et al., 2019). The 
spraying conditions were optimised and, to assess the optimal number of 
layers, the sample was observed using microscopy when different layers of 
matrix were applied. It was found that 11 layers of matrix were required to give 
a good consistency in crystal size and excellent coverage of tissue.  
Figure 2.5 shows MALDI-MS images of the distribution of terbinafine parent 
compound at m/z 292.2 in a section of Labskin following treatment with 20 μL of 
terbinafine (1% (w/w) in emulsion acetone/olive oil (80:20)) for 24 hours. To 
increase the lateral spatial resolution of the MALDI-MS image, it was decided to 
reduce the pixel size to 10 μm. This was possible using the Autoflex III (Bruker 
Daltonic) instrument, which offered the advantage of changing the laser focus 
diameter down to 10 µm, allowing the generation of high resolution images, 
without oversampling. From the image it can be seen that the terbinafine signal 
appeared to be localised solely to the epidermal layer, with no penetration 
within the dermal region. The absence of the drug in the deeper layer of the skin 
was as expected considering the high lipophilicity and keratophilicity of the 
molecule, which leads  to its accumulation solely onto the epidermal layer 
(Pretorius et al., 2008). 
From the image it was also possible to detect an undesirable migration/diffusion 
of the analyte. The analyte delocalisation could represent a major drawback 
when spray-coating is used; primarily due to the presence of the solvent 
responsible for tissue wetting during the spraying (Schwartz, Reyzer and 
Caprioli, 2003; Puolitaival et al., 2008). In addition, other parameters could 
affect analyte delocalisation, i.e. the pressure with which the matrix solution hits 
the tissue, nozzle movement and height. Although these parameters could be 
optimised to minimise analyte delocalisation, the presence of a solvent is 
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necessary to prepare the matrix solution for this method and hence it cannot be 
completely eliminated.  
 
 
Figure 2.5 A) MALDI-MS image showing the distribution of terbinafine 
hydrochloride ([M+H]+; m/z 292.2). (Spatial resolution = 10 µm). B) Overall 
MALDI-MS spectra, inlay shows zoom at m/z 292.2. Image is generated by 
using TIC normalisation. 
 
2.7.3  Sublimation  
To increase the spatial resolution, sublimation, a solvent-free matrix deposition 
technique was examined. Kim et al. were the first to describe the use of 
sublimation/deposition for direct MALDI analysis (Kim, Shin and Yoo, 1998). In 
the study, the authors highlighted the excellent advantage of employing this 
technique to deposit both sample and matrix when they were not soluble with 
each other (Kim, Shin and Yoo, 1998). Over the years, the use of sublimation 
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for direct sample analysis by MALDI-MS imaging applications has been more 
widely established (Hankin, Barkley and Murphy, 2007; Caughlin et al., 2017; 
Bøgeskov Schmidt et al., 2018; Kaya et al., 2018). A wide sublimation study 
was performed by Thomas et al. on 12 different matrices (Thomas et al., 2012). 
From the study it was found that the sublimation of the matrix 1,5-
diaminonaphthalene (DAN) was particularly efficient for high spatial resolution 
imaging of lipids in both positive and negative ion polarities.  
In this work 0.2 mg/cm2 of organic matrix CHCA alone was applied by 
sublimation onto a section of Labskin treated with terbinafine (1% (w/w) in 
acetone/olive oil (80:20)) for 24 hours. In agreement with results obtained using 
the automatic sprayer system, MS images of Labskin section showed no 
delivery of the drug into the dermis, but confirmed the localisation of terbinafine 
hydrochloride at m/z 292.2 only in the outmost layer of the skin, the epidermis 
(Figure 2.6). The localisation of drug was also supported by haematoxylin and 
eosin staining performed on the same section of Labskin after sublimation 
(Figure 2.7). 
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Figure 2.6  A) MALDI-MS image showing the distribution of terbinafine 
hydrochloride ([M+H]+; m/z 292.2). (Spatial resolution= 10 µm). B) Overall 
MALDI-MS spectra, inlay shows zoom at m/z 292.2. Image is generated by 
using TIC normalisation. 
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Figure 2.7 Haematoxylin & eosin stained optical image of the sublimated 
section after MALDI-MSI A) 4X magnification B) 10X magnification C) 20X 
magnification. 
 
After sublimation, a recrystallisation step can be performed on the sample in 
order to rehydrate it (Bouschen et al., 2010). The necessity to execute this 
additional step on sublimed samples was considered in order to increase the 
analyte extraction. The extraction efficiency may be relatively low without a 
recrystallisation because of absence of solvent in the sublimation (Shimma et 
al., 2013; Morikawa-Ichinose et al., 2019). The choice of solvent used for 
rehydration of sample depends on the analyte and matrix used. One water-
based solvent, with addition of TFA, was chosen to incorporate the analyte into 
 
         
        
          
          
       
       .  
         
        
A) 
B) C) 
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the sublimated matrix, following the recrystallisation procedure developed by 
Yang and Caprioli (Yang and Caprioli, 2011).  
 
The recrystallisation was performed on a sublimated sample treated with 
terbinafine for 24 hours in the same composition examined previously. MALDI 
MS/MS imaging was performed on the recrystallised sample while keeping high 
spatial resolution at 10 µm. Figure 2.8 shows the MALDI-MS/MSI spectrum 
obtained from the major product ion at m/z 141. 
 
 
Figure 2.8 A) MALDI-MS/MSI distribution of terbinafine fragment [M+H]+ at m/z 
141 of  LSE 24 hours post-treatment  B) Haematoxylin & eosin stained optical 
image of the same section 1) 10X magnification 2) 20X magnification C)  
MALDI-MS/MSI spectrum showing the major product ion at m/z 141. 
 
Although the MS/MS data supported the MALDI-MSI data, which showed that 
the localisation of drug was confined in the epidermal layer, the spatial 
resolution appeared to be lost with the additional recrystallisation step. This 
drawback could be due to the fact that the exposure with the vapor may lead to 
an excessive water condensation on the glass surface, generating a non-
 /z 141 
300 µm 
80 µm 
epidermis 
dermis 
epidermis dermis 
A) B1) 
B2) 
C) 
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homogenous matrix composition and consequently causing analyte migration 
from the tissue. Although this aspect could be improved with further optimisation 
of solvents and time (Yang and Caprioli, 2011; Dueñas, Carlucci and Lee, 
2016), by analysing the signal of terbinafine hydrochloride (m/z 292.2) in two 
sections of Labskin, one exposed only to matrix sublimation and the other 
exposed to matrix sublimation/recrystallisation, an increase of intensity was not 
detected in the latter (data not shown). However, it is important to note that the 
analysis was performed on different sections of Labskin and on different days, 
hence, a direct comparison was not suitable. In this study it was decided to not 
proceed further with a recrystallisation step after sublimation. 
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2.8 Comparison of automated sprayer and sublimation 
methods for terbinafine mass spectrometry imaging  
The MALDI-MS images obtained by automated sprayer and sublimation were 
directly compared. Both images showed a relatively uniform intensity of 
terbinafine across the outermost layer of skin, the epidermis, although a 
significant enhancement of the spatial resolution was obtained when the matrix 
was applied by sublimation (Figure 2.9). 
 
 
Figure 2.9 Comparison of MALDI-MS images of terbinafine hydrochloride 
([M+H]+; m/z 292.2) by applying CHCA with A) optimised automatic sprayer and 
B) optimised sublimation method to Labskin section 24 hours post-treatment. 
 
It is common knowledge that, beside the laser spot size, the quality of the image 
could be strongly limited by factors including crystal size and uniformity of the 
matrix. In regards to this, the analysis of the matrix morphology was 
investigated. The spraying of 11 layers of ANI-CHCA produced a 
heterogeneous matrix deposition with splits and many incongruities, whereas 
very small crystal size and high uniformity of matrix was achieved with CHCA 
applied by sublimation (Figure 2.10). The superiority of a dry-coating approach 
for the imaging of small molecules was emphasised also by Lauzon et al. 
(Lauzon et al., 2015). Yang and Caprioli also highlighted the benefit of a 
sublimation approach for achieving high spatial resolution for imaging of large 
molecules, proteins up to m/z 30000 on mouse and rat brain (Yang and 
Caprioli, 2011).  
m/z 292.2 m/z 
292.2 
A) B) 
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Figure 2.10  Optical images comparing matrix coverage and crystal morphology 
for the A) optimized automatic sprayer, and B) optimized sublimation matrix 
application methods using CHCA as matrix. 
 
The ion peak patterns generated by the matrix were also investigated. In this 
regard, regions of interest (ROIs) with equal area (24 pixels) were selected in 
the tissue-free regions and the signal from CHCA applied by these two different 
techniques was extracted and compared. The overall spectrum from the 
sprayed ANI-CHCA showed multiple matrix sodium/potassium-adduct peaks 
([M+K]+, m/z 228; [M-Na+K]+, m/z 250) hardly detectable in the overall spectrum 
from the sublimed CHCA (Figure 2.11). The reduction of the intensity of CHCA 
cluster peaks in the spectrum from sublimed CHCA was attributable to the 
higher purity of matrix and this aspect guaranteed less interference in the 
spectrum in the low m/z range, minimising possible peak interference 
drawbacks with the terbinafine hydrochloride ion peak. 
 
m/z 292.2 
m/z 292.2 
A) 
B) 
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Figure 2.11 Overall MS spectra of CHCA matrix peaks (with no sample) when 
applied to ITO glass slide with A) optimised automated spraying and B) 
optimised sublimation matrix application methods. Spatial resolution = 30 µm. 
Inlays show the MS spectra zoomed in the lower m/z range (m/z 200-300). TIC 
normalisation. 
 
2.9  Optimisation of percutaneous delivery of 
terbinafine hydrochloride  
Once established that the uniform coating of matrix and small crystal sizes 
achieved by sublimation ensured a better spatial resolution and limited analyte 
delocalisation compared to the automatic sprayer method, this study proceeded 
with the optimisation of the terbinafine percutaneous delivery. 
 
As discussed in Chapter 1.8.1, the inclusion of chemical penetration enhancers 
(CPEs) within a drug formulation could represent a valid strategy to enhance 
the drug penetration through the stratum corneum (the limiting barrier to drug 
absorption). In the work reported by Erdal et al. (Erdal et al., 2014) three CPEs 
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(nerolidol, dl-limonene and urea) were investigated. From this study it emerged 
that the addition of nerolidol in a topical terbinafine formulation increased the 
delivery of the drug within deeper layers of epidermis, allowing potentially the 
treatment of deep cutaneous infections (Erdal et al., 2014). 
 
Specifically, in the study presented in this chapter, the assessment of enhanced 
topical delivery of terbinafine by using DMI based formulation was investigated 
(Figure 2.12). DMI is a "sustainable" solvent widely included in cosmetic and 
pharmaceutical formulations (Durand et al., 2009). In this context the term 
"sustainable" refers to a solvent where the production process includes pollution 
prevention/control and resource-usage reduction (Glavič and Lukman, 2007). 
DMI acts as chemical enhancer by improving the partitioning of active agents 
into the stratum corneum and leading to a greater penetration of them into the 
epidermis (Zia et al., 1991; Otto et al., 2008).  
 
 
 
Figure 2.12 Structure of isosorbide dimethyl ether. 
 
 
Figure 2.13 shows MALDI-MSI images of the distribution of the terbinafine 
parent compound at m/z 292.2 in a section of Labskin following treatment with 
20 μL of terbinafine (1% (w/w) in 100% DMI) for 24 hours. As can be seen from 
the figure, the main concentration of terbinafine was focused in the epidermis. 
Tandem MS/MS imaging experiments carried out on the [M+H]+ signal for 
terbinafine at m/z 292.2 showed the expected major product ion at m/z 141 and 
supported the presence of terbinafine in the epidermis (Figure 2.14). These 
results find support from previous unpublished studies performed on ex-vivo 
human skin, in which it was shown that the inclusion of DMI within vehicle 
  
113 
 
enhanced the drug penetration only within the epidermal layer and did not lead 
to penetration into the dermis (personal communication).  
 
 
 
Figure 2.13  A) MALDI-MSI distribution of terbinafine [M+H]+ at m/z 292.2 of 
LSE 24 hours post-treatment in 100% DMI. Matrix (CHCA) applied by 
sublimation. Spatial resolution = 30 μm. B) Haematoxylin & eosin stained optical 
image of the sublimated section. 4X magnification. 
 
 
 
m/z 292.2 
(A) (B) 
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Figure 2.14  (A) MALDI-MS/MSI distribution of terbinafine fragment [M+H]+  at 
m/z 141 of LSE 24 hours post-treatment in 100% DMI. Matrix (CHCA) applied 
by sublimation. Spatial resolution = 10 µm. (B) Haematoxylin & eosin stained 
optical image of the same section. (B1) 4X magnification. (B2) 10X 
magnification. (B3) 20X magnification. 
. 
 
 
 
 
 
 
 
 
 /z 141 
          
       
(A) (B1) 
(B2) (B ) 
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2.10  Concluding remarks   
In this study, a commercial LSE model was treated with terbinafine 
hydrochloride dissolved in different solvent mixtures. Additionally, MALDI-MSI 
was used to identify the localisation of the drug in samples of the LSE. Data 
was obtained after depositing the matrix onto the sample using two different 
matrix deposition techniques, spraying and sublimation. Use of the sublimation 
was shown to give a better spatial resolution of the images obtained from the 
samples 24 hours post-treatment. This result was due to several factors 
associated with the sublimation technique: microcrystalline morphology of the 
matrix deposition, increased purity of deposited matrix, evenness of deposition 
and less spreading of analyte due to solvent deposition during matrix 
application.  
 
It was demonstrated that 24 hours post-treatment terbinafine was localised only 
in the epidermal layers of the LSE, either when the drug was formulated with 
acetone/olive oil (80:20) or with a known penetration enhancer 100% DMI.  
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Chapter 3: Optimisation of 
methodology for quantitation in 
MALDI-MSI. 
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3.1 Introduction 
The quantitation of drugs in tissues is an essential part of pharmaceutical 
discovery and development. The determination of the concentration of a drug at 
the site of action is extremely important for the assessment of its efficacy.  
Quantitative whole-body autoradiography (QWBA) and liquid chromatography 
tandem mass spectrometry (LC-MS/MS) represent traditional techniques widely 
employed to detect the amount of drugs and metabolites in biological tissues 
after their administration (Hamm, Bonnel, Legouffe, Pamelard, J.-M. Delbos, et 
al., 2012).  
Quantitative whole body autoradiography (QWBA) is an advancement of whole 
body autoradiography (WBA), which is an imaging technique able to visualise 
the in situ distribution of radiolabelled molecules throughout tissue sections of 
laboratory animals, usually rodents  (Solon and Kraus, 2001).  
In brief, the WBA technique comprises first of the administration of a 
radiolabelled molecule (typically 14C or 3H) to lab animals and then euthanasia 
at specified time points. The entire animal carcass is then snap-frozen, 
embedded in carboxymethylcellulose and cryosectioned to obtain a 
representative slice (Solon and Kraus, 2001). By exposing tissue sections to a 
detector capable of measuring radioactivity (x-ray film or phosphor image plate) 
it is possible to obtain information about the distribution and the relative 
concentration of radiolabelled material in an animal body. To generate absolute 
quantitative data, Schweitzer et al. (Schweitzer, Fahr and Niederberger, 1987) 
introduced a robust and simple quantitation method that consisted of spiking a 
range of radioactive calibration standards within blood samples and embedding 
them with the animal. 
The QWBA technique allows spatial information to be retained and it is highly 
sensitive and reliable. In addition, the images generated are of high resolution. 
However, this technique presents several drawbacks that need to be 
contemplated too. Firstly, it is a technique which can only be used for targeted 
analysis and it is expensive in terms of instrumentation and synthesis of 
radiolabels. In addition, the quantitation relies only on the concentration of 
radioactivity, which could include as well as the parent compound its 
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metabolites or degradation products. This can  lead to misleading results for the 
amount of parent compound in the section (Solon et al., 2010). For this reason, 
often liquid chromatography tandem mass spectrometry (LC-MS/MS) is used as 
a complementary technique to support QWBA data. In the pharmaceutical 
industry LC-MS/MS has been indicated as technique of choice for the 
identification and quantitation of drugs and metabolites in biological tissues 
(Rönquist-Nii and Edlund, 2005). Although this technique offers the enormous 
advantage that it can give excellent separation of compound mixtures as well as 
reliable quantitation, it has the disadvantage of losing spatial information from 
the sample. LC-MS/MS analysis cannot be carried out directly on intact tissue 
sections, but analytes of interest have to be extracted out of the tissue. This 
increases the complexity of sample preparation and leads only to an average 
concentration within the tissue sample being obtained. 
In light of these considerations, in the last decade the potential of mass 
spectrometry imaging (MSI) technology for quantitative studies has been 
extensively examined. This technology combines the benefit of keeping the 
spatial information of non-labelled compounds in the tissues with the specificity 
of mass spectrometry. A comprehensive review into quantitative MSI strategies 
for biomedical applications was conducted by Ellis et al. (Ellis, Bruinen and 
Heeren, 2014). 
The major drawbacks in generating quantitative mass spectrometry imaging 
(QMSI) data from biological tissue sections concern the ionisation of the analyte 
of interest. Indeed, the ion intensity of the analyte depends strongly on both the 
nature of the analyte as well as on the histological microenvironment that is 
sampled with the analyte. This latter aspect is responsible for what are defined 
as "matrix" or "ion suppression" effects. In addition the recovery of the analyte 
from the tissue also needs to be considered (Porta et al., 2015). 
In this regard, methods to overcome the limitations and increase the potential of 
MSI for quantitative analysis are highly sought after and developed. In 
particular, the imaging techniques most commonly employed to acquire 
absolute quantitative data include matrix assisted laser desorption ionisation 
mass spectrometry imaging (MALDI-MSI) (Groseclose and Castellino, 2013), 
and desorption electrospray ionisation (DESI-MSI) (Vismeh, Waldon and Zhao, 
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2012; Groseclose and Castellino, 2013; Hansen and Janfelt, 2016). 
Additionally, a recent study reported by Swales et al. described the application 
of liquid extraction surface analysis mass spectrometry imaging (LESA-MSI) for 
spatial quantitation of drugs in tissues (Swales et al., 2016). 
The generation of calibration curves based on the use of serial dilution of 
standards represents a pivotal aspect to assess absolute quantitation. A 
comprehensive review on calibration/standardisation strategies for quantitation 
of small molecules using MALDI-MSI has been conducted by Rzagalinski and 
Volmer (Rzagalinski and Volmer, 2017). In order to mimic ion suppression 
effects within tissue a common approach used is by using mimetic arrays 
created from tissue homogenates (Groseclose and Castellino, 2013; Jadoul, 
Longuespée and Noël, 2015) and surrogate material (pseudo-tissue) (Takai, 
Tanaka and Saji, 2014a) or to spot working standard solutions using a control 
tissue in two different ways: (1) by spotting a range of standard concentration 
onto the tissue prior to depositing the matrix or (2) by spotting a range of 
concentration underneath the tissue prior to positioning the tissue and 
depositing the matrix.  
Lagarrigue et al. used spotting onto tissue in order to quantify the amount of 
pesticide chloredecon within mouse liver sections (Lagarrigue et al., 2014). In 
this study six replicates were performed and a good linearity coefficient was 
achieved (R2 from 0.9807 to 0.9981). In contrast, Pirman et al. spotted a range 
of calibration standards underneath a control brain tissue in order to quantify 
levels of cocaine by visualisation of the expected major product ion at m/z 182 
using MALDI-MS/MS imaging (Pirman et al., 2013).  
In MALDI-MSI, the nature of analyte ionisation depends strongly on the entity of 
the analyte as well as the tissue. The same molecule can be subjected to 
varying ion suppression effects in different tissues or across the same tissue in 
response to a changeable histological framework as well as to the ionisation 
competition with compounds within the morphological microenvironment 
(Hamm, Bonnel, Legouffe, Pamelard, J. M. Delbos, et al., 2012). This aspect in 
addition to the variation of ion signals due to heterogeneity of matrix deposition 
represent the major issues that need to be addressed in the development of 
MALDI-MSI as a method for quantitative mass spectrometry imaging (QMSI). 
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In order to correct for the issues that could compromise MALDI-MSI spectral 
quality different normalisation strategies were developed (Fonville et al., 2012). 
The basic principle of normalisation is to employ a factor against which to 
correct each mass spectrum. Total ion current (TIC) normalisation represents 
the most commonly used correction approach. In previous studies, TIC was 
used to normalise MALDI-MSI spectra acquired from rat brain tissue sections 
and perform quantitative analysis of both several neurotransmitters and drugs 
(Goodwin et al., 2011; Shariatgorji et al., 2014) .  
Although the TIC normalisation approach has been widely used to eliminate 
systematic artefacts derived from matrix crystal distribution, this approach may 
generate misleading conclusions from MALDI-MSI spectra, especially when the 
intensity of the analyte varies in different regions of the tissue (Deininger et al., 
2011). 
In order to correct for "matrix" or "ion suppression" effects, largely highlighted in 
the study carried out by Stoeckli et al. (Stoeckli, Staab and Schweitzer, 2007), 
different normalisation strategies for MALDI-MSI data have been developed and 
examined.   
The normalisation method developed by Hamm et al. based on a factor called 
the tissue extinction coefficient (TEC) aimed to correct for the ion suppression 
effects of the analyte of interest in a particular organ or region of interest 
(Hamm, Bonnel, Legouffe, Pamelard, J. M. Delbos, et al., 2012). This technique 
was adopted to quantify the amount of olanzapine specifically in rat kidney 
sections as well as quantify the amount of propranolol in multiple organs of a 
mouse. The method consisted of covering a glass slide and a control tissue 
section with the analyte mixed with matrix. The average intensity of the analyte 
extracted from the tissue section was divided by the average intensity of the 
analyte on the glass slide and, in this way, the tissue extinction coefficient 
(TEC) was calculated. Then a calibration curve was generated by spotting a 
range of standards near a dosed tissue; the average intensity of the analyte 
from the dosed tissue was extracted and multiplied by the TEC and, then, 
compared to the calibration curve in order to assess the quantity of the drug in 
the tissue. 
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Matrix peaks have also been used to normalise the intensity of the analyte of 
interest and in the literature it is possible to find a large variety of applications of 
this approach to perform quantitative MALDI imaging of small molecules 
(Bunch, Clench and Richards, 2004; Takai et al., 2012). In the works reported 
by Takai et al. a DHB matrix peak was employed to normalise the signal 
intensity of the drug raclopride in multiple organs by using whole-body sections 
(Takai et al., 2012). Instead, Bunch et al. investigated the normalisation to a 
CHCA sodium adduct peak at m/z 212 for the determination of the drug 
ketoconazole in the skin (Bunch, Clench and Richards, 2004). 
Multiple studies have shown how normalisation to an internal standard 
increases the quantitative capabilities of MSI analysis (Pirman and Yost, 2011; 
Prentice, Chumbley and Caprioli, 2017). The internal standard is a molecule 
with chemical and physical characteristics similar to analytes under study. 
During MSI analysis the internal standard mimics the behaviour of the analyte of 
interest in terms of ionisation efficiency and compensates for the tissue-
dependent ion signal variations of the analyte. This aspect causes an 
improvement in relative signal ion reproducibility and image quality due to an 
increase in pixel to pixel precision (Pirman et al., 2013; Chumbley et al., 2016). 
The growing interest in the QMSI field has led to the necessity of developing 
software packages designed for QMSI data. For this purpose, ImaBiotech 
developed the package software Quantinetix™ (www.imabiotech.com); 
whereas, more recently, Uppsala University (Sweden) developed msIQuant 
freeware software available from www.maldi-msi.org. It is a novel and 
established software designed for visualising and processing quantitative 
analysis of a large MSI data set, supporting multiple functions and MSI 
normalisation factors (Källback et al., 2016).  
In this study, different methods for generating accurate quantitative data of 
terbinafine hydrochloride in treated Labskin have been investigated. Different 
calibration/standardisation approaches have been compared, including: 1) cell 
films; on-tissue application of standards by 2) spraying and 3) microspotting; 
and 4) cell plug. In addition, preliminary quantitative data of terbinafine levels in 
Labskin tissues treated with different formulations have been obtained and the 
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performance of the penetration enhancer dimethyl isosorbide (DMI) in 
increasing the drug penetration has been assessed. 
 
3.2 Aims of the chapter 
In the following chapter we aimed to develop a robust, sensitive and 
reproducible methodology for generating accurate quantitative analysis of 
terbinafine hydrochloride, in Labskin, by using MALDI-MSI. The capability of the 
penetration enhancer dimethyl isosorbide (DMI) was also investigated. 
 
3.3 Materials and methods 
3.3.1 Chemicals and materials 
Alpha cyano-4-hydroxycinnamic acid (α-CHCA), phosphorus red, terbinafine 
hydrochloride standard (TBF HCl, MW 327.89), isosorbide dimethyl ether (DMI), 
haematoxylin, eosin and xylene substitute were purchased from Sigma-Aldrich 
(Gillingham, U.K.). X-tra® slides and Pertex mounting medium was obtained 
from Leica Microsystems (Milton Keynes, U.K.). Industrial methylated spirit 
(Ims) was purchased from Thermo Fisher Scientific (USA). 
Labskin living skin equivalent (LSE) samples were provided by Innovenn (U.K.) 
Ltd. (York, England). 
 
3.3.2 Tissue preparation  
3.3.2.1 Cell culture 
Normal human dermal fibroblasts (NHDF) were purchased from PromoCell 
(Heidelberg, Germany) and cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) media (Lonza Ltd, UK) supplemented with 10% foetal bovine serum 
(FBS) and 1% penicillin and streptomycin (Thermo Scientific, USA). 
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Immortalised human epidermal keratinocytes (T0345) were obtained from ABM 
(Richmond, BC, Canada) and cultured in Green's media. Green's media was 
obtained by mixing under sterile conditions the following: Hams F12 media 
(Lonza Ltd, UK) (108 mL), DMEM media (330 mL), L-glutamine (5 mL; 200mM), 
10% FBS, 1% penicillin and streptomycin, adenine (2 mL, 4.62 x 10-2 M), and 
insulin-transferrin-selenium (ITS-G, 100 X; 2.5 mL), hydrocortisone (80 µL of 2.5 
mg/mL), isoproterenol (80  µL of 2.5 mg/mL) and epidermal growth factor (EGF) 
(25 µL of 1 mg/mL). 
All cell lines were maintained in a humidified atmosphere containing 5% CO2 at 
37 oC. They were cultured until they reached 80% confluence. Once confluent, 
the cell lines were passaged by trypsinisation, subsequent centrifugation, 
resuspension in fresh medium and seeded in new flasks. 
 
3.3.2.2 Living skin equivalent samples 
Living skin equivalent (LSE) samples were obtained and cultured as described 
in Chapter 2.3.2. For these experiments, Labskin was treated with 20 μL of 
terbinafine hydrochloride at 1% (w/w) dissolved either in 100% DMI or in an 
emulsion made up of water/olive oil (80:20 v/v) with 10% and 50% DMI; and 
incubated for 24 hours. For the blank tissue, used for generating on-tissue 
calibration array, Labskin was left untreated and incubated for 24 hours. For the 
vehicle control tissue, instead, Labskin was treated with 20 µL of vehicle 
water/olive oil (80:20) alone and incubated for 24 hours. After incubation, the 
samples were taken, snap-frozen with liquid nitrogen cooled isopentane (2−5 
min) and stored at −80 °C. For cryosectioning, LSEs were transferred into the 
cryostat (Leica 200 UV, Leica Microsystems, Milton Keynes, U.K.), mounted 
onto cork ring using diH2O at −25 °C for 30 min to allow to thermally equilibrate. 
The 12 μm tissue sections were cryosectioned, thaw mounted onto poly-L-
lysine glass slides, and stored at −80 °C. Before standards and matrix 
application the samples were freeze-dried under vacuum (0.035 mbar) for 2 
hours to avoid delocalisation of the analyte and preserve the integrity of the 
tissues. 
 
  
124 
 
3.3.3 Strategies for generating standard curves 
3.3.3.1 Cell films 
Working standards were made to 1, 10, 50, 100 and 500 ng/µL of TBF HCl in 
MeOH/H2O (50:50) and deposited onto a “film” of keratinocyte and fibroblast 
cells cultured on a poly-L-lysine glass slide. Before culturing the cells, the glass 
slide was prepared and cleaned. A wax pen was used to draw on the slide a 
square constituting of hydrophobic barriers, inside of which the cells could be 
cultured. The slide was then sterilised by submerging in Ims 70% for 10 sec, 
and then it was washed with phosphate buffered saline (PBS) twice for 10 sec 
and Green's media for 10 sec. At this point the cells were prepared; 
keratinocyte (T0345) and fibroblast cells (NHDF) were cultured as described in 
Section 3.3.2.1. Once confluent, they were trypsinised and counted; 45000 
keratinocytes and 15000 fibroblasts were mixed in order to mimic the same ratio 
composition present in the Labskin tissue (3:1) and then, 300 μL of the mixture 
was deposited onto the slide. The slide with cells was maintained in a 
humidified atmosphere containing 5% CO2 at 37 
oC overnight in order to allow 
the cells to settle onto the slide. The day after the excess media was tapped off 
and the slide was washed twice in PBS and the cells were fixed in formalin 10% 
for 30 min at room temperature. The glass containing the cell film was kept in 
PBS at + 4 oC until performing MALDI-MSI experiments. For MALDI-MSI 
analysis, the slide containing the cell film was washed with 0.1 M ammonium 
bicarbonate solution in order to remove the excess PBS and kept freeze-dried 
under vacuum (0.035 mbar) for 2 hours. The working solutions of TBF HCl 
(from 1 to 500 ng/µL) were deposited onto different areas of cell film using the 
SunCollectTM automated sprayer (KR Analytical, Sandbach, UK). The standards 
were sprayed in a series of four layers using a flow rate of 4 µL/min.  
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3.3.3.2 On-tissue application of standards 
For quantitative MALDI-MSI experiments the second approach investigated was 
based on generating a calibration curve by applying a dilution series of 
terbinafine hydrochloride standard onto blank tissue sections. Working 
standards were made to 0.1, 1, 100, 500, 1000, 1500, 2000, 3000 and 4000 
ng/μL of TBF HCl in MeOH/H2O (50:50). Calibration standards were applied 
onto the epidermis area of 12 μm thick of blank tissue sections using both 
spraying and microspotting. 
 
3.3.3.3 Spraying 
Terbinafine hydrochloride standards (0.1-4000 ng/ μL in MeOH/H2O (50:50)) 
were deposited onto blank Labskin sections using the SunCollectTM  automated 
sprayer (KR Analytical,  Sandbach,  UK).  A tissue section was used for each 
drug concentration. The standards were sprayed in a series of two layers and 
with a flow rate of 5 µL/min.  
 
3.3.3.4 Microspotting  
Terbinafine hydrochloride standards (0.1-4000 ng/μL in MeOH/H2O (50:50)) 
were applied onto the epidermis area of 12 µm thick section of blank Labskin 
tissue using an acoustic robotic spotter (Portrait 630, Labcyte Inc., Sunnyvale, 
CA). For application of the standards the number of cycles for each spot was 
set to 20 for a total volume of 3.4 nL of each deposited solution. Five extra 
spots were applied outside the tissue to give a “drying time” between each 
cycle. 
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3.3.3.5 Cell plug 
Working standards were made to 3, 300, 1500, 3000, 9000, 15000, 21000 and 
42000 ng/μL of TBF HCl in MeOH/H2O (50:50). 20 µL of these standards were 
mixed with 40 µL of non-homogenised keratinocytes cells. The resulting 
suspension was pipetted into a gelatin block in order to generate a calibration 
array. The gelatin block was made by pouring 20% gelatin (w/v) into an ice cube 
mould, which was set in the fridge at +4 ºC for 4 hours before being frozen 
overnight in -80 ºC. Before the loading process, the top of the block was 
cryosectioned in order to obtain an even surface and 10 holes were drilled into 
the frozen gelatin at a drill diameter of 2.5 mm and depth of 10 mm. The holes 
were filled with the suspensions made up of non-homogenised cells mixed with 
drug standards in a ratio 2:1 v/v. In order to generate non-homogenised 
keratinocytes, T0345 cells were cultured in 2D conditions as explained in 
Section 3.3.2.1. Once confluent the cells were trypsinised and counted; to fill 
the 10 holes to generate a full cell plug array ≥ 11,000,000 cells were 
necessary. The cells were centrifuged, the supernatant was removed, and the 
residue of media was washed out using 0.1 M ammonium bicarbonate without 
perturbing the pellet. The cells were then mixed with drug standards (2:1 v/v), 
the suspension loaded into the gelatin holes and kept at -80 ºC. Mixtures with 
cells resulted in dilution of the drug standards by a factor of 3, thus the final 
concentration of drug standards in the calibration array was 1, 100, 500, 1000, 
3000, 5000, 7000, 14000 ng/µL. Before MALDI-MSI analysis the cell plug was 
cryosectioned at a -30 ºC using Leica Cryostat (Leica 200 UV, Leica 
Microsystems, Milton Keynes, U.K.) to obtain a section of 12 µm.  
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3.4 Matrix deposition 
3.4.1 Sublimation 
The matrix CHCA was applied by the sublimation technique as described in 
Chapter 2.4.2.1.2. 
 
3.5  Instrumentation 
3.5.1  Mass spectrometry  
All imaging experiments were performed using a Waters MALDI HDMS Synapt 
G2 mass spectrometer (Waters Corporation, Manchester, U.K.) equipped with a 
neodynium:yttrium aluminum garnet (Nd:YAG) laser operated at 1 kHz. The 
instrument calibration was performed using phosphorus red. MALDI-MS images 
were acquired in positive mode, in full scan “sensitivity” mode at a range of m/z 
100−1500, (resolution 10 000 FWHM) at pixel size of 60 μm × 60 μm, and with 
laser energy set to 250 arbitrary units. The ion mobility function of the 
instrument was not enabled. It was only possible to convert MSI raw files to 
imzML format by disabling the ion mobility function, which is the format 
supported by msIQuant software. 
 
3.5.2 Data processing  
 MALDI-MSI data were processed using the HDI 1.4 (Waters Corporation, U.K.) 
software tool. Using this software, MSI raw data files were converted to imzML 
format and imported into msIQuant software. With msIQuant software, region of 
interest (ROIs) were selected and peak intensities from them were extracted in 
order to perform quantitative investigation. 
 
Statistical analysis was performed using StatDirect software (StatsDirect, 
Cheshire, U.K.). 
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3.6  Histological analysis  
3.6.1  Haematoxylin and eosin staining  
Haematoxylin and eosin staining on the cell films was performed as reported in 
Chapter 2.6.1. 
 
3.7 Results and discussion 
3.7.1 Strategies for generating calibration curves 
3.7.1.1 Cell films 
The first method investigated consisted of generating a "cell array slide" made 
by spraying standards of terbinafine hydrochloride onto a microscope glass 
slide on which keratinocyte and fibroblast cells were cultured.  
The culture of cells directly on microscope slides is a technique widely used in 
cell biology since it offers the high advantage of performing studies on a small, 
accessible culture area, where the cells are fixed after being treated or 
manipulated (Koh, 2013). 
In the following work, the purpose of using this technique was to culture the 
main cells that constitute Labskin, keratinocytes and fibroblasts, onto slides in 
order to produce a "cell films" model able to mimic the histological framework of 
Labskin. This would, consequently, reproduce the "ion suppression effects" 
arising after a serial dilution of standards are sprayed onto it. 
Figure 3.1 shows the microscope view of keratinocyte and fibroblast cells 
cultured onto a poly-lysine glass slide in the same ratio composition present in 
the Labskin tissue (3:1). 
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Figure 3.1 Keratinocyte and fibroblast co-culture (ratio 3:1) on a poly-lysine 
glass slide viewed through light microscopy. 
 
To perform QMSI investigations a serial dilution of standards (from 1 ng/µL to 
500 ng/µL) were sprayed onto different areas of the “cell films” by using the 
SunCollectTM  automated sprayer.  
Figure 3.2 shows the MALDI-MS image of the TBF HCl in source generated 
fragment ion at m/z 141, which is derived from the parent compound [M+H]+ m/z 
292.2, recorded at 60 μm pixel size following the spraying of the drug dilution 
series.  
 
 
  
130 
 
 
Figure 3.2 MALDI-MS image showing the TBF HCl in source generated 
fragment ion (m/z 141), derived from the spraying of the drug dilution range 
onto different areas of a "cell films" model, made up of keratinocyte and 
fibroblast cells. Resolution image = 60 µm. 
 
Three regions of interest (ROIs) were selected for each drug concentration and 
processed using msIQuant software (Figure 3.3A).  
A calibration curve was also obtained by plotting the average intensity of the 
TBF HCl ion at m/z 141 (TIC normalisation) versus the concentration of 
terbinafine hydrochloride expressed in ng/mm2 (Appendix I). The calibration 
curve observed in Figure 3.3B showed a coefficient of linearity R2 of 0.9618; the 
limit of detection (LOD) and limit of quantitation (LOQ) was found to be 30.96 
ng/mm2 and 93.82 ng/mm2, respectively. The LOD and LOQ represent the 
analyte concentration giving a signal equal to the blank signal (only solvent 
without drug) plus 3.3 and 10 times (respectively) the standard deviation 
obtained from the replicate measurements of the blank. From the calibration 
curve, it is possible to estimate LOD and LOQ using the formulas LOD= 3.3s/b 
and LOQ= 10s/b, where s is the standard deviation of the blank and b is the 
slope of the curve. 
 
blank 1 ng/µL 10 ng/µL 
50 ng/µL 100 ng/µL 500 ng/µL 
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Figure 3.3 A) MALDI-MS image showing the TBF HCl in source generated 
fragment ion (m/z 141), derived from the spraying of the drug dilution range 
onto different areas of a "cell films" model. By using msIQuant software three 
ROIs were selected for each standard concentration and the peak intensity was 
extracted. B) A calibration curve obtained for terbinafine dilution ranges onto 
"cell films" model is presented. 
 
A good calibration curve was achieved (R2 = 0.9618) from the pilot experiment. 
This methodology offered the advantage of being simple and relatively cost-
effective, but it also presented several drawbacks. Firstly, it was not possible to 
obtain full homogenous coverage of the entire slide with cells. This aspect is 
due to the fact that keratinocytes, which represent the highest portion of cells 
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seeded onto the slide, prefer to grow in patches, leading to cell empty areas 
throughout the slide. The distribution of cells onto the slide was visualised using 
MALDI-MSI by plotting an endogenous lipid marker at m/z 184, attributed to the 
phosphocholine head group of phosphatidylcholines (PC), the most abundant 
lipids present in cell membranes (Hossen et al., 2015). As shown in Figure 
3.4A, the cells did not appear homogenously distributed throughout the slide, 
but they were found to be more confluent in certain areas than others; this 
aspect was also confirmed by H&E staining (Figure 3.4B). 
 
Figure 3.4 A) MALDI-MS image of the phosphocholine head group of the PC at 
m/z 184, used as histological marker to visualise the cells distribution onto the 
slide. B) Haematoxylin and eosin staining of "cell films" slide after MALDI-MSI 
(20X magnification). 
 
 
m/z 184 
A) 
B) 
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Additionally, there was a difficulty with controlling the cell films compactness 
onto the slide; the patches of cells could generate aggregates exhibiting 
different thicknesses. In the work conducted by Sugiura et al. the impact of 
section thickness on MALDI-MSI analysis was emphasised, reporting that 
thinner sections improved peak intensity and signal-to-noise ratio (Sugiura, 
Shimma and Setou, 2006).  
It is understandable that the lack of cells in some areas of the slide in addition 
with variable cell films thickness could affect the intensity of terbinafine 
standards, which would then no longer mimic matrix ion suppression effects of 
compound from the sample. This aspect could lead to the production of 
misleading results and the generation of an unreproducible calibration curve. 
Another disadvantage that could occur using this methodology was represented 
by the overlapping of standard solutions during the spraying. Although 
parameters, such as pressure, flow rate, distance of spray head to slide and 
speed of spray, were set to obtain a highly focused beam of small spray drops 
for each standard concentration, a risk of possible overlap was still possible due 
to the limited area in which each standard solution needed to be applied. As 
shown in Figure 3.5 the higher intensity of terbinafine peak at m/z 141 in the 
regions sprayed with 10 ng/µL and 100 ng/µL could be caused by the spread of 
the highest concentrated solution of terbinafine hydrochloride (500 ng/µL), 
which was sprayed last. 
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Figure 3.5 MALDI-MS image showing the TBF HCl in source generated 
fragment ion (m/z 141), derived from the spraying of the drug dilution range 
onto different areas of a "cell films" model. The inserts show a higher intensity 
of TBF HCl that could derive from the spread of the neighbour solution (500 
ng/µL). 
 
In light of all these considerations, it was decided that "cell films" model would 
not produce a suitable method for generating an accurate and precise QMSI 
analysis of terbinafine hydochloride in Labskin and other methodologies were 
explored. 
 
3.7.1.2 Application of standards onto tissue 
The second method investigated was based on the application of standards 
onto blank tissue sections by using two different techniques, spraying and 
microspotting.  
 
3.7.1.2.1 Application of standards by automated spraying 
The application of analytical standards by spraying was previously investigated 
for quantitative MALDI-MSI of cocaine on user hair samples. Using this 
 
blank 1 ng/µL 10 ng/µL 
50 ng/µL 100 ng/µL 500 ng/µL 
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technique, a dilution range of cocaine standards were applied onto blank hair 
sections and a calibration line was generated (Flinders et al., 2017). 
In this study, instead, it was decided to use blank sections of Labskin (12 µm) 
sprayed with a serial dilution of terbinafine hydrochloride (0.1-4000 ng/μL in 
MeOH/H2O (50:50)). To overcome the inconvenience of possible standard 
spray overlapping encountered with the “cell films” method, each standard was 
sprayed onto a separate serial section of Labskin. Between three and four 
Labskin sections were thaw mounted onto each glass slide after cryosectioning. 
After spraying of standards, the application of matrix by sublimation was 
performed for each glass slide at different times; for the imaging experiment, the 
areas of the glass slides containing the sprayed sections were cut, combined 
together onto the MALDI plate and imaged in the same run.  
Figure 3.6 shows the MALDI-MS image of the TBF HCl source generated 
fragment ion at m/z 141 in ten blank sections of Labskin recorded at 60 μm pixel 
size following the spraying of drug dilution series.  
 
 
Figure 3.6 MALDI-MS image showing the TBF HCl source generated fragment 
ion (m/z 141), following the spraying of the drug dilution range onto blank 
Labskin sections. Resolution image= 60 µm. TIC normalisation. 
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However, from qualitative investigation of the distribution of terbinafine 
hydrochloride in dosed tissue sections (discussed in Chapter 2) it was found 
that the presence of drug was restricted only into the epidermal layer of the skin 
without penetration into the dermis. Based on these observations, it was 
decided to calibrate the response specifically for calibrant signals arising from 
the epidermis to achieve "matrix matched standards".  
To distinguish the epidermis and stratum corneum from the dermis, two peaks 
from endogenous species at m/z 184 and m/z 264 were used, respectively 
attributed to a fragment ion of phosphocholine-type lipids, which was more 
apparent in the tightly packed cells of the epidermis and a ceramide fragment 
peak, primarily expressed in the stratum corneum. By superimposing the MALDI 
images of the peaks at m/z 184 and m/z 264, it was possible to visualise mostly 
the epidermis of the blank tissue sections (Figure 3.7A). However, different 
scale bar values were selected to make possible the visualisation of the 
endogenous lipid marker phosphocholine (m/z 184) in all blank sections (which 
can be noted from the colour scales near the images).  
Once identified the epidermis of the sprayed sections, ROIs were drawn only on 
at this level by using msIQuant software and an average intensity for the signals 
of each concentration of TBF HCl was extracted (Figure 3.7B).  
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Figure 3.7  A) MALDI-MSI of phosphocholine head group in blue (m/z 184) 
superimposed with ceramide fragment peak in green (m/z 264). By exploiting 
endogenous lipids it was possible to distinguish epidermis and stratum corneum 
from the dermis. B) MALDI-MSI of the TBF HCl source generated fragment ion 
in red (m/z 141) superimposed with phosphocholine head group in blue (m/z 
184) and ceramide fragment peak in green (m/z 264). Three ROIs for each drug 
concentration were drawn solely to the epidermal layer and the signal for TBF 
HCl in source fragment peak was extracted by using msIQuant software. TIC 
normalisation. 
 
  
138 
 
The calibration curve was obtained by plotting the average intensity of m/z 141 
(TIC normalisation) versus the concentration of terbinafine hydrochloride 
expressed in ng/mm2 (Appendix I). The calibration curve observed in Figure 3.8 
showed a coefficient of linearity R2 of 0.7767. The limit of detection (LOD) and 
limit of quantitation (LOQ) were 329.51 ng/mm2 and 998.52 ng/mm2, 
respectively. 
 
 
Figure 3.8 Calibration curve generated plotting the average intensity of m/z 
141, derived from standards sprayed onto blank Labskin sections, versus the 
concentration of terbinafine hydrochloride expressed in ng/mm2. TIC 
normalisation. 
 
The advantage of this technique was that the standard intensity was extracted 
solely from histology and MSI guided well-defined epidermal layer of blank 
sections, allowing to mimic cell type ionisation response of the analyte from the 
dosed tissue sections. In addition, the blank sections were cryosectioned 
keeping the same thickness of the dosed tissue sections and thus differences in 
terms of analyte peak intensity section thickness-dependent should not occur. 
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However, the main disadvantages of this technique were that it was time 
consuming and not cost-effective. Multiple sections of blank tissue were 
necessary to obtain a calibration array, making their analysis using MALDI-MSI 
time consuming. Although for all sections the data acquisition conditions were 
identical, the matrix application could not be performed at the same time, 
leading to possible differences in terms of matrix thickness influencing the 
results. In addition, before spraying each standard solution, washing of the 
capillary was required in order to remove the "carry-over" from the previous 
calibrant solution within it. The washing step was performed by flushing 
acetonitrile through the capillary for 30 min; making the spraying of all standard 
solutions very time consuming.  In light of these considerations, it was decided 
to proceed to investigate alternative QMSI techniques.  
 
3.7.1.2.2 Application of standards by microspotting 
The next approach investigated for generating robust and reproducible 
calibration curves was based on microspotting analytical standards onto a blank 
section of Labskin.  
For this purpose, the use of an acoustic picoliter droplet ejector, employed 
previously as a MALDI matrix deposition device (Aerni, Cornett and Caprioli, 
2006), was used to spot 3.4 nL of working standard (from 0.1 ng/μL to 4000 
ng/μL) in MeOH/H2O (1:1) onto the epidermis of a blank section of Labskin to 
create a calibration array.  
Figure 3.9 shows MALDI-MSI image of the terbinafine hydrochloride in source 
generated fragment ion at m/z 141 in a blank section of Labskin recorded at 60 
μm pixel size following the microspotting of drug dilution series. As shown, the 
application of working standards of terbinafine hydrochloride by using this 
methodology allowed a uniform distribution across the epidermis with minimal 
lateral diffusion. Assuming the high reproducibility of the spots size generated 
with the acoustic spotter, the appearance of increased spot area in Figure 3.9 
was attributed solely to an increment of drug concentration. Evidence of the 
reproducibility of the spot size using the acoustic spotter is reported in Chapter 
4.7.1. 
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Figure 3.9 MALDI-MS image showing the TBF HCl source generated fragment 
ion (m/z 141), following the microspotting of the drug dilution range directly on 
the epidermis of a blank section of Labskin. Resolution image = 60 µm. 
 
As previously described, by exploiting endogenous markers, the epidermis and 
the stratum corneum of the microspotted blank section was visualised and, 
thus, region of interests (ROIs) were selected for each drug concentration solely 
in the epidermis area by using msIQuant software. 
Figure 3.10 shows the MALDI-MS image of terbinafine hydrochloride in source 
fragment peak (m/z 141) superimposed with phosphocholine head group in blue 
(m/z 184) and ceramide fragment peak in green (m/z 264.2).  
 
Increment of 
Terbinafine 
hydrochloride 
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Figure 3.10 MALDI-MSI of the terbinafine hydrochloride source generated 
fragment ion in red (m/z 141) superimposed with phosphocholine head group in 
blue (m/z 184) and ceramide fragment peak in green (m/z 264). TIC 
normalisation. 
 
The average intensity of each ROI (TIC normalisation) was extracted and 
plotted against the respective standards expressed in ng/mm2 (Appendix I). The 
calibration curve observed in Figure 3.11 showed a coefficient of linearity R2 of 
0.9617. The LOD and LOQ were found to be 36.11 ng/mm2 and 109.44 
ng/mm2, respectively.  
  
142 
 
 
Figure 3.11 Calibration curve generated plotting the average intensity of m/z 
141, derived from standards microspotted onto a blank Labskin section, versus 
the concentration of terbinafine hydrochloride expressed in ng/mm2. TIC 
normalisation. 
 
The major advantage of the application of standards using the acoustic spotter 
was the possibility to apply sub-microliter volumes of standard solutions (3.4 nL) 
directly onto a small and well-defined epidermal area of a blank Labskin section 
with the same thickness of dosed sections, leading to mimic cell type-based 
ionisation response of the analyte from the treated tissue sections. In addition, 
this technique was relatively fast and time effective as only one section was 
necessary to generate a calibration curve. Unlike the sprayed sections, use of 
the microspotted section was beneficial as it could be placed directly next to 
treated sections and analysed under the same condition in terms of data 
acquisition and sample preparation.  
 
 
  
143 
 
3.7.1.3 Cell plug 
The last approach investigated involved the construction of a calibration array 
by spiking a known amount of terbinafine hydrochloride standard mixed into a 
non-homogenised “cell plug” of keratinocytes T0345. It was decided to use only 
keratinocytes since they are the dominant cell type within the epidermis of skin, 
which is the region of interest for the evaluation of tissue-based matrix effects.  
Moreover, it was thought that the incorporation of analytical standards with cells 
would have corrected not only the ion suppression effects, but also the 
extraction efficiency effects, leading to a more reliable calibration approach for 
QMSI analysis. 
 
Once prepared, the gelatine block including the cell plug array was presented 
as shown in Figure 3.12. 
 
 
Figure 3.12 Optical image showing the cell plug array. 
 
Cell plug design was thought to represent a remarkable alternative to previously 
employed techniques, such as homogenates and surrogate tissue models. 
Considering the small thickness of the epidermal layer (the region of interest), a 
 
blank 
1 ng/µL 100 ng/µL 
500 ng/µL 1000 ng/µL 3000 ng/µL 
5000 ng/µL 7000 ng/µL 14000 ng/µL 
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large number of blank Labskin tissues would have been necessary for the 
generation of a serial homogenate dilution, resulting in an extremely expensive 
and laborious process. It might be thought that the use of a surrogate tissue 
could offer a solution to this problem. In the work reported by Takai et al.  blank 
liver homogenates spiked with a serial dilution of raclopride were used to 
generate a calibration curve from which the concentration of the drug could be 
extrapolated not only in liver but also in brain, lung, and kidney tissue sections 
with MALDI-MSI (Takai, Tanaka and Saji, 2014b), However, the use of a 
surrogate tissue should rely on the assumption that the extraction of the drug of 
interest from different organs is similar to that occurring from the surrogate 
model. A criticism of this assumption was discussed in the work by Hansen et 
al. (Hansen and Janfelt, 2016). The authors analysed the extraction efficiency of 
the drug amitriptyline spiked at the same concentration into different 
homogenised (liver, brain, kidney, lung and heart) by using DESI-MSI. The 
results showed a statistical decrease of the signal when the drug was extracted 
from brain and lung tissue, potentially due to the protein binding effect. It is 
understandable that a different extraction efficiency would compromise the 
reliability of quantitative results. However, independently from the issue relating 
to the protein binding effect, a broader concept of tissue-specific influence on 
analyte ionisation has been widely examined in literature; and  this seems to 
strengthen the inadequacy of using surrogate models to generate QMSI 
(Stoeckli, Staab and Schweitzer, 2007; Hamm, Bonnel, Legouffe, Pamelard, J.-
M. Delbos, et al., 2012). In line with these considerations, as discussed 
previously, cell plugs were generated by using only intact keratinocytes, the 
principal cells compositing the epidermis. It was believed that the use of intact 
cells, differently from homogenates, offered the advantage of avoiding the 
release of intercellular debris that could lead to a higher suppression of the 
analyte signal. In addition, assuming that the drug diffused within the cells, it 
was hypothesised that cell plug may represent a better model for resembling 
the ionisation efficiency/extraction of the analyte from dosed tissues.  
To reproduce the thickness of treated Labskin sections, the cell plug was 
cryosectioned at 12 µm. During the sectioning process, the cryostat cut the 
gelatin block smoothly, but as soon as the knife reached the cells, however 
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these were torn off the section completely. At the end of the process, a slide of 
gelatine block without cells within the holes was produced. 
Fisher et al. described a protocol for cryosectioning tissues and highlighted the 
possible problems that could occur during the process. In particular, the 
difficulty of cutting a tissue may be attributed to a blunt knife; this happens 
especially in the presence of support media used to embed the tissue (Fischer 
et al., 2008).   
In this regard, to troubleshoot the problem of cryosectioning the cell plug array, 
different approaches were tried, including replacing the blade as well as 
changing the temperature of the chamber and the angle of crysection, but no 
improvement in results was achieved. 
Another possible problem affecting the cryosection could be due to the nature of 
a tissue that makes it difficult to cut, such as in the case of watery or fatty tissue 
(Fischer et al., 2008). In the case of cell plug array the keratinocyte cells were 
mixed with solutions (50% MeOH) of standard and the poor sectioning could be 
because of the presence of this liquid mixed with cells which would compromise 
their consistency. However, removing liquid from the sample was not possible, 
since it was necessary to dissolve the drug in order to produce the calibration 
array. 
Since it was not possible to produce a calibration array, it was decided not to 
investigate the cell plug technique further. Beside the cryosection problems, it 
offered other challenges. Firstly, the entire method was extremely time 
consuming requiring the culture of at least 11,000,000 cells to obtain one 
calibration array. In addition, to reach such high amount of cells, multiple 
passages of cell culture were required; for this reason, immortalised primary 
keratinocyte cells were employed, which are very delicate and expensive, 
making the technique much less cost-effective than the cell films and on-tissue 
approaches previously investigated. 
Although prior to use, high expectations were put on the cell plug design, it 
turned out that this method was extremely complicated, long and not practical 
for quantitation in Labskin samples. 
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3.7.2 Quantitative analysis of terbinafine in Labskin 
The optimal methodology for performing QMSI analysis should be able to 
generate an accurate and precise calibration curve, which enables absolute 
quantitation. In addition, the technique should be advantageous in terms of time 
and cost as well as easy to perform.  
Among all procedures examined previously, the application of analytical 
standards on top of a blank Labskin section by microspotting appeared to be 
the most promising technique. In Figure 3.13 the main aspects of the different 
methods used for absolute quantitation via MALDI-MSI are compared.  
 
Figure 3.13 Comparison of several methods explored for performing absolute 
QMSI analysis.  The cell plug routine was not able to reproduce matrix matching 
since the cryosection of cell plug array was not obtained. The cell films 
technique was not able to reproduce accurately matrix ion suppression effects, 
since the cells were distributed throughout the slide with different density and 
thickness, leading to the formation of cell empty areas. 
 
By using an acoustic spotter it was possible to obtain a uniform distribution of a 
serial dilution of terbinafine hydrochloride directly across the epidermal layer of 
a blank section with minimal lateral diffusion. This aspect offered the enormous 
advantage of generating a calibration array directly onto a very thin and well-
defined epidermal region of Labskin matching the ionisation efficiency of analyte 
present in the dosed sample. In addition, by using this technique, aspects such 
as Labskin thickness reproducibility, effectiveness in time and cost were 
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sufficient and a good linearity in the calibration curve (as indicated by the R2 
value) was obtained (Figure 3.14). 
Based on all these considerations, the microspotting of standards in 
combination with matrix sublimation and recently developed software for 
quantitative mass spectrometry imaging was employed to obtain preliminary 
data of the levels of terbinafine hydrochloride in the epidermal region of a full 
thickness living skin equivalent model. In this study, issues in the use of 
sublimation over spraying as matrix deposition technique were observed. As 
previously described (Chapter 2.7.3), being a solvent-free method, sublimation 
can affect the analyte-matrix interaction and hence the method sensitivity. This 
is the main reason why this technique found mainly application in MSI of lipids, 
which are extracted even with solvent-free methods (Hankin, Barkley and 
Murphy, 2007; Kaletaş et al., 2009). However, in the study reported in this 
chapter, the main advantage of the sublimation technique in allowing the 
increase of spatial resolution was selected over the sensitivity. In fact, as well 
as the sensitivity, for QMSI experiments, the possibility of precisely monitoring 
the analyte distribution in the sample is a critical factor, since analyte 
delocalisation could generate variation in analyte ionisation, generating 
misleading ion intensity values. In line with these theories, an interest of also 
using sublimation for the detection of small molecules had increased. Jirásko et 
al. (Jirásko et al., 2014) decided to use sublimation technique to study the 
distribution of atorvastatin and its metabolites in rat tissues by using MALDI-
Orbitrap-MS. In this study 13 matrices for small molecules in both polarities 
were investigated by sublimation and DHB in MALDI-positive mode and DAN in 
MALDI negative mode represented the best matrices. In the work reported by 
Goodwin et al., based on the same principles as sublimation, a solvent-free dry 
CHCA matrix coating was employed to perform quantitative investigation  of 4-
bromophenyl-1,4- diazabicyclo(3.2.2)nonane-4-carboxylate in rat brain tissues 
(Goodwin et al., 2010).
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Figure 3.14 Calibration curves generated using different routines: A) cell films; B) application of standards by spraying; C) application of 
standards by microspotting; D) cell plug. 
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In order to perform QMSI analysis, a blank section of Labskin microspotted with 
working standard solutions was imaged alongside two sections of Labskin 
treated with 20 µL of terbinafine 1% (w/w) in 100% isosorbide dimethyl ether 
(DMI) for 24 hours. The image was performed using Water Synapt G2 without 
the ion mobility function enabled (Figure 3.15). 
 
 
Figure 3.15 MALDI-MS image at 60 µm X 60 µm spatial resolution of the TBF 
HCl source generated fragment ion ([C11H9]
+; m/z 141) A) microspotted directly 
on the epidermal layer of blank tissue section and B) present in two Labskin 
sections treated with terbinafine 1% (w/w) in 100% DMI for 24 hours. C) 
Average MALDI-MSI spectra showing the peak of the terbinafine hydrochloride 
fragment ion at m/z 141. 
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As previously discussed, regions of interest (ROIs) were selected for each drug 
concentration solely to the epidermis area (identified by using endogenous lipid 
markers) of the blank tissue section, the intensity of drug from each ROI was 
extracted and the calibration curve was generated by using msIQuant software. 
The coefficient of linearity (R2) was 0.9617 and the LOD was found to be 36.11 
ng/mm2 or 3.01 mg/g tissue, whereas the LOQ was found to be 109.44 ng/mm2 
or 9.12 mg/g tissue (Figure 3.16A-B). It is important to highlight that for every 
image to be quantified, an individual set of calibration points was imaged 
alongside the treated tissue sections. 
 
 
Figure 3.16 MALDI-MS image at 60 µm X 60 µm spatial resolution of the TBF 
HCl source generated fragment ion ([C11H9]
+; m/z 141) A) microspotted directly 
on the epidermal layer of blank tissue section and B) calibration curve 
generated plotting the average intensity of m/z 141 (TIC normalisation) versus 
the concentration expresses in ng/mm2. 
 
By resolving the equation, the amount of drug in the treated Labskin sections 
was obtained in ng/mm2. To calculate the quantitative concentration of 
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terbinafine hydrochloride in milligrams per grams of tissue, first, the amount in 
grams of tissue in 1 mm2 was calculated. The volume of tissue in 1 mm2 was 
calculated multiplying the area (1 mm2) by the thickness of the section (0.012 
mm). Then, the volume (0.012 mm3) was multiplied by the density of Labskin 
(assumed to be 1 mg/mm3) and the amount of tissue (g) in 1 mm2 was obtained 
(0.000012 g). By dividing in turn, the concentration of terbinafine from each ROI 
selected on treated sections (ng/mm2) to the gram of tissue in 1 mm2, the 
concentration of the drug was converted in milligrams per gram of tissue. The 
values derived from ROIs were averaged and the mean concentration of 
terbinafine hydrochloride was calculated.  
From these initial experiments the levels of drug were found to be 3.41 ± 0.62 
mg/g tissue within section 1 and 4.2 ± 0.81 mg/g tissue within section 2.  The 
levels of terbinafine detected in both sections were above the LOD, but below 
the formal LOQ (Figure 3.17). 
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Figure 3.17 MALDI-MS image of the terbinafine hydrochloride in source 
generated fragment ion ([C11H9]
+; m/z 141) in A) two Labskin sections treated 
with terbinafine 1% (w/w) at 100% DMI for 24 hours. Several ROIs were drawn 
around the epidermis of each section, the peak intensity of m/z 141 was 
extracted (TIC normalisation) from each ROI and compared to the calibration 
curve. B) Graph showing the QMSI levels of terbinafine from the sections of 
Labskin. 
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The data shown gave preliminary results for the levels of TBF HCl in Labskin 
tissue treated with a DMI based formulation. However, to perform investigation 
on the effects of the penetration enhancer DMI on levels of terbinafine in the 
epidermal layer of tissue, other formulations containing different percentages of 
DMI require examination. 
 
3.7.3 Effect of the penetration enhancer DMI on levels of 
terbinafine in the epidermal layers of Labskin 
To assess the potential of the penetration enhancer DMI to increase drug 
permeability into the upper epidermal layer of Labskin, Labskin tissue was 
treated with formulations containing levels of DMI similar to those present within 
commercially available formulations. 
A technical publication reported by Grant Industries Inc. indicates that there are 
no commercial drug formulations consisting of 100% DMI, but the 
recommended levels of DMI in skin care products usually ranges from 5% to 
50% in aqueous systems and from 40% to 90% in non-aqueous systems 
(https://www.univar.com/US/Industries/~/media/PDFs/US%20Corp%20Region
%20PDFs/PC/Naturals/Gransolve%20DMI%20from%20Univar%20Application
%20Guide.ashx) . 
In light of these considerations, experiments were conducted in which Labskin 
was treated with water based formulations containing either 10% or 50% DMI.  
In addition, for quantitative analysis the presence of a section derived from a 
negative control tissue (treated only with vehicle without drug) within the image 
set is necessary to confirm that the drug detection is specific and not a 
background peak interfering. 
For this reason, in this experiment a section of Labskin treated with vehicle 
water/olive oil (80:20) alone was also included.  
The vehicle and the treated sections were imaged alongside a blank Labskin 
section microspotted with a dilution range of terbinafine hydrochloride, from 
which a calibration curve could be generated by using msIQuant software. 
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Figure 3.18 shows the MALDI-MS image of the distribution of the in source 
generated terbinafine fragment ion at m/z 141 on (A) a blank tissue section 
microspotted with working standards (B) vehicle control section and two Labskin 
sections treated with terbinafine 1% (w/w) in water/olive oil (80:20) with either 
(C) 10% or (D) 50% isosorbide dimethyl ether (DMI) for 24 hours.  
 
Figure 3.18 MALDI-MS image at 60 μm × 60 μm spatial resolution of the 
terbinafine hydrochloride fragment ion ([C11H9]
+; m/z 141) on (A) microspotted 
section, (B) vehicle control treated with emulsion water/olive oil (80:20) alone, 
two Labskin sections treated with terbinafine 1% (w/w) in water/olive oil (80:20) 
with either (C) 10% or (D) 50% isosorbide dimethyl ether (DMI) for 24 hours. E) 
Average MALDI-MSI spectra showing the peak of the terbinafine hydrochloride 
fragment ion at m/z 141. 
 
In this case, the values for the construction of the calibration curve were 
reduced to a smaller range spanning the expected values, in order to prevent 
distortion of the standard array due to presence of high concentrations. The 
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problem relating the distortion of the calibration curve in MALDI-MSI was 
previously experienced by Pirman et al. (Pirman et al., 2013); and such 
behaviour was suggested to be correlated to matrix-to-analyte ratio changes as 
the analyte concentration increased. However, in a recent work conducted by 
Sammour et al. the phenomenoum of non-linearity in MALDI-MSI was 
addressed differently (Abu Sammour et al., 2019). In this study the authors 
highlighted the difficulty of obtaining a linear calibration curve despite the effort 
of optimising the matrix-to-analyte ratios and, hence they introduced a novel 
nonlinear regression model to fit the data generated by MALDI-MSI. It was 
suggested that, by using this novel model, more accurate and reliable 
quantitative information of the uptake and distribution of the drug imitanib into 
gastrointestinal stromal tumor tissue was guaranteed. To support the superiority 
of this model, the comparison of the residual standard error (RSE) of the 
calibration generated by both linear and nonlinear regressions with MALDI-MSI 
was also performed. The results showed a much better fit when the generalised 
nonlinear calibration was used and, in addition, the quantitative data based on 
this model well compared the data obtained by UPLC-ESI-QTOF-MS. 
In the work reported here, it was instead decided to fit the data in a linear 
calibration curve; and in this regard, it was necessary to compromise to a 
limited concentration range. The coefficient of linearity (R2) was 0.9941 and the 
LOD was found to be 11.40 ng/mm2 or 0.95 mg/g tissue, whereas the LOQ was 
found to be 34.56 ng/mm2 or 2.88 mg/g tissue (Figure 3.19). 
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Figure 3.19 MALDI-MS image at 60 µm X 60 µm spatial resolution of the 
terbinafine hydrochloride source generated fragment ion ([C11H9]
+; m/z 141) A) 
microspotted directly on the epidermal layer of blank tissue section and B) 
calibration curve generated plotting the average intensity of m/z 141 (TIC 
normalisation) versus the concentration expresses in ng/mm2. 
 
In order to calculate the levels of terbinafine in the treated sections ROIs were 
drawn around the epidermis of the vehicle and treated Labskin sections. The 
intensity of the peak at m/z 141 was extracted and compared to the calibration 
curve using msIQuant software. In the vehicle control section, the levels of 
terbinafine were not detectable, at 10% DMI the levels were found to be 0.24 ± 
0.12 mg/g tissue (below the formal LOD), at 50% DMI the levels of drug were 
found to be 1.47 ± 0.74 mg/g tissue (above the LOD, but below the formal 
LOQ).  
A statistical unpaired t test was performed on the data from both tissues treated 
with terbinafine with either 10% DMI or 50% DMI. The concentration of the drug 
resulting statistically increased in the tissue when the percentage of DMI 
increased in the formulation (two sided P= 0.0201) (Figure 3.20). 
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Figure 3.20 MALDI-MS image of the terbinafine hydrochloride source 
generated fragment ion ([C11H9]
+; m/z 141) in A) vehicle control section and two 
Labskin sections treated with terbinafine 1% (w/w) at B) 10% or C) 50% DMI for 
24 hours. Five ROIs were drawn around the epidermis of each section, the peak 
intensity of m/z 141 was extracted (TIC normalisation) from each ROI and 
compared to the calibration curve. D) Graph showing the QMSI levels of 
terbinafine from the sections of Labskin. The error bars illustrate the standard 
deviation of the levels of drug in five different epidermal regions of each section. 
The concentration of the drug resulted statistically increased in the tissue when 
the percentage of DMI increased in the formulation (two sided P= 0.0201). 
 
The data reported here has demonstrated the capability of the penetration 
enhancer DMI to increase terbinafine penetration into the upper epidermis of a 
living skin equivalent model.  
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Although the microspotting technique has shown to be able to generate a robust 
calibration curve and provide the detection of terbinafine levels in the tissue, an 
optimisation step of this method is required in order to increase its quantitative 
potential. 
One approach could concern the normalisation strategy to adopt. Over the past 
year, the normalisation to a stable isotope internal standard has been shown to 
increase the quantitative capabilities of MSI analysis (Pirman and Yost, 2011; 
Prentice, Chumbley and Caprioli, 2017). In this study, in the absence of an 
internal standard, the MSI data were normalised to total ion current (TIC). 
Although this approach has been widely used in the past, it may generate 
misleading conclusions from MALDI-MSI spectra, especially when the intensity 
of the analyte changes in different regions of the tissue (Deininger et al., 2011). 
For this reason, in order to increase the quantitative potential of the technique, 
the data needs to be assessed by using an internal standard molecule and, in 
addition, they need to be validated by using complementary reliable techniques, 
such as LC-MS/MS. 
In addition, to assess the reproducibility of the microspotting technique multiple 
technical replicates are necessary. 
 
3.8 Concluding remarks   
In this study, different calibration strategies have been investigated to assess 
the most valid and robust technique for the generation of accurate quantitative 
analysis by using MALDI-MSI.  
The methods reported here include cell films, on-tissue application of standards 
by either spraying or microspotting and cell plug. 
The use of an acoustic spotter for generating QMSI analysis turned out to be 
the most favourable approach for the determination of the amount of an active 
pharmaceutical ingredient, terbinafine hydrochloride, in a living skin equivalent 
model. This technique offered the enormous advantage of being practical, 
relatively fast and cost-effective; only one blank section was required to 
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generate a calibration array, allowing dosed tissue sections to be placed next by 
and imaged at the same time to perform quantitative investigations. 
In addition, in this study, a quantitative assessment of the effect of the addition 
of the penetration enhancer (dimethyl isosorbide (DMI)) added to the delivery 
vehicle at different percentages was also assessed. Preliminary QMSI data 
demonstrated an increase of concentration of terbinafine into the upper 
epidermis of Labskin in response to an increase of percentage of DMI in the 
delivery vehicle.  
However, the data obtained in this study requires assessment with an internal 
standard and validation using a complementary technique, such as LC-MS/MS.  
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Chapter 4: Quantitative investigation 
of terbinafine hydrochloride 
absorption into a living skin 
equivalent model by using MALDI-
MSI. 
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4.1 Introduction 
In Chapter 3 the main aspects hampering the use of MALDI-MSI for quantitative 
analysis have been discussed. The major limitations for performing QMSI are 
represented by the inhomogeneous distribution of the matrix and variation in ion 
suppression of the analyte of interest that could occur intra or inter tissue 
sample (Wang et al., 2016).  
The necessity for homogeneity of matrix coverage in MALDI-MSI has been 
debated in Chapter 2. Use of sublimation was shown to be an excellent 
methodology for the production of high-resolution images of the drug in the 
tissue Labskin, and for this reason, it has been chosen for qualitative as well as 
quantitative investigations.  
In Chapter 3 several strategies were compared for quantifying the amount of an 
antifungal agent, terbinafine hydrochloride, in the defined epidermal layer of a 
3D skin model, Labskin. It is important to note that the effect of the tissue 
composition on signal response in MSI has large implications when skin is the 
target organ for quantitative experiments. The layers of the skin comprise 
distinct cell types and hence each skin layer would be expected to give a 
slightly different response for the same amount of analyte. This implies that 
mimetic arrays created from skin homogenates would not be a suitable 
methodology for calibration in this instance. Instead, the use of acoustic 
microspotting (Aerni, Cornett and Caprioli, 2006) of analytical standards 
specifically onto the epidermal layer as a way of calibrating QMSI experiments  
resulted in being the optimum approach over all the different 
calibration/standardisation approaches investigated. 
Over the past years, the employment of an internal standard has been 
demonstrated to increase the quantitative capabilities of MSI analysis (Pirman 
and Yost, 2011; Prentice, Chumbley and Caprioli, 2017). The choice of an 
appropriate internal standard represents a crucial aspect for a successful 
MALDI quantitative investigation (Wilkinson et al., 1997). The internal standard 
must be a molecule with chemical and physical characteristics similar to the 
analyte under study as well as similar fragmentation pathway. Sleno and 
Volmer investigated the fundamental properties that a molecule should match 
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with the analyte to be selected as a suitable internal standard. In particular, 
affinity between the in-solution ionisation properties of the analyte and its 
internal standard, such as log D, pka, molecular weight and solubility, was 
emphasised (Sleno and Volmer, 2005).  
During MSI analysis the internal standard mimics the behaviour of the analyte of 
interest in terms of ionisation efficiency and compensates for the tissue-
dependent ion signal variations of the analyte. This aspect causes an 
improvement of relative signal ion reproducibility and image quality due to an 
increase of pixel to pixel precision (Pirman et al., 2013; Chumbley et al., 2016). 
For this reason, most commonly, a stable-isotope labelled (SIL) version of the 
analyte represents the first choice.  
The study reported by Pirman et al. introduced the employment of a stable 
isotope labelled internal standard in the MSI workflow. In this work, the authors 
used a deuterated version of acetyl-l-carnitine (AC) in order to assess the 
endogenous concentration of AC in piglet brain tissue (Pirman, Heeren and 
Yost, 2013). It was reported that the use of a deuterated labelled internal 
standard against which to normalise the analyte peak helped to correct for both 
signal variations and tissue specific ion suppression. 
However, in the absence of a labelled version of the analyte due to impractical 
synthesis, cost and time problems, structural analogues represent a valid 
alternative (Prideaux et al., 2011; Takai, Tanaka and Saji, 2014a). In a recent 
study, Rao et al. developed a method to quantify the drug octreotide, a synthetic 
somatostatin analogue, in mouse tissues (Rao et al., 2017). In this study, due to 
the impossibility of using labelled internal standards, multiple somatostatin 
analogues (native somatostatin-14, lanreotide, vapreotide) were investigated 
and it was found that lanreotide was the best candidate for its excellent stability.  
Whichever internal standard is decided to use, either a stable labelled or a 
structural analogue, it is essential that it is applied uniformly and is detected in 
the same MS scan as the analyte of interest, in order to guarantee reliable 
signal intensity correction in MSI (Pirman, Heeren and Yost, 2013). Different 
approaches for applying a constant concentration of internal standard uniformly 
to the tissue have been investigated. Most commonly, an automatic spray-
coating device is used to deposit an internal standard either premixed with 
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MALDI matrix (Källback et al., 2012; Lagarrigue et al., 2014; Poetzsch et al., 
2014) or prior to matrix deposition (Clemis et al., 2012; Buck et al., 2015; Sun et 
al., 2016) onto the tissue. An alternative approach was employed in the work 
reported by Chumbley et al., in a quantitative study of rifampicin in liver tissues. 
Here  the internal standard was applied using an acoustic spotter investigating 
four different strategies (Chumbley et al., 2016). These included: 1) application 
of the internal standard on top of the tissue prior to matrix deposition; 2) 
application of the internal standard under the tissue section; 3) application of ½ 
internal standard under the tissue and ½ onto the tissue (sandwich method); 4) 
application of matrix and internal standard simultaneously as a mixture. The 
effect of each method on the QMSI analysis of the drug in the tissue was 
analysed and it was reported that only the method involving the application of 
the internal standard on top of the tissue prior to matrix deposition offered 
quantitative data comparable to those obtained with LC-MS/MS performed on 
extracted tissue. 
In the study reported in this chapter further improvement and validation of the 
microspotting technique (described in Chapter 3) to obtain absolute quantitation 
of the amount of terbinafine hydrochloride in the epidermal layer of Labskin has 
been performed. Here, a deuterated version of terbinafine hydrochloride has 
been employed as an internal standard and the improvement of the quantitation 
capabilities of mass spectrometry imaging has been examined. QMSI data have 
been compared to data obtained from LC-MS/MS measurements of 
homogenates of isolated epidermal tissue. 
 
4.2 Aims of the chapter 
In the following chapter we aimed to determine absolute quantitation of 
terbinafine hydrochloride in the epidermal region of a full thickness living skin 
equivalent model. Validation of the data using LC-MS/MS technique was also 
performed. 
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4.3 Materials and methods 
4.3.1  Chemicals and materials 
Alpha cyano-4-hydroxycinnamic acid (α-CHCA), acetonitrile (ACN), phosphorus 
red, terbinafine hydrochloride standard (TBF HCl, MW 327.89), isosorbide 
dimethyl ether (DMI), haematoxylin, eosin, xylene substitute, ethanol (EtOH) 
and formic acid ≥ 96% (FA) were purchased from Sigma-Aldrich (Gillingham, 
UK). 
Pertex mounting medium was obtained from Leica Microsystems (Milton 
Keynes, UK). LC-grade methanol (MeOH) and LC-grade acetonitrile (ACN) 
were purchased from Fisher Scientific (Loughborough, UK). 18 MΩ water was 
obtained from an ELGA water purification system (Buckinghamshire, UK). The 
internal standard terbinafine-d7 hydrochloride (TBF-d7 HCl, MW 334.93) was 
obtained by Clearsynth (Maharashtra, India). Gentian violet 1% was purchased 
from De La Cruz Laboratories Inc. (Califiornia, USA). 
 
Labskin living skin equivalent (LSE) samples were provided by Innovenn (UK) 
Ltd (York, England). 
 
4.3.2  Living skin equivalent samples 
Living skin equivalent (LSE) samples were obtained and cultured as described 
in Chapter 2.3.2. For the experiment, three LSE samples were treated with 20 
μL of terbinafine hydrochloride (1% w/w) dissolved in an emulsion made up of 
water/olive oil (80:20 v/v) with either 10% or 50% DMI and incubated for 24 
hours. For the vehicle control group, three LSEs samples were treated with 20 
μL of the emulsion water/olive oil (80:20 v/v) alone and incubated for 24 hours. 
After incubation, the samples were taken and washed with LC-grade MeOH to 
remove excess formulation and, then, snap-frozen with liquid nitrogen cooled 
isopentane (2–5 min) and stored at −80 °C. 
For cryosectioning, LSEs were transferred into the cryostat (Leica 200 UV, 
Leica Microsystems, Milton Keynes, U.K.), mounted onto cork ring using diH2O 
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at −25 °C for 30 min to allow thermal equilibration. The 12 μm tissue sections 
were cryosectioned, thaw mounted onto poly-lysine glass slides, and stored at 
−80 °C. Before matrix application and imaging the samples were freeze-dried 
under vacuum (0.035 mbar) for 2 hours to avoid delocalisation of the analyte 
and preserve the integrity of the tissues. 
 
4.3.3  Preparation of standard curves 
For MALDI-MSI experiments, working standards were made to 0.01, 0.1, 1, 10, 
100, 500, 1000, and 1500 ng/μL of TBF HCl with 100 ng/μL of the internal 
standard TBF-d7 HCl in MeOH/H2O (50:50). Calibration standards were applied 
onto the epidermis area of 12 μm thick sections of blank tissue sections using 
an acoustic robotic spotter (Portrait 630, Labcyte Inc., Sunnyvale, CA). 
Nine microspots of internal standard TBF-d7 HCl (100 ng/μL in MeOH/H2O 
(50:50)) were deposited onto the epidermis of a vehicle control Labskin section 
treated with water/olive oil (80:20) alone and two Labskin samples treated with 
terbinafine hydrochloride 1% w/w in water/olive oil (80:20) with either 10% or 
50% DMI. 
For application of the standards and internal standard, the number of cycles for 
each spot was set to 20 for a total volume of 3.4 nL of each deposited solution. 
Five extra spots were applied outside the tissue to give a “drying time” between 
each cycle. 
For LC–MS/MS, calibration standards were made to 0.001, 0.01, 0.05, 0.1, 0.5, 
1, 10 ng/μL of terbinafine hydrochloride with 0.1 ng/μL of internal standard 
terbinafine-d7 hydrochloride in acetonitrile + 0.1% formic acid/ultrapure water + 
0.1% formic acid (80:20). 
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4.4 Matrix deposition 
4.4.1 Sublimation 
The matrix CHCA was applied by a sublimation technique as described in 
Chapter 2.4.2.1.2 
 
4.5 Instrumentation 
4.5.1 MALDI mass spectrometry  
All tissues were imaged using a Waters MALDI HDMS Synapt™ G2 mass 
spectrometer (Waters Corporation, Manchester, UK) equipped with a 
neodynium: yttrium aluminium garnet (Nd:YAG) laser operated at 1 KHz. The 
instrument calibration was performed using phosphorous red. MALDI-MS 
images were acquired in positive mode, in full scan “sensitivity” mode at a range 
of m/z 100-1500, (resolution 10,000 FWHM) at spatial resolution of 60 µm x 60 
µm, and with laser energy set to 250 arbitrary units. The ion mobility function of 
the instrument was not enabled. 
 
4.5.2  LC-MS/MS  
All LC–MS/MS experiments were performed using a Xevo G2-XS QTof (Waters 
Coorporation, Manchester, U.K.) with ionisation mode ESI+ with analyser in 
sensitive mode. The LC conditions were made of an ACQUITY UPLC HSS T3 
C18 1.7 μm, 2.1 × 100 mm (p/n 186003539) column. The mobile phase 
consisted of ultrapure water (solvent A) and acetonitrile (solvent B) containing 
both 0.1% formic acid. The flow rate and the injection volume were 0.2 mL/min 
and 2 μL, respectively. The gradient eluition was performed as follows: 0.0–2.0 
min (A, 95%; B, 5%), 2.0–12.0 min (A, 5%; B, 95%), 12.0–30.0 min (A, 5%; B, 
95%), 30.0–40.0 min (A, 95%; B, 5%), 40.0–44.0 min (A, 95%; B, 5%). 
The experimental instrument parameters used were capillary voltage, 3.0 kV; 
cone voltage, 35.0 V; source temperature, 140 °C; desolvation temperature, 
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250 °C; desolvation gas, 1000 L/h; and cone gas, 50 L/h. Argon was utilized as 
a collision gas and the collision energy was set at 19 eV. 
A multiple reaction monitoring (MRM) method was used to detect the product 
ion of terbinafine (292.3 → 141.1 m/z) and the product ion of terbinafine-d7 (IS) 
(299 → 148 m/z). The retention time was ∼10.6 min. 
 
4.5.3 Skin extraction  
The vehicle control and treated Labskin tissues were placed for 2 min in 1X 
PBS pre-heated at 60°C; then, the epidermis was separated from the dermis by 
using a forceps, transferred to tubes and weighted. 
The tissue homogenisation and drug extraction were performed by a small 
modification of previously published work carried out by Sachdeva et al 
(Sachdeva et al., 2010). The modification made was that after the second 
extraction, the back extraction was not performed; instead, the organic layer 
containing the extracted drug was evaporated under nitrogen and, then 
reconstituted in 1.8 mL of ACN/H2O (80:20) + 0.1% FA. The solution was 
filtered through a 0.22 µm filter and 0.2 mL of internal standard TBF-d7 HCl (0.1 
ng/µL in ACN/H2O (80:20) + 0.1% FA) was added to the solutions prior to 
analysis.  
 
4.5.4  Data processing  
MALDI-MSI data were processed using the HDI 1.4 (Waters Corporation, UK) 
software tool. Using this software, MSI raw data files were converted to imzML 
format and imported into msIQuant software for quantitative investigations. 
 
For LC-MS/MS data, the chromatograms peaks for terbinafine hydrochloride 
and terbinafine-d7 hydrochloride were integrated and processed using Mass 
Lynx (Waters Corporation, UK) software tool. 
Statistical analysis was performed using the StatDirectsoftware (StatsDirect, 
Cheshire, UK). F test and T test were used to evaluate the statistical 
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significance in terms of precision and accuracy, respectively, between the 
values obtained by MALDI-MSI and LC/MS/MS techniques. 
Three replicate measurements (n = 3) were used and the level of significance 
was set to 5%. 
Outlier point identifications were performed using Prism software. The method 
selected was Grubbs' test for outliers (α = 0.05). 
 
4.6 Histological analysis  
4.6.1  Haematoxylin and eosin staining 
Haematoxylin and eosin staining on LSE sections was performed as reported in 
Chapter 2.6.1. 
Optical images were obtained using a Cytation 5 imaging reader and analysed 
with Gen5 software (BioTek, Swindon, UK). 
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4.7  Results and discussion 
4.7.1 Reproducibility of droplet size of the Portrait 630 
Manually spotting of calibrants onto control tissues has constituted one of the 
major approaches for generating calibration arrays in previous QMSI 
experiments (Nilsson et al., 2010; Källback et al., 2012; Lagarrigue et al., 2014; 
Barré et al., 2016). Although widely practiced, this technique is not without 
limitations. One of the major drawbacks of manual pipetting is the difficulty in 
depositing sub-microliter volumes of solutions. This makes it difficult to localise 
standards to small defined regions of tissue. Furthermore, manually applied 
spots are susceptible to variations in size and, hence, the amount of standards 
in the spots is difficult to control. 
In this study we decided to measure and compare the perimeter and area of the 
droplet spots generated by the Portrait 630 in order to assess the reproducibility 
and accuracy of this device. In order to perform the experiment, a solution of 
0.1% of gentian violet in MeOH/H2O (1:1) was used as a spot size marker and 9 
microspots of the solution were deposited onto the epidermal layer of a 12 µm 
thick blank Labskin section. In each spot the number of cycles was set to 20, 
with a total deposited volume of 3.4 nL per spot. The experiment was performed 
twice and, after spotting, the sections were imaged with a Cytation 5 imaging 
reader equipped with Gen5 software, while the perimeter and area of each spot 
on recorded images was measured by using ImageJ software 
(https://imagej.nih.gov/ij/). 
As shown in Figure 4.1A the presence of the dye in the solution allowed easy 
visualisation of the spots onto the tissue. The average perimeter of spots for two 
Labskin sections was found to be 0.5 ± 0.041 mm and 0.53 ± 0.035 mm, 
respectively, while the average area was found to be 0.019 ± 0.003 mm2 and 
0.021 ± 0.028 mm2, respectively. The relative standard deviations of the 
measurements were as follow: 14.35% (area) and 8.21% (perimeter) from 
section 1; 13.5% (area) and 6.62% (perimeter) from section 2 (Figure 4.1B-C). 
These data demonstrate the high reproducibility in the size of the dye spots 
intra and inter sections when the Portrait spotter was used. The area and 
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perimeter values detected from the spots in two sections of Labskin tissue were 
not statistically different. The use of the Portrait 630 acoustic spotter to generate 
microspots with constant size and minimal lateral diffusion allowed better 
control of the concentration of analyte and also avoided the possibility of cross 
contamination that could occur for direct contact of the pipette with the 
substrate. 
 
Figure 4.1 A) Optical image of 9 spots of gentian violet dye solution across the 
epidermis of two blank Labskin sections performed using the Portrait 630. B) 
Graphs showing the results of spot size measurements with the error bars 
displaying the standard deviation of 9 spots for each Labskin section. C) Table 
displaying the arithmetic mean, standard deviation and relative standard 
deviation (RSD%) of either area or perimeter measurements from gentian violet 
spots in two sections of Labskin samples. Consistency between the size of 
spots intra and inter tissues was evidenced. No statistically significant difference 
was found between the spot parameters from two sections. 
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4.7.2  Method used for quantitation  
Figure 4.2A-C shows MALDI-MSI images of the distribution of the terbinafine 
fragment ion at m/z 141 in three sections of Labskin recorded at 60 µm pixel 
size following treatment with (A) 20 µL of emulsion water/olive oil (80:20) alone 
(vehicle control) and 20 µL of terbinafine 1% (w/w) in water/olive oil (80:20) with 
(B) 10% or (C) 50% isosorbide dimethyl ether (DMI) for 24 hours. It can be seen 
that the terbinafine signal appears to be localised to the epidermis and that 
there is an increase in its intensity with increasing amount of DMI, in agreement 
with the results shown in Chapter 3.   
In addition, from the spectra a unique signal belonging to DMI ([M+H]+ m/z 
175.1) could not be identified, as an isobaric  background peak was present in 
all of samples, including those without DMI. To obtain more details about the 
possible presence of DMI, it could be interesting to perform the experiment by 
using an ion mobility function or ultra-high mass resolution.   
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Figure 4.2 MALDI-MSI at 60 μm × 60 μm spatial resolution of the terbinafine hydrochloride fragment ion ([C11H9]
+; m/z 141) on (A) 
vehicle control section and two Labskin sections treated with terbinafine 1% (w/w) in water/olive oil (80:20) with either (B) 10% or  (C) 
50% isosorbide dimethyl ether (DMI) for 24 hours. (D) Average MALDI-MSI spectra showing the peak of the terbinafine hydrochloride 
fragment ion at m/z 141. (E) Haematoxylin & eosin stained optical image of the sublimated sections after MALDI-MSI (4X magnification).
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In order to quantify the amount of terbinafine in the epidermis from such images 
it is necessary to calibrate the response specifically for signals arising from the 
epidermis to achieve "matrix matched standards". Previous studies have shown 
that the epidermis of Labskin consists of a very thin differentiated layer with an 
average thickness of 32 µm (Mitchell et al., 2015; Harvey et al., 2016). As 
discussed previously, this makes preparing standards by tissue spotting 
challenging. Therefore in this work, the use of an acoustic picoliter droplet 
ejector, used previously as a MALDI matrix deposition device (Aerni, Cornett 
and Caprioli, 2006) was used to spot 3.4 nL of the working standards (from 0.01 
ng/µL to 1500 ng/µL) in MeOH/H2O (1:1) onto the epidermis of a blank section 
of Labskin to create a calibration array. Internal standard terbinafine-d7 
hydrochloride (100 ng/µL) was included into standard solutions prior to spotting. 
The application of analytical and internal standards onto an untreated section of 
Labskin by microspotting allowed a uniform distribution across the epidermis 
with minimal lateral diffusion (Figure 4.3A-B). In this study, it was considered 
beneficial to apply the internal standard onto the tissue by microspotting in order 
to preserve the localisation of the calibration analyte, whereas it was found to 
migrate when the solution of terbinafine-d7 hydrochloride was sprayed 
homogenously onto the tissue (data not shown). 
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Figure 4.3 MALDI-MSI at 60 µm X 60 µm spatial resolution of A) the dilution 
range of terbinafine fragment ion ([C11H9]+; m/z 141) mixed with B) a constant 
concentration of terbinafine-d7 hydrochloride fragment ion ([C11D7H2]
+; fragment 
ion; m/z 148) microspotted directly on the epidermis of an untreated section of 
Labskin. Volume of each spot = 3.4 nL. 
 
Additionally 9 spots of internal standard (100 ng/µL) were applied to the 
epidermal region of each treated sample for analysis (again using the acoustic 
picoliter droplet ejector). In this work, it was decided to use a deuterated 
analogue of terbinafine hydrochloride with seven deuterium ions on naphtalene 
group in order to distinguish the fragment of the internal standard from the 
fragment of analyte in the mass spectrum, leading to an increase of selectivity.  
Figure 4.4A-D shows the MS image of the distribution of the m/z 148 fragment 
ion of terbinafine-d7 on (A) untreated sample along with the calibration array, (B) 
vehicle control skin sample treated with 20 µL of the emulsion water/olive oil 
(80:20) alone and skin samples treated with terbinafine 1% (w/w) in water/olive 
oil (80:20) with either (C) 10% or (D) 50% isosorbide dimethyl ether (DMI) for 24 
hours. The distribution of the internal standard can be clearly seen for each spot 
on each section and hence these data are suitable for the definition of the area 
of spots created by the acoustic picoliter droplet ejector.  
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Figure 4.4 MALDI-MSI at 60 μm × 60 μm spatial resolution of the terbinafine-d7 hydrochloride source generated fragment ion ([C11D7H2]
+; 
m/z 148) microspotted directly on the epidermal layer of (A) untreated sample along with the calibration array, (B) vehicle control section 
and two Labskin sections treated with terbinafine 1% (w/w) in water/olive oil (80:20) with either (C) 10% or (D) 50% isosorbide dimethyl 
ether (DMI) for 24 hours.  
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The msIQuant software (Källback et al., 2016) allows a number of methods for 
the definition of regions of interest (ROI) and extraction of peak intensities from 
them for quantitative analyses. Here the methodology used was to exploit 
signals from endogenous species to define the epidermis and stratum corneum 
of the tissue section (m/z 184, the phosphocholine ion signal, to define the 
tightly packed cells of the epidermis and m/z 264, the ceramide fragment ion, to 
define the stratum corneum). Then using the software an average intensity for 
the signals of the terbinafine and the terbinafine-d7 of a ROI located to solely 
the epidermis for each spot could be extracted (Figure 4.5A-B). 
The generation of the calibration curve (n = 3) was obtained by plotting either 
the average intensity of m/z 141 (Figure 4.5C) or the average intensity ratio of 
m/z 141/148 (Figure 4.5D) versus the concentration of terbinafine expressed in 
ng/mm2. In agreement with previous studies, we found that the normalisation of 
the analyte signal to its deuterated analogue caused a significant improvement 
in the calibration curve linearity with a correlation coefficient (R2) from 0.9968 to 
0.9992 upon normalisation. The limits of detection (LOD) and quantitation 
(LOQ) were calculated; from these calibration data the LOD was found to be 
1.30 ng/mm2 or 0.11 mg/g tissue, whereas, LOQ was found to be 3.93 ng/mm2 
or 0.33 mg/g tissue. By expressing the LOD and LOQ in mg/g tissue it is 
assumed that the droplets containing the analyte standards diffuse over the 
entire thickness (12 µm) of the blank Labskin section. Furthermore, in this study 
the values of LOD resulted to be higher than that typically found in literature, 
expressed in terms of µg/g tissue (Lagarrigue et al., 2014; Hansen and Janfelt, 
2016). However, it is thought that multiple factors could influence this increase 
value of LOD, such as the ionisation efficiency of the analyte, the tissue-specific 
ion suppression, the sensitivity of the analyser as well as the background noise 
derived from matrix ionisation and matrix clusters that have a critical impact on 
LOD and LOQ. 
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Figure 4.5 (A) MALDI-MSI of the terbinafine-d7 source generated fragment ion 
in red (m/z 148) superimposed with phosphocholine head group in blue (m/z 
184) and ceramide fragment peak in green (m/z 264). (B) Haematoxylin & eosin 
stained optical image of the sublimated section after MALDI-MSI (4X 
magnification). Calibration curve (n = 3) generated using (C) the average 
intensity of m/z 141 (no normalisation) and (D) the ratio average intensity of m/z 
141/148. Normalisation to the internal standard m/z 148 improved the linearity 
of the calibration curve. 
 
Considering the thin layer of the epidermis, for MALDI-MSI experiments ideally 
a pixel size smaller than 60 µm would have increased the spatial resolution in 
the imaging experiments. However, the Synapt instrument, unlike the Bruker 
Autoflex III instrument, does not offer the user the possibility of changing the 
laser focus diameter, which is set during installation. This aspect compromises 
the possibility of using the smallest pixel size for high resolution images without 
excessive oversampling and loss of signal occurring. In addition, considering 
the number of sections (4) which were imaged in each QMSI experiment, a 
smaller pixel size would have also resulted in a significant increase of both the 
throughput time as well as instrument contamination during the analysis. In light 
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of these considerations, 60 µm pixel size was chosen, although the possibility of 
a set-up with a smaller pixel size would be highly advantageous for future work. 
 
4.7.3 Quantitation of the drug within the tissue 
Using the method described above the concentration of terbinafine in the 
epidermis of (a) vehicle control Labskin and Labskin treated with 20 µL of 
terbinafine 1% (w/w) in water/olive oil (80:20) with either (b) 10% or (C) 50% 
isosorbide dimethyl ether (DMI) for 24 hours was determined. In order to 
perform the experiment, a total of nine microspots with a known concentration 
of terbinafine-d7 hydrochloride (100 ng/µL) was deposited onto the epidermal 
layer of the vehicle control and treated Labskin samples. ROIs for each 
microspot of the TBF-d7 fragment ion (m/z 148) were drawn in correspondence 
of the epidermal layer. Even in this case, the localisation of the microspots of 
the terbinafine-d7 fragment ion onto the epidermis and stratum corneum was 
visualised by superimposing the internal standard fragment ion signal (m/z 148) 
with the phosphocholine ion signal (m/z 184) and the ceramide fragment ion 
signal (m/z 264). Using msIQuant software, the average intensity of the 
terbinafine fragment ion on each ROI was extracted and normalised to the 
average intensity of the terbinafine-d7 fragment ion (m/z 141/148). Then, the 
average intensity ratio (m/z 141/148) from each spot was compared to the 
calibration curve, as shown in Figure 4.6A-C. 
 
  
179 
 
 
Figure 4.6 MALDI-MSI of the terbinafine-d7 fragment ion in red (m/z 148) 
superimposed with phosphocholine head group in blue (m/z 184) and ceramide 
fragment peak in green (m/z 264) in (A) vehicle control section and two Labskin 
sections treated with terbinafine 1% (w/w) at (B) 10% or (C) 50% DMI for 24 
hours. The intensity of the analyte normalised to the internal standard was 
extracted from each ROI and compared to the calibration curve. 
 
By resolving the calibration equation, the amount of drug from each spot was 
obtained in ng/mm2. As described in Chapter 3, to calculate the quantitative 
concentration of terbinafine hydrochloride in milligrams per gram of tissue, first, 
the amount in grams of tissue in 1 mm2 was detected. The volume of tissue in 
1mm2 was calculated multiplying the area (1 mm2) by the thickness of the 
section (0.012 mm). Then, the volume (0.012 mm3) was multiplied by the 
density of Labskin (1 mg/mm3) to obtain the value of grams of tissue in 1 mm2. 
By dividing in turn the concentration of terbinafine from each spot (ng/mm2) to 
the grams of tissue in 1 mm2, the concentration of terbinafine was converted in 
milligrams per gram of tissue. The concentration values derived from the spots 
applied onto each Labskin tissue was averaged and the main concentration of 
terbinafine hydrochloride in each Labskin tissue was calculated. 
In initial experiments the apparent levels of the drug were found to be 0.15 ± 
0.11 mg/g tissue in vehicle control, 0.35 ± 0.047 mg/g tissue within Labskin 
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treated with terbinafine at 10% DMI, and, 0.84 ± 0.14 mg/g tissue within Labskin 
treated with terbinafine at 50% DMI.  
On investigation it was found that the internal standard solution used contained 
a small amount of the unlabelled drug. Figure 4.7 shows the distribution of the 
average intensity ratio of the unlabelled drug (m/z 141) normalised to its internal 
standard (m/z 148) extracted from each microspot of the terbinafine-d7 
hydrochloride solution deposited onto the epidermal layer of three control 
Labskin sections at different times. It was noticed that the intensity average ratio 
increased over time, due to an increase of the unlabelled counterpart of the 
internal standard in the solution.  
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Figure 4.7 Distribution of the intensity ratio of terbinafine to its internal standard 
(m/z 141/148) extracted from each microspot of the internal standard solution 
(terbinafine-d7 hydrochloride (100 ng/µl) in MeOH/H2O (1:1)) deposited onto the 
epidermis of three control Labskin sections over time. 
 
It is interesting to note that, considering the structure of the terbinafine d7 
(Figure 4.8), the deuterium-hydrogen exchange happened on unusual sites, that 
not easily undergo to hydrogen-deuterium exchangeability (Englander et al., 
1996).  
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Figure 4.8 Structure of Terbinafine-d7. 
 
However, the problem related to deuterium-hydrogen exchange in deuterated 
compounds was previously described by Chavez et al. (Chavez-Eng, 
Constanzer and Matuszewski, 2002) and can lead to an overestimation of the 
concentration of unlabelled analyte. A number of ways were investigated to 
correct for this problem. Since the degradation of the internal standard in 
solution increased over time, the concentration of the analyte in the treated 
tissues could be affected in different percentage in each QMSI experiment. For 
this reason, it was decided that the optimum approach was to subtract the 
amount of terbinafine detected in the vehicle control from the amount of 
terbinafine detected in the treated tissues for each QMSI experiment. 
After this correction, at 10% DMI the concentration of TBF was found to be 0.20 
± 0.072 mg/g of tissue (below the formal limit of quantitation), and at 50% the 
level was found to be 0.69 ± 0.23 mg/g tissue (Figure 4.9A-B). 
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Figure 4.9  A) Graph showing the initial QMSI levels of terbinafine from the 
sections of Labskin. B) Graph showing the final levels of terbinafine from the 
sections of Labskin after correction for the degradation of the internal standard. 
 
After experiencing the degradation of the internal standard that occurred in 
solution, it was decided to investigate also the possible degradation of the 
internal standard on tissue. This experiment is described in the supplementary 
information (Appendix II).  
In order to validate the MALDI-MSI data LC-MS/MS experiments were 
performed using the methodology described by Sachdeva et al. (Sachdeva et 
al., 2010). LC-MS/MS is a high sensitivity technique, widely used in previous 
studies for quantitation of terbinafine hydrochloride (Brignol et al., 2000; 
Dotsikas et al., 2007). Although it is common knowledge that LC-MS/MS 
provides reliable quantitation, analysis using this technique cannot be carried 
out directly on the intact surface skin, but analytes of interest have to be 
extracted out of the tissue, increasing the complexity of sample preparation, 
time of analysis and loosing spatial information. In addition, another drawback 
of using LC-MS/MS is represented by the amount of tissue necessary for 
homogenisation (from 0.5 mg to 50 mg) compared to the small amount of tissue 
that can be analysed using MALDI-MSI (0.010-0.012 mg).  
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Furthermore, also in chromatographic analysis the purpose of using internal 
standards is to increase the quantitative performance of the technique. In this 
case, the internal standard is meant to correct mainly for random and 
systematic error of the detection, in LC-MS/MS principally (Wieling, 2002; 
Stokvis, Rosing and Beijnen, 2005). 
In this study, LC-MS/MS experiment was repeated three times per each tissue 
of Labskin. The calibration curve was generated by plotting the concentration of 
terbinafine hydrochloride versus the response ratio. The response ratio was 
calculated by dividing the peak area of the analyte by the peak area of the 
internal standard. 
The calibration curve observed in Figure 4.10A showed a coefficient of linearity 
R2 of 0.9989. The limit of detection (LOD) and quantitation (LOQ) were 
assessed at 0.42 µg/mL and 1.27 µg/mL, respectively. In the vehicle control 
sample, the levels of terbinafine were below the limit of detection, whereas, at 
10% DMI and 50% DMI the levels were above the LOQ and they were found to 
be 0.28 ± 0.04 mg/g tissue and 0.66 ± 0.057 mg/g tissue, respectively (Figure 
4.10B). 
 
Figure 4.10 A) Calibration curve (n = 3) generated using the peak area ratio 
(analyte/internal standard) B) Graph showing the final levels of terbinafine 
obtained from LC-MS/MS measurements of homogenates of isolated epidermal 
tissue. 
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A statistical unpaired T test was performed on the data from both tissues 
treated with terbinafine with either 10% DMI or 50% DMI. The concentration of 
the drug resulted statistically increased in the tissue when the percentage of 
DMI increased in the formulation in both QMSI (two sided P = 0.0256) and LC-
MS/MS (two sided P = 0.0007) (Figure 4.11A-B). Furthermore, in order to 
compare the values obtained by QMSI and LC-MS/MS, F test and paired T test 
between the methods were performed. With the F test, the variances between 
the values of terbinafine at 10% DMI and 50% DMI were found to be not 
statistically different between the methods (at 10% DMI; two sided P = 0.478; at 
50% DMI, two sided P = 0.1116). When the paired T test was performed, also 
the means between the values of terbinafine at 10% DMI and 50% DMI were 
found to be not statistically different between the methods (at 10% DMI, two 
sided P = 0.0726; at 50% DMI, two sided P = 0.8361) (Figure 4.11C).  
These data have demonstrated the development of a QMSI method for the 
determination of the amount of an active pharmaceutical ingredient in skin. In 
addition the capability of the penetration enhancer DMI to increasing the drug 
penetration in the upper epidermis of living skin equivalent has been 
demonstrated. 
 
 
 
 
   
6
1
 
1
8
5
 
1
8
5 
 
Figure 4.11 A) Graph showing the final levels of terbinafine from the sections of Labskin by using MALDI-MSI. B) Graph showing the 
final levels of terbinafine from LC-MS/MS measurements of homogenates of isolated epidermal tissue. C) Graph showing comparison 
between the results obtained from MALDI-MSI and LC−MS/MS, the error bars illustrate the standard deviation of three repeats for each 
method. No significant differences between the two methods were found.  
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4.8 Concluding remarks   
In this chapter, a novel approach for quantitative mass spectrometry imaging 
(QMSI) of terbinafine hydrochloride in the epidermal region of a full thickness 
living skin equivalent model has been presented. The use of an acoustic spotter 
turned out to be ideal for applying precise and uniform analytical and internal 
standards onto a thin and well-defined epidermal layer of the Labskin tissue, 
leading to mimic cell-type based ionisation response of the analyte from the 
treated tissue sections. The combination of microspotting technique and matrix 
sublimation allowed preservation of the spatial distribution of the analyte and 
achieving better mass spectral quality and reproducibility. 
 
The study presented here also provided an innovative method to assess the 
performance of the penetration enhancer DMI added to the delivery vehicle. 
QMSI data demonstrated an increase in concentration of terbinafine into the 
upper epidermis of Labskin in response to an increase of percentage of DMI in 
the delivery vehicle. QMSI data were satisfactory in showing no statistically 
significant differences from LC–MS/MS measurements of homogenates of 
isolated epidermal tissue, leading accuracy and precision between the methods 
to be the same. 
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Chapter 5: An "on-tissue" 
derivatisation approach for 
improving sensitivity and detection 
of hydrocortisone by MALDI-MSI. 
 
(This data was obtained during a placement period spent in Croda US 
laboratories and the work was carried out in collaboration with Brian Malys). 
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5.1 Introduction 
In Chapter 4, a novel approach for the quantitation of terbinafine hydrochloride 
by using MALDI-MSI was illustrated. Terbinafine is a molecule easily detected 
using mass spectrometry due to the straightforward protonation of its amine 
group. However, when an analyte of interest contains functional groups with low 
protonation/deprotonation efficiency, detection by MS is compromised. A 
chemical derivatisation approach is often employed to overcome this drawback.  
Derivatisation offers the potential advantage of increasing analyte signal 
intensity by introducing groups with permanent charges or with high ionisation 
efficiency (Zaikin and Halket, 2006). Another advantage of this approach is that 
the molecular mass of the targeted analyte can be increased, resulting in 
analyte peaks shifted to a higher mass region. This aspect is particularly 
beneficial when low molecular mass compounds are analysed by MALDI-MS, 
since the derivatisation can help to avoid matrix-related background 
interference present in the lower mass range, which can be an issue with low 
mass resolution instruments (Tholey et al., 2002). A comprehensive review on 
the main reactions available for derivatisation of functional groups analysed by 
mass spectrometry techniques  was recently conducted by Huang et al. (Huang 
et al., 2019).  
Over the years, on-tissue derivatisation strategies have been reported for 
increasing the sensitivity and specificity of MSI analysis of exogenous and 
endogenous compounds, while preserving spatial localisation (Prideaux et al., 
2007; Flinders et al., 2015; Esteve et al., 2016; Schulz et al., 2019). On-tissue 
derivatisation approaches have also been used to improve identification of 
proteins from tissue sections by MALDI-MSI (Franck et al., 2009).  
An interesting aspect of derivatisation for the purpose of MALDI analysis is that 
often the tags used, in addition to derivatising the analyte, promote its co-
crystallisation with the matrix. Furthermore, reagents able to absorb at UV/IR 
wavelengths can be used for direct analysis without the aid of common MALDI 
matrices (Huang et al., 2019). In this capacity the reagents are considered as 
"reactive matrices" since they induce both derivatisation and ionisation of 
molecules. 2,4-dinitrophenylhydrazine (DNPH) is an example of a reactive 
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matrix commonly used for the derivatisation of carbonyl containing compounds 
(Brombacher, Owen and Volmer, 2003; Teuber et al., 2012; Flinders et al., 
2015). The typical derivatisation reactions of carbonyl compounds rely on the 
formation of oximes, by reaction with hydroxylamines, and hydrazones, by 
reaction with hydrazine derivatives (Zaikin and Halket, 2006). The formation of  
Schiff's bases, semicarbazones, and thiosemicarbazones has also been 
reported (Zaikin and Halket, 2009).  
Currently, multiple derivatisation agents are commercially available and their 
selection depends strongly on the targeted analyte. However, all of the chemical 
tags should satisfy several desirable characteristics: 1) they have to contain a 
charge or an "easily" ionisable group; 2) they have to contain an appropriate  
reactive group; and 3) they have to be available to purchase or, at least, their 
synthesis should be cost-effective (Cartwright et al., 2005; Zaikin and Halket, 
2006; Flinders et al., 2015). 
In this study the attention was moved from MALDI-MSI analysis of an "easily" 
detectable molecule, terbinafine hydrochloride, to the analysis of a molecule 
with low ionisation efficiency, hydrocortisone. Hydrocortisone is a steroid 
medicine widely used in dermatologic therapy due to its potent anti-
inflammatory and antiproliferative activities (Hengge et al., 2006). The 
application of mass spectrometry techniques for analysis and measurements of 
steroid hormones represents an important aspect for clinical research, public 
health assessments and patient care (Cook-Botelho, Bachmann and French, 
2017). However, steroid hormones are characterised by a chemical structure 
with multiple carbonyl groups, which make difficult their detection by mass 
spectrometry. To date, in literature there has been multiple studies reported that 
employ chemical derivatisation strategies for steroid hormones to improve the 
sensitivity of mass spectrometry analysis (Díaz-Cruz et al., 2003; Xu et al., 
2007; Rangiah et al., 2011). 
In this chapter an in-solution and on-tissue derivatisation approach have been 
investigated to enhance the detection of hydrocotisone in ex-vivo skin by using 
MALDI-MSI. 
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5.2 Aims of the chapter 
The aim of this chapter was to improve the detection of hydrocortisone in ex-
vivo skin tissue by MALDI-MSI using a hydrazine-based derivatisation approach 
investigation. 
 
5.3 Materials and methods 
5.3.1 Chemicals and materials  
2,5-dihydroxybenzoic acid (DHB), phosphorus red, methanol (MeOH), 
trifluoroacetic acid (TFA), Girard's reagent T (GirT), hydrocortisone (HC) and 
conductive indium tin oxide (ITO)-coated microscope glass slides were 
purchased from Sigma-Aldrich.  
 
5.3.2 Ex-vivo skin samples 
Ex-vivo human skin (obtained under licence from the New York Firefighters Skin 
Bank) was  treated  for 48 hours with 800 μL of hydrocortisone at concentration 
0.1% (w/w) dissolved in ethanol/water solution (15:85) using Franz-type 
diffusion cells (Seo, Kim and Kim, 2016). (This tissue already treated was kindly 
provided by Croda Inc. (Delaware) and these experiments were conducted in 
Croda's US Laboratories in Delaware USA). 
The tissue was transferred into the Leica Cryostat (Leica CM3050 S) and 12 μm 
tissue sections were cryosectioned, thaw mounted onto ITO glass slides, and 
stored at −80 °C. 
 
5.3.3 In-solution derivatisation 
The in-solution derivatisation was performed by mixing 100 μL of hydrocortisone 
standard (200 μg/mL in MeOH 70%) with 100 μL of GirT (5 mg/mL in MeOH 
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with 0.2% TFA); the final concentration of HC was 0.28 mM. The reaction was 
left at room temperature for 30 minutes.  
5.3.4  Mass spectrometric profiling  
Standard hydrocortisone (100 μg/mL in MeOH 70%; the final concentration of 
HC was 0.28 mM) and derivatised hydrocortisone with Girard's reagent T (GirT-
HC) (prepared as previously described), were mixed with DHB matrix (10 
mg/mL in 70% MeOH with 0.2% TFA) in ratio 1:1 by using the dried droplet 
method. Then, three spots (0.5 μL) from each mixture were deposited across 
the length of the MALDI stainless steel plate and then allowed to dry at room 
temperature prior to mass spectrometric analysis. 
 
5.3.5 On-tissue derivatisation 
On-tissue derivatisation was performed following the protocol by Barré et al. 
(Barré et al., 2016). Briefly, 18 layers of GirT (5 mg/mL in MeOH with 0.2% 
TFA) were sprayed onto 12 μm thick ex-vivo skin sections by using a 
SunCollectTM automated sprayer (SunChrom, USA). The flow rate was set at 10 
μL/min for the first layer, at 15 μL/min for the second layer and at 20 μL/min for 
the remaining layers.  Prior to matrix deposition, the tissue sections were placed 
in a pipette tip box containing 60 mL of 50% MeOH with 0.2% TFA and 
incubated at 40 °C for 150 min.  
 
5.3.6 Matrix deposition 
After spraying the derivatisation reagent, the matrix (10 mg/mL DHB in 70% 
MeOH with 0.2% TFA) was deposited onto the tissue sections surface using the 
SunCollectTM automated sprayer (SunChrom, USA). 29 layers of matrix were 
sprayed with a flow rate of 10 μL/min for the first layer, 15 μL/min for the second 
layer and 20 μL/min for the following 27 layers. 
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5.3.7  Instrumentation 
5.3.7.1 MALDI mass spectrometry profiling (MALDI-MSP) 
The MALDI-MSP spectra were manually acquired in positive mode using an 
Autoflex III (Bruker Daltonik GmbH, Germancy) equipped with a 200-Hz 
SmartbeamTM laser. The mass range was set at 100-1000 m/z and six hundred 
laser shots were acquired for each spectrum. External mass calibration was 
achieved using a phosphorus red standard at approximately 200 ppm. 
 
5.3.7.2 MALDI mass spectrometry imaging (MALDI-MSI) 
For MALDI-MSI, the experiments were performed using an Autoflex Speed 
equipped with SmartbeamTM II laser (Bruker Daltonik GmbH). MALDI-MS 
images were acquired in positive mode at a range of m/z 100-700. The spatial 
resolution was set to 50 μm. 
 
5.3.7.3 Data processing  
MALDI-MSP data were acquired using FlexControl (Bruker Daltonics, 
Germany), converted to .txt file format using FlexAnalysis (Bruker Daltonics, 
Germany) and analysed using Mmass v5 open source software (Strohalm et al., 
2010) 
For MALDI-MSI, the data were processed using FlexImaging 4.1 software 
(Bruker Daltonics, GMbH) and were normalised to the total ion current (TIC).  
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5.4 Results and discussion 
5.4.1  MALDI-MS profiling 
To illustrate the low ionisation efficiency of the targeted analyte, a standard 
solution of hydrocortisone (100 μg/mL) was first examined by MALDI-MS 
profiling using DHB matrix. As shown in Figure 5.1 a low signal intensity of the 
protonated peak of HC [M+H]+ at m/z 363 was observed. The MALDI-MS 
spectrum displayed, instead, an abundance of matrix related peaks, including 
the [M+H2O+H]
+ peak at m/z 137; the [M]+ peak at m/z 154; [M+H]+ peak at m/z 
155; the [M+Na]+ peak at m/z  273; and the [2M-2H2O+H]
+ peak at m/z 273. The 
peaks at m/z 304 and at m/z 332 could derive from the stainless steel MALDI 
plate, as described by Yang et al. (Yang et al., 2010). 
 
 
Figure 5.1 MALDI-MS spectrum of hydrocortisone standard (100 μg/mL) in 
positive mode using DHB as matrix. The protonated HC peak [M+H]+ at m/z 363 
was detected at low intensity. 
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5.4.2 In-solution chemical derivatisation 
Because of its hydrophobic properties, the detection of hydrocortisone by 
MALDI-MS was highly challenging and, for this reason, a chemical 
derivatisation approach was tested. The target for the reaction was the carbonyl 
group and the Girard's reagent T (GirT) was chosen as reagent for the 
derivatisation. GirT is a hydrazine derivative that reacts with carbonyl 
compounds to form hydrazones. Figure 5.2 illustrates the reaction scheme of 
GirT with HC. 
 
Figure 5.2  Reaction scheme for GirT reagent reaction with HC 
 
The permanent positive charge of this reagent leads to a highly abundant [M]+ 
ion for the derivatised product, detected in mass spectra (Griffiths et al., 2003). 
Generally, the GirT reaction with carbonyl functionalities takes place in organic 
solvents in the presence of an acidic catalyst at high temperatures (Naven and 
Harvey, 1996; Cobice et al., 2016). In this study, the reaction was performed at 
room temperature for 30 minutes. 
Figure 5.3 shows the spectrum of hydrocortisone following the in-solution 
derivatisation reaction with GirT analysed with DHB as matrix. The MALDI-MS 
spectrum displayed the hydrazone derivative ([M]+) peak at m/z 476 and the un-
reacted Girard's reagent T ([M]+) at m/z 132, which represented the highest 
peak. 
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Figure 5.3 MALDI-MS spectrum displaying hydrocortisone following the in-
solution derivatisation reaction with GirT. The spectrum shows the derivatised 
hydrocortisone [M]+ at m/z 476 and the un-reacted GirT [M]+ at m/z 132. 
 
Although HC contains two carbonyl functionalities only the derivatisation of one 
carbonyl group was detected potentially due to the steric accessibility. As 
shown in Figure 5.4A-B the derivatisation reaction successfully increased the 
sensitivity and detection of the derivatised hydrazone ion (m/z 476) by 
approximately 11 fold compared to the un-derivatised HC (m/z 363) using 
MALDI-MS. The greatly increased signal intensity for GirT-HC was also 
confirmed when the relative intensity was investigated (intensity peak of 
targeted analyte/intensity peak of matrix) (Figure 5.3C).  
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Figure 5.4 A) Comparison of positive ion MALDI MS spectra of  hydrocortisone 
(HC) standard (without derivatisation) and derivatised hydrocortisone with 
Girard's reagent T (GirT-HC). Graph showing absolute B) and relative intensity 
C) of HC (I) and GirT-HC (II). For relative intensity, the peaks of HC ([M+H]+; 
m/z 363) and GirT-HC ([M]+; m/z 476) were normalised with the [DHB+H]+ peak 
at m/z 155. The error bars illustrate the standard deviation of nine spectra per 
analyte. 
 
5.4.3 On-tissue chemical derivatisation 
Once the derivatisation reaction had shown successful results in solution, the 
GirT reagent was used for on-tissue derivatisation experiments to facilitate the 
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detection of hydrocortisone in ex-vivo skin samples by using MALDI-MS 
imaging. Previous MALDI-MS imaging experiments reported the use of GirT 
derivatisation to improve the detection of endogenous androgens in mouse 
testis (Cobice et al., 2016), and corticosterone in rat adrenal and mouse brain 
sections (Cobice et al., 2013). In a more recent work, instead, Barré et al. used 
GirT derivatisation to localise and quantify the levels of triamcinolone acetonide 
in cartilaginous tissue by using MALDI-MSI (Barré et al., 2016). It is 
understandable that for a molecule with poor ionisation efficiency, detection in 
tissue is increasingly difficult, since its ionisation will also be affected by ion 
suppression effects from the presence of other compounds in the tissue. 
Figure 5.5A-B shows MALDI-MSI of the distribution of the un-reacted Girard’s 
reagent T (GirT [M]+; m/z 132) and the derivatised hydrocortisone (GirT-HC 
[M]+; m/z 476) recorded at 50 μm pixel size following a derivatisation reaction on 
2 of 6 sections of ex-vivo skin treated with hydrocortisone 0.1% (w/w) for 48 
hours. A defuse signal was observed for the un-reacted Girard's reagent T, 
whereas a very clear signal for the derivatised HC appeared localised only onto 
the epidermal layer of the skin.  
The on-tissue derivatisation approach was successful therefore in increasing 
the sensitivity of the drug in an imaging experiment, when otherwise it could not 
be detected (data not shown). 
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Figure 5.5 MALDI-MS images displaying the localisation of A) the un-reacted 
Girard’s reagent T ([M]+; m/z 132) and B) the derivatised hydrocortisone (HC-
GirT, [M]+; m/z 476). Spatial resolution = 50 µm; TIC normalisation. 
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5.5 Concluding remarks   
In this chapter, an in-solution and on-tissue derivatisation approach for the 
detection of hydrocortisone (HC) in ex-vivo skin tissue were tested.  
The derivatisation reaction using the Girard reagent T, a hydrazine based 
reagent, led to greatly increased sensitivity and detection of the respective 
hydrazone derivative ([M]+) over the non-derivatised HC. To our knowledge, this 
is the first study to report the localisation of hydrocortisone in ex-vivo skin 
samples by using MALDI-MSI. This represents a notable advantage over the 
traditional techniques since the spatial information is preserved. The localisation 
of hydrocortisone-derivative was found to be only in the epidermal layer of ex-
vivo skin tissue after 48 hours of treatment. Future experiments are necessary 
to optimise the derivatisation method to generate a further increase of the 
derivatised analyte. These include changing the temperature and time of 
derivatisation reaction as well as selection of an optimal matrix for analysis. 
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Chapter 6: Investigation of 
xenobiotic metabolising enzymes in 
Labskin using MALDI-MSI.   
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6.1 Introduction 
In Chapter 1 the role of skin as a protective barrier to the environment and 
valuable site for drug administration was comprehensively investigated. 
Although skin biology has been widely studied over the years, the current state 
of knowledge regarding metabolic activity of this organ is still poor (van Eijl et 
al., 2012; Oesch et al., 2014; Manevski et al., 2015). Understanding of the 
metabolic activity of skin is extremely important in order to assess the 
pharmacological as well as toxic effects of exposure to xenobiotic compounds, 
such as environmental chemicals, cosmetics and pharmaceuticals. In this 
regard, a pivotal role is represented by xenobiotic-metabolising enzymes 
(XMEs) and information about their expression in the skin is crucial.  
 
The European Legislation, Directive 76/768 ECC prohibited the use of animal 
models for the toxicity testing of cosmetics and cosmetic ingredients; leading to 
an increased interest in the use of reconstructed 3D skin models (EU, 2003). In 
addition, given the difficulties in reliably obtaining human skin for metabolism 
studies (and sufficient skin for a representative study given issues including 
race, gender, age, and genetic polymorphisms) there has been interest in the 
use of 3D models in this area. In the United Kingdom, the NC3Rs (National 
Centre for the Replacement, Refinement, and Reduction of Animals in 
Research) instigated in 2016 a challenge to researchers “To establish, both 
qualitatively (which metabolites are produced) and quantitatively (concentration 
of the metabolites produced), the extent to which skin metabolism determines 
xenobiotic availability in human skin” (https://crackit.org.uk/challenge-20-
metaboderm). 
In this regard, a growing interest in using 3D skin models to investigate the 
metabolic activity of human skin has spread rapidly (Sugibayashi et al., 2004; 
Wiegand, Hewitt and Merk, 2014). A detailed review comparing the xenobiotic-
metabolising enzymes in human skin and reconstructed skin models was 
recently published by Oesch et al. (Oesch, Fabian and Landsiedel, 2018). 
Contradicting the earlier published work in the field  (Ahmad and Mukhtar, 2004; 
Baron et al., 2008), more recent studies have reported a low expression of 
cytochrome P450 (CYP) enzymes in human skin and stated that they have an 
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insignificant role in the metabolism of substances.  In the work described by van 
Eijl et al. a detailed proteomic study was performed to investigate phase 1 and 
phase 2 enzymes in whole ex-vivo human skin (10 donors) and in 4 in-vitro 
epidermal models (Epiderm, Episkin, RHE, and HaCat cells) (van Eijl et al., 
2012). Results from this study indicated that low levels of CYP enzymes were 
detected in the skin and the main metabolic activity of the skin was due to the 
presence of other enzyme families. The enzymes detected belonged to the 
families of: alcohol dehydrogenases, aldehyde dehydrogenases oxidases, e.g. 
amine oxidase, carbonyl reductases, epoxidases and carboxylesterase 
hydrolyses (from phase 1 enzymes) and several isoforms of glutathione S 
transferase (from phase 2 enzymes). Similarly, Hewitt et al. (Hewitt et al., 2013) 
and Wiegand et al. (Wiegand, Hewitt and Merk, 2014) also reported no or a low 
expression of CYP enzymes in ex-vivo human skin and in-vitro skin models. In 
all of these studies in-vitro skin models highly mirrored the enzymatic profiles of 
whole ex-vivo skin, indicating that these are a valuable alternative to human or 
animal skin for experimentation in this area. 
Working towards this aim, mass spectrometry imaging (MSI) has been 
employed to localise the presence of metabolising enzymes in full thickness ex-
vivo human skin and a commercial skin model. In order to achieve this, the 
Clench group developed “substrate-based mass spectrometry imaging” 
(SBMSI) (Newton et al., 2017). In the work reported by Newton et al. the 
surface of the skin or model was treated with a known substrate for a specific 
metabolising enzyme, left to incubate for 48 hours before a section through the 
skin model was examined by MALDI-MSI. Results indicated a presence of 
esterase activity in a full thickness skin model using methylparabens as a probe 
(Abbas et al., 2010).  
There are several reports in the literature which highlight the expression of 
esterases in skin, with predominant levels in the epidermal layer and hair 
follicles (Müller et al., 2003). In the work reported by Tokudome et al. the levels 
of carboxylesterase activity in human epidermal cultured skin models (LabCyte 
EPI-MODEL and EPI-DERM) were deemed comparable to those detected in 
human and rat epidermis (Tokudome, Katayanagi and Hashimoto, 2015).  
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Carboxylesterases act by adding water to an ester group leading to the release 
of a carboxylic acid and an alcohol, increasing in this way the polarity of the 
molecule and facilitating its elimination (Laizure et al., 2013). Two main 
carboxylesterase isozymes have been found in humans: carboxylesterase 1 
(CES1) and carboxylesterase 2 (CES2). The activity of these strongly depends 
on the substrate structure: esters with a large acyl group and a small alcohol 
group are preferentially hydrolysed by CES1, whereas esters with a small acyl 
group and a large alcohol group are preferentially hydrolysed by CES2 
(Taketani et al., 2007). 
In the following chapter, two CES1 substrates, methylparaben and 
methylphenidate, have been chosen in order to investigate the esterase activity 
in a commerical living skin equivalent model, Labskin (Innovenn Ltd York UK), 
by using MALDI-MSI following the SBMSI approach. A chemical derivatisation 
approach was additionally performed in order to increase the sensitivity of both 
methylparaben and its metabolite 4-hydroxybenzoic acid and allow their 
detection by MALDI mass spectrometry. As described in Chapter 5, molecules 
containing functional groups with low protonation efficiency are challenging to 
analyse by mass spectrometry tools and a chemical derivatisation strategy is 
often employed as solution to overcome this drawback. Furthermore, LC-
MS/MS analysis on extracts of epidermis and dermis derived from substrate-
treated Labskin was performed for comparison with the MALDI-MSI data. 
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6.2 Aims of the chapter 
The aim of this chapter was to investigate the metabolic esterase activity of 
Labskin using MALDI-MSI by employing the approach of “substrate-based mass 
spectrometry imaging” (SBMSI). 
 
6.3 Materials and methods 
6.3.1 Chemical and materials  
Alpha cyano-4-hydroxycinnamic acid (α-CHCA), N-(1-naphthyl) 
ethylenediamine dihydrochloride (NEDC), trifluoroacetic acid (TFA), phosphorus 
red,  methylphenidate hydrochloride (MPH HCl), ritalinic acid (RA), 
methylparaben (MP), 4-hydroxybenzoic acid (4-HBA) and isosorbide dimethyl 
ether (DMI), ethanol (EtOH), formic acid ≥ 96% (FA), 2-fluoro-1-
methylpyridinium p-toluenesulfonate (FMPTS), and triethylamine (TEA) were 
purchased from Sigma Aldrich (Gillingham, UK). Acetonitrile (ACN) and 
methanol (MeOH) were purchased from Fisher Scientific (Loughborough, UK). 
 
6.3.2 Living skin equivalent samples 
Living skin equivalent (LSE) samples were obtained and cultured as described 
in Chapter 2.3.2. For the experiment, three LSE samples were treated with 20 
μL of methylphenidate hydrochloride (0.5% w/w) dissolved in an emulsion made 
up of water/olive oil (80:20 v/v) with 10% DMI; three LSE samples were treated 
with 20 μL of methylparaben (0.5% w/w) dissolved in acetone/olive oil (80:20) 
with 10% DMI. The samples were incubated for 24 hours. After incubation, the 
samples were taken and washed with LC-grade MeOH to remove the excess 
formulation and, then snap-frozen with liquid nitrogen cooled isopentane (2-5 
min) and stored at - 80 °C. 
For cryosectioning, LSEs were transferred into the cryostat (Leica 200 UV, 
Leica Microsystems, Milton Keynes, U.K.), mounted onto a cork ring using 
diH2O at −25 °C for 30 min to allow thermal equilibration. Tissue sections were 
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cryosectioned at 12 μm, thaw mounted onto poly-lysine coated glass slides, and 
stored at −80 °C.  
 
6.3.3 In-solution derivatisation  
The in-solution derivatisation was performed on the hydroxyl group of MP and 
4-HBA by following previously published work carried out by Beasley et al. 
(Beasley, Francese and Bassindale, 2016). 40 μL of FMPTS (10 mg/mL in 
acetonitrile) and 10 μL of triethylamine were mixed by vortexing. Then, 20 μL of 
MP and 4-HBA solution, both at concentration of 350 μg/mL in MeOH/H2O (1:1, 
v/v)) was added. The reactions were left for 5 min at room temperature. The 
final concentration of MP and 4-HBA was 0.66 mM and 0.72 mM, respectively.  
 
6.3.4 Mass spectrometric profiling 
Standard methylparaben (MP), methylphenidate (MPH), 4-hydroxybenzoic acid 
(4-HBA), ritalinic acid (RA) prepared at 100 µg/mL in MeOH/H2O (1:1, v/v)), as 
well as derivatised MP and 4-HBA with FMPTS reagent (prepared as previously 
described), were analysed by using MALDI-MS profiling. For positive mode the 
matrix used was 5 mg/mL of α-CHCA in ACN/0.5%TFA (7:3, v/v), whereas for 
negative mode the matrix used was 7 mg/mL of NEDC in MeOH/H2O (7:3, v/v). 
Each standard and derivatised compound (FMPTS-MP and FMPTS-4-HBA) 
were mixed with matrix solution (ratio 1:1) by using the dried droplet method.  
Then, three spots (0.5 μL) from each mixture were deposited across the length 
of the MALDI stainless steel plate and then allowed to dry at room temperature 
prior to mass spectrometric analysis. 
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6.4 Instrumentation 
6.4.1 MALDI mass spectrometry profiling (MALDI-MSP) 
The MALDI-MSP spectra were manually acquired in both positive and negative 
mode using a Waters MALDI HDMS SynaptTM G2 operated with a 1 KHz 
Nd:YAG laser (Waters Corporation, Manchester, UK) and an Autoflex III (Bruker 
Daltonik GmbH, Germancy) equipped with a 200-Hz SmartbeamTM laser.   
The mass range was set at 100-1500 m/z and external mass calibration was 
achieved using a phosphorus red standard at approximately 200 ppm. 
 
6.4.2 MALDI mass spectrometry imaging (MALDI-MSI) 
All tissues were imaged using the Synapt™ G2. MALDI-MS images were 
acquired in positive mode, in full scan “sensitivity” mode at a range of m/z 100-
1500, (resolution 10,000 FWHM) at spatial resolution of 60 μm x 60 μm, and 
with laser energy set to 250 arbitrary units. The ion mobility function of the 
instrument was not enabled. 
 
6.4.3 LC-MS/MS  
All LC–MS/MS experiments were performed using a Xevo G2-
XS QTof (Waters Coorporation, Manchester, U.K.) set to ionization mode ESI+ 
with analyzer in sensitive mode. The mobile phase composition, the gradient 
elution, as well as the flow rate and the injection volume were set as described 
in Chapter 4.6.2.  
 
The experimental instrument parameters used were capillary voltage, 3.0 kV; 
cone voltage, 30.0 V; source temperature, 150 ºC; desolvation temperature, 
500 ºC; desolvation gas, 1000 L/h; and cone gas, 150 L/h. Argon was utilised 
as a collision gas and the collision energy was set at 15 eV. 
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A multiple reaction monitoring (MRM) method was used to monitor the following 
transitions for methylphenidate (m/z 234.2  84) and for ritalinic acid (m/z 
220.1 84). The retention time for methylphenidate was ~ 7.88 mins, whereas 
for ritalinic acid it was ~ 7.34 mins 
 
6.4.4 Skin extraction 
The extraction of CES1 substrates and metabolites from Labskin was 
performed as reported in Chapter 4.5.3. 
 
6.4.5 Data processing 
MALDI-MSP spectra on the Bruker Autoflex III were acquired using FlexControl 
(Bruker Daltonics, Germany) and converted to .txt file format using FlexAnalysis 
(Bruker Daltonics, Germany).  
MALDI-MSP spectra on the Waters Synapt G2 were acquired and converted to 
.txt file format using MassLynx™ software (Waters Corporation, UK).  
The spectra exported as .txt files were analysed using Mmass v5 open source 
software (Strohalm et al., 2010). 
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6.5 Results and discussion 
6.5.1 MALDI-MS profiling of carboxylesterase 1 probes and 
metabolites 
6.5.1.1 Methylparabens/4-hydroxybenzoic acid 
Methylparaben belongs to the parabens class and it is widely included as 
preservative in food and cosmetic formulations (Tahan et al., 2016). It is 
metabolised by CES1 enzyme to 4-hydroxybenzoic acid, as shown in Figure 
6.1. 
 
 
Figure 6.1 Metabolism of methylparaben. 
 
Prior to investigating the metabolic activity in Labskin tissue, standards of 
methylparaben and its metabolite 4-hydroxybenzoic acid (100 µg/mL) were first 
analysed by MALDI-MS profiling using CHCA as matrix. As shown in Figure 6.2 
from MALDI MSP spectra no protonated peaks were detected for both analytes 
(methylparabens [M+H]+, m/z 153.05; 4-hydroxybenzoic acid [M+H]+, m/z 
139.04). 
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Figure 6.2 MALDI-MS spectrum acquired in positive mode on A) the spot of 
methylparaben (100 µg/mL) and B) 4-hydroxybenzoic acid mixed with the matrix 
α-CHCA. There was no evidence of the expected protonated peaks [M+H]+ at 
m/z 153.05 and at m/z 139.04 for methylparabens and 4-hydroxybenzoic acid, 
respectively. 
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The difficulty of detecting MP and 4-HBA analytes in positive mode was due to 
the low protonation efficiency of their functional groups: hydroxyl and carboxyl 
acid groups. Compounds containing hydroxyl groups bonded to an aliphatic 
structure (alcohols) are neutral molecules, and hence, they are not easily 
ionised in either positive or negative mode; instead, compounds containing the 
hydroxyl group bonded to a phenyl group (phenols) are slightly acidic and, 
hence, they are more likely to ionise in negative mode (Quirke, Adams and Van 
Berkel, 1994; Bajpai et al., 2005). Similarly, compounds containing carboxylic 
groups have been previously shown to be  more suited to ionisation in negative 
mode (Shroff and Muck, 2007). In this regard, MP and the metabolite 4-HBA 
(100 µg/mL) standards were also analysed with negative polarity by using 
NEDC as matrix. The signals of the deprotonated peak of MP (m/z 151.04) and 
4-HBA (m/z 137.02)  were detected exclusively when the MALDI-MSP spectra 
were acquired by using an Autoflex III mass spectrometer (Bruker Daltonik 
GmbH, Germany) (Appendix III Figure 1-Figure 2). This finding is due to the fact 
that a Smartbeam laser, unlike conventional Nd:YAG lasers is more suitable to 
work with a wider range of matrices; hence, it is more likely to perform better 
analysis in negative mode (Holle et al., 2006). The Smartbeam laser in the 
Bruker is a Nd:YAG laser and, as the Nd:YAG laser present in the Synapt, the 
laser wavelengh in both instruments is of 355 nm; however, the better  
performance of the Smartbeam laser for several MALDI matrices is due  to the 
laser beam profile. The Nd:YAG laser (in Synapt) is characterised by a very 
focused Gaussian profile whereas, Smartbeam laser (in Bruker) presents a 
structured beam profile, similar to that of N2 laser. In the work reported by Holle 
et al. the influence of the laser beam profile, more than the wavelength, on the  
MALDI performance was highlighted; and, a comprehensive description of the 
modulation of the Nd:YAG in the Bruker was offered (Holle et al., 2006). As 
consequence of this modulation, the Smartbeam laser "mimics" the beam 
profile, and hence the distribution of the intensity over the target surface, of the 
N2 laser.  
Besides NEDC matrix, in this study it could have been interesting to investigate 
a larger number of negative mode matrices in order to assess the potential 
detection of MP and 4-HBA also with Synapt. However, considering the high 
performance of Nd:YAG laser in Synapt instrument with CHCA matrix in positive 
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mode, a derivatisation strategy, fast and cost-effective, seemed to be a valid 
alternative over the matrix optimisation step, that could have been extensive 
and time consuming.    
 
6.5.1.1.1 In-solution derivatisation 
To increase the sensitivity of the methylparaben and 4-hydroxybenzoic acid in 
positive mode a derivatisation approach was investigated. The hydroxyl group 
was chosen as target group for the derivatisation, since it was a common 
functional group for both compounds. 2-fluoro-1-methylpirydinium p-
tolunesulfonate (FMPTS) was selected as derivatisation reagent, which reacts 
with hydroxyl groups, in the presence of the basic catalyst triethylamine to form 
the corresponding N-methylpyridinium ether derivative, as shown in Figure 6.3.  
 
Figure 6.3 Reaction scheme for 2-fluoro-1-methylpyridinium p-toluensulfonate 
(FMPTS) with a generic hydroxyl containing compound. 
 
In previous studies FMPTS has been reported to increase the detection of 
hydroxyl containing compounds, due to its positive permanent charge, by using 
LC-MS (Dunphy et al., 2001; Thieme, Sachs and Thevis, 2008), LC-MS/MS 
(Faqehi et al., 2016; Baghdady and Schug, 2018) and MALDI-MS profiling 
(Hailat and Helleur, 2014). Furthermore, by using this reagent the derivatisation 
reaction could be performed rapidly at room temperature, making it extremely 
straightforward. 
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As shown in Figure 6.4 the in-solution derivatisation approach using FMPTS 
resulted in an  increase in  sensitivity for the  MP and 4-HBA peaks, which were 
detected in the derivative forms [M]+, FMPTS-MP (m/z 244.10) and FMPTS-4-
HBA (m/z 230.08). 
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Figure 6.4 MALDI-MS spectra showing MP and 4-HBA following the in solution 
derivatisation reaction with FMPTS. The spectra show the derivatised MP [M]+ 
at m/z 244.10 (A) and the derivatised 4-HBA at m/z 230.08 (B). 
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6.5.1.2 Methylphenidate/ritalinic acid 
Another substrate chosen to investigate metabolic activity in the skin was 
methylphenidate. Methylphenidate is a central nervous system stimulant, used 
as medication for the treatment of attention-deficit/hyperactivity disorder 
(ADHD); it is commercially available in oral formulations in the forms of tablets, 
chewable tablets and liquid (Challman and Lipsky, 2000; Guzman, 2019). 
Although it is not possible to find a methylphenidate based topical formulation, 
in this study it was decided to treat Labskin with this substrate to analyse the 
expression of carboxylesterase enzymes in the skin. Like methylparabens, 
methylphenidate is metabolised by CES1 enzyme activity and its major 
metabolite is represented by ritalinic acid (Figure 6.5). 
 
 
Figure 6.5 Metabolism of methylphenidate. 
 
Standard solutions of methylphenidate (100 µg/mL) and its metabolite ritalinic 
acid (100 µg/mL) were analysed by MALDI-MS profiling using CHCA as matrix. 
MALDI-MS spectra showed the protonated peak of methylphenidate at m/z 
234.14 and ritalinic acid at m/z 220.13 (Figure 6.6). The easy detection of these 
compounds by MALDI-MS can be attributed to the protonation efficiency of the 
amine group on the piperidine moiety. Although ritalinic acid contains two 
functional groups (amine and carboxylic acid) only the peak arising from 
monoprotonation was detected [M+H]+. As discussed previously this aspect is 
due to the low protonation affinity of carboxylic groups in positive mode, which, 
instead, ionise preferably in negative mode.  
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Figure 6.6 MALDI-MS spectrum acquired in positive mode on a) the spot of 
methylphenidate (100 µg/mL) and B) ritalinic acid mixed with the matrix α-
CHCA. MALDI-MSP spectra showed expected protonated peaks [M+H]+ at m/z 
234 and at m/z 220 for methylphenidate and ritalinic acid, respectively. 
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6.5.2 Analysis of skin metabolism by MALDI-MSI 
Following MALDI-MSP, MALDI-MSI experiments were performed to examine 
the carboxylesterase activity in Labskin by using the "substrate-based mass 
spectrometry imaging” (SBMSI) approach. For this purpose, Labskin tissue was 
treated with 0.5% w/w of CES1 substrates (methylparaben and 
methylphenidate) for 24 hours. 
As previously discussed, an in-solution derivatisation with FMPTS was essential 
to increase the detection of methylparaben and its metabolite 4-hydroxybenzoic 
acid by using MALDI-MSP. In the work reported by Beasley et al. an in-situ 
derivatisation using FMPTS was exploited to detect cannabinoids in hair 
samples by MALDI-MSI (Beasley, Francese and Bassindale, 2016). For this 
experiment, the authors airbrushed FMPTS onto hairs derived from cannabis 
users and nonusers before spraying CHCA matrix. Six different cannabinoids, 
previously undetectable, were detected in hair samples by using this approach.  
Following the same principle, in this study, an on-tissue derivatisation approach 
onto Labskin treated with methylparaben for 24 hours was attempted. The 
FMPTS reagent was manually sprayed onto treated Labskin sections and 
CHCA matrix was applied by sublimation. However, no successful images were 
achieved (data not shown). Lack of signal was most likely because an 
insufficient matrix coverage of derivatised Labskin sections was obtained with 
the sublimation method and hence further sample optimisation is required. 
Experiments were then focused on the metabolic analysis by using 
methylphenidate substrate. A Labskin section treated with methylphenidate 
0.5% (w/w) in water/olive oil (80:20) for 24 hours was imaged alongside a blank 
Labskin section (without treatment). The epidermal layer in the Labskin was 
identified by selecting an endogenous peak at m/z 186.91 (Figure 6.7A). 
Figure 6.7B-C shows MALDI-MSI images of the distribution of methylphenidate 
ion at m/z 234 and ritalinic acid ion at m/z 220 in both blank and treated Labskin 
sections recorded at 60 µm spatial resolution.  Standard methylphenidate and 
ritalinic acid (1 mg/mL) were spotted alongside the Labskin sections as 
references. It can be seen that the metabolite ritalinic acid signal appeared to 
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be localised in the outer layer of skin, epidermis. This suggests that the CES1 
enzymes are potentially located in the epidermal layer of Labskin.  
Additional work now needs to be performed in order to assess the levels of 
CES1 detected in Labskin and their comparability with those present in human 
skin.   
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Figure 6.7 MALDI-MSI on blank Labskin section and a section of Labskin 
treated with methylphenidate (0.5% w/w) for 24 hours showing the distribution 
of A) an endogenous peak at m/z 186 for the detection of epidermal layer; B) 
methylphenidate peak at m/z 234; C) ritalinic acid peak at m/z 220. 
blank section 
blank section 
blank section 
treated section 
treated section 
treated section 
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6.5.3 LC-MS/MS 
LC-MS/MS was used to enhance the sensitivity and selectively for the 
simultaneous determination of methylphenidate (MPH) and ritalinic acid (RA) in 
epidermal and dermal tissue extracts. Previous studies have reported the use of 
LC-MS/MS for the detection of MPH and RA in hair (Jang et al., 2019) and urine 
samples (Danaceau, Freeto and Calton, 2018).  
Figure 6.8 shows a representative MRM chromatogram of MPH and RA 
standards (10 ng/mL) obtained by selecting the transition of 234.2  84 for 
MPH (A) and 220.1  84 for RA (B). The retention time for MPH and RA was ~ 
7.88 min and 7.34 min, respectively.  
 
 
Figure 6.8 Extracted ion chromatogram (XIC) for A) 10 ng/mL of 
methylphenidate and B) 10 ng/mL of ritalinic acid. 
 
It is important to note that higher concentrations of methylphenidate standard 
appeared to contain a percentage of ritalinic acid, probably as a degradation 
product.  Furthermore, an insistent interfering MPH peak was observed in the 
following chromatograms (reagent blanks and ritalinic acid standards), due to 
the problem of an extended carry-over. Analyte carry-over is one of the most 
common drawbacks for LC-MS/MS during method development (Weng and 
  
220 
 
Hall, 2002). It mainly depends on the analyte contamination which can be 
selectively retained in the column as well as in the system. To troubleshoot this 
problem multiple investigations are necessary, such as changing the 
composition and the elution type of the mobile phase; using a strong needle 
washing solvent, increasing the number of blanks from one run to another; 
reducing the contact surface between analyte and needle.  
In this case, as shown in Figure 6.9A to obtain a reagent blank chromatogram 
entirely free of MPH and RA an intense flushing of the column for several hours 
with acetonitrile was necessary. Figure 6.9 shows representative 
chromatograms of B) epidermis and C) dermis extracts derived from Labskin 
treated with MPH 0.5% (w/w) for 24 hours. 
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Figure 6.9 Representative MRM ion chromatograms of methylphenidate (MPH) and ritalinic acid (RA) in reagent blank (A), epidermis (B) 
and dermis (C) extracts derived from Labskin treated with MPH (0.5% w/w) for 24 hours 
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The MPH peak was detected at low intensity in the extracts of both epidermis 
and dermis of treated Labskin. However, it was not possible to associate 
completely this peak to the presence of MPH in the tissue; this is because a 
small interfering MPH peak was also detected in extracts of dermis derived from 
untreated Labskin (blank matrix) (data not shown).  
In contrast to the MPH peak, a slightly more intense and clear signal for ritalinic 
acid was detected only in extracts derived from the epidermis of treated 
Labskin. Even in this case, this finding seemed to suggest that the presence of 
CES1 and, hence, the majority of MPH metabolism occurred in the epidermal 
region of skin, supporting MALDI-MSI data. 
 
6.6 Concluding remarks 
In this chapter, a commercial living skin equivalent model, Labskin, was used to 
investigate the localisation of carboxylesterase 1 (CES1) activity by MALDI-MSI. 
Substrate based mass spectrometry imaging (SB-MSI) was chosen as the 
technique to perform the experiments, which included the treatment of Labskin 
tissue with 2 substrates enzymes, methylparaben and methylphenidate. 
A derivatisation strategy using FMPTS reagent was assessed in order to detect 
MP and its metabolite 4-HBA by mass spectrometry. An in-solution 
derivatisation with FMPTS resulted in a significant increase in signal of MP and 
4-HBA analytes, which were detected in the derivatised form [M]+ in MALDI-
MDP spectra. In contrast, an on-tissue derivatisation approach involving the 
application of FMPTS reagent onto Labskin sections treated with MP for 24 
hours, did not show successful results, leading to the inopportunity of using this 
substrate for metabolic analysis before more optimisation of the technique is 
performed.  
 
In this regard, MALDI-MSI was performed on Labskin sections treated with the 
alternative substrate MPH, which with its metabolite RA was easily detected by 
mass spectrometry. The localisation of carboxylesterase 1 was detected mainly 
in the epidermal layer of the tissue. This data was compared with LC-MS/MS 
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analysis, which displayed a peak belonging to MPH metabolite (ritalinic acid) 
only on the extract of isolated epidermis derived from treated Labskin tissue.  
 
Additional future work is necessary to investigate reproducibility of the results. 
These include: optimising sample preparation steps for both MALDI and LC-
MS/MS analysis; increasing the number of technical and biological repeats; and 
increasing the number of CES1 substrates tested. Furthermore, a comparison 
of the metabolic enzyme distribution found in Labskin to those found in human 
skin is required in order to assess the pharmacokinetic similarities between 
these two models.  
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Chapter 7: Conclusion and future 
work 
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Conclusion  
3D in-vitro tissue models of human skin represent a valid alternative to 
monolayer 2D cell culture, ex-vivo human and animal skin models, and, at the 
present time, their application finds a place in many skin research fields 
(Schäfer-Korting, Mahmoud, et al., 2008; Xie et al., 2010; Ali et al., 2015; De 
Vuyst et al., 2017; Lewis et al., 2018; Bataillon et al., 2019). 3D in-vitro skin 
models offer several advantages; they have a higher resemblance to the in-vivo 
human skin microenvironment compared to monolayer 2D cell culture, they 
guarantee a higher quality of preservation compared to ex-vivo skin, as they are 
still living systems they are easy to obtain without requiring an individual ethical 
licence, and they represent a valid replacement to animal testing in line with the 
principle of the UK organisation 3Rs (Replacement, Reduction and 
Refinement). For years ex-vivo and animal skin models have represented the 
gold standards for skin research but not without problems. The major issues 
related to ex-vivo skin are the short viability period (< 24h), donor variability 
(race, gender, age) and genetic polymorphism, making a standardised assay 
complicated (Rodrigues Neves and Gibbs, 2018). Similarly, when using animal 
models, inter-species differences (animal versus human), such as thickness of 
the stratum corneum (SC), composition of intercellular SC lipids, density of hair 
follicles, could generate misleading results (Bronaugh, Stewart and Congdon, 
1982; Netzlaff et al., 2006).  Considering all of these factors in addition to ethical 
problems relating to the use of ex-vivo and animal skin models, there are great 
benefits to transitioning to 3D in vitro skin equivalents. 
However, it is important to consider that differences between 3D skin models 
and native skin inevitably are present, due to the simplified structure of the 
models. For this reason, currently, technology and progress are focused on 
improving 3D skin models in order to increase their similarity to human skin.  
The work presented in this thesis demonstrates the success of the combination 
of MALDI mass spectrometry imaging (MSI) with a full thickness living skin 
equivalent model, Labskin, for a label-free investigation of either drug 
absorption or drug biotransformation in skin.  
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The development of quantitative methodologies for the detection of an 
antifungal agent, terbinafine hydrochloride, in Labskin, by MALDI-MSI has been 
reported, and the performance of the penetration enhancer (dimethyl isosorbide 
(DMI)) added to the delivery vehicle has also been assessed. Furthermore, 
approaches to improve the detection of pharmaceutical agents with low 
protonation/deprotonation efficiency and preliminary analysis of the metabolic 
activity of Labskin was also described.  
In the study reported in this thesis only technical replicates were carried out, 
and, in future work, it would be interesting to perform biological repeats in order 
to assess the reproducibility of the model. In fact, although Labskin has already 
been studied extensively, more validation studies are necessary to test the 
robustness of the model and its ability to represent human skin. 
 
7.1 MALDI-MSP method optimisation 
In MALDI analysis the choice of the matrix represents a fundamental factor 
since it strongly influences the desorption/ionisation process and the spectral 
quality (Lemaire et al., 2006). In Chapter 2 a "trial and error" approach was 
employed both in positive and in negative mode in order to determine the ideal 
matrix able to enhance the signal of the standard terbinafine hydrochloride. With 
negative polarity no signal was detected, whereas in positive mode a variety of 
matrix compositions, including also binary matrices and liquid matrices were 
investigated. The spectral quality of terbinafine hydrochloride was enhanced 
when the liquid ionic matrix aniline-CHCA was employed; both when the 
absolute and relative intensity of the analyte under investigation was 
considered. However, there are a variety of matrices and solutions which were 
not tested in this work, and further investigations into a more ideal matrix could 
be appropriate to enhance further analyte signal by MALDI-MSP. 
 
7.2  MALDI-MSI method optimisation  
In Chapter 2, to detect the localisation of terbinafine hydrochloride in Labskin by 
using MALDI-MSI, two different matrix deposition techniques, automated 
  
227 
 
spraying and sublimation, were investigated. The localisation of drug after 24 
hours treatment was found to be solely in the epidermal layer of skin using both 
approaches. However, the sublimation method ensured a more uniform coating 
of matrix and smaller crystals as well as a better spatial resolution and limited 
analyte delocalisation compared to spraying technique. The permeation of 
terbinafine hydrochloride solely in the epidermal layer of Labskin was also 
visualised with MALDI-MSI when the chemical enhancer (dimethyl isosorbide 
(DMI)) was included in the formulation used for the treatment of Labskin for 24 
hours. In future work, it would be useful also to optimise a recrystallisation step 
after sublimation as well as test an acoustic droplet ejector, as matrix deposition 
technique, alongside spraying and sublimation, to investigate an increase of 
analyte signal, while preserving the analyte localisation.  
 
7.3 Quantitative mass spectrometry imaging (QMSI) 
Although MALDI-MSI has been widely used for qualitative analysis, its 
application for quantitative analysis represents one of the major critical 
challenges in the field. The possibility of identifying and quantifying 
pharmaceutical agents in specific locations within skin by MALDI-MSI 
represents a potential advantage over traditional quantitative techniques.  
All of QMSI analysis were performed by using a Water Synapt G2 instrument. 
The main reason for the decision to use the Synapt instrument instead of the 
Bruker instrument (Chapter 2) was related to the possibility of processing MSI 
data with msIQuant software, specific for MSI quantitative analysis. To import 
the data into msIQuant software it was necessary to convert MSI raw data files 
to imzML format; this conversion was enabled by only the software tool present 
in the Synapt (HDI 1.4. software), but was absent in the Bruker software 
(FlexImaging 3.0), limiting, hence, its application.  
In the work presented in Chapter 3 different approaches to generate robust and 
sensitive quantitative mass spectrometry imaging (QMSI) data were developed. 
The first method included the application by automatic sprayer of a serial 
dilution of standards onto keratinocytes and fibroblasts, co-cultured directly onto 
a glass slide. The second method included the application of a serial dilution of 
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terbinafine standards onto untreated sections of Labskin using an automated 
sprayer. The third method included the microspotting of serial dilution of 
standards solely onto the epidermis of an untreated Labskin section by using an 
automated acoustic spotter Portrait 630. The last method included the 
construction of a cell plug, consisting of the spiking of serial dilution of 
standards within intact keratinocyte cells embedded in frozen gelatin. MsIQuant 
software, recently developed for quantitative mass spectrometry imaging, was 
used to create calibration curves from MSI data. However, the impossibility of 
generating the calibration curve with the cell plug method made it impracticable 
for QMSI investigations and it was not considered further. Among the other 
methods, the application of analytical standards on top of an untreated Labskin 
section by microspotting was the most favourable technique, since it offered the 
enormous advantage of generating a linear calibration curve, being practical, 
relatively fast and cost-effective; only one blank section was required to 
generate a calibration array, allowing treated tissue sections to be located next 
to sample sections and imaged at the same time to perform quantitative 
investigations. From preliminary quantitative analysis an increase of 
concentration of terbinafine into the upper epidermis of Labskin in response to 
an increase of percentage of DMI in the delivery vehicle was shown. 
The further work presented in Chapter 4 emphasised the success of including 
an internal standard (deuterated terbinafine) in the analysis to enhance the 
quantitative capabilities of MSI. QMSI data was also validated with a traditional 
and widely accepted quantitative LC-MS/MS method; no statistical difference in 
the levels of drug detected in Labskin by the two techniques was detected.  
However, in the work reported in Chapter 4 problems related the degradation of 
the deuterated internal standard were experienced and future work in this area 
to investigate a more suitable internal standard as well as the optimal conditions 
in which to conserve the internal standard could be useful in order to avoid 
degradation. 
 
  
229 
 
7.4 Derivatisation  
Pharmaceutical compounds containing functional groups with low 
protonation/deprotonation efficiency are challenging to investigate with mass 
spectrometry techniques. In Chapter 5 the problems relating to the low 
sensitivity and detection of hydrocortisone hydrochloride in ex-vivo skin samples 
after treatment were raised. In Chapter 5 the success of a chemical 
derivatisation approach to overcome this problem was presented. The target for 
the reaction was the carbonyl group of the hydrocortisone and Girard's reagent 
T (GirT), a hydrazine based agent, was chosen as reagent for the derivatisation. 
An increase of signal of the derivative hydrocortisone was obtained using both 
an in-solution and on-tissue derivatisation approach; the on-tissue derivatisation 
allowed visualisation of the localisation of the derivatised drug in the epidermal 
layer of ex-vivo skin tissue, when otherwise it could not be detected. More 
experiments are necessary to optimise the derivatisation method to examine a 
further increase of the derivatised analyte using MALDI-MSI. These include 
investigating different derivatisation agents, changing the temperature and time 
of derivatisation reaction as well as choosing the optimal matrix for analysis. 
 
7.5 Metabolic activity in Labskin 
As well as investigating drug absorption in the skin, it is important to investigate 
drug biotransformation in order to assess the pharmaceutical as well as toxic 
effects of pharmaceuticals. In Chapter 6, the metabolic esterase activity of 
Labskin using MALDI-MSI was assessed by employing the approach of 
"substrate-based mass spectrometry imaging" (SBMSI). This approach included 
the treatment of Labskin tissue with 2 substrates carboxylesterase 1 enzyme, 
methylparaben (MP) and methylphenidate hydrochloride (MPH). Methylparaben 
and its metabolite 4-hydroxybenzoic acid (4-HBA) could not be detected in 
MALDI-MSP spectra in positive mode, due to the low protonation efficiency of 
the hydroxyl and carboxyl acid groups. As reported in Chapter 5, to enhance the 
signal a derivatisation approach was investigated using the hydroxyl group as 
target, since it was present in both analytes (MP and 4-HBA) and 2-fluro-1-
methypyridinum p-tolunesulfonate (FMPTS) was selected as a derivatisation 
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agent to give the corresponding N-methylpyridinium ether derivatives. The in-
solution derivatisation showed a significant increase in the signal of MP and 4-
HBA derivatives, whereas an on-tissue derivatisation was not successful. 
Further work is necessary to optimise the on-tissue derivatisation of MP and, 
attempt to observe the metabolite 4-HBA; this includes investigating the amount 
of derivatisation reagent to use for the reaction, the deposition technique, as 
well as time and reaction conditions. Attention in future work could be also be 
focused on investigating different reagents selective for the hydroxyl functional 
group. 
On the other hand, it was possible to investigate the metabolic activity of skin 
using methylphenidate (MPH) and its metabolite ritalinic acid (RA) due to the 
presence of the easily ionisable amine group in the molecules. Using MALDI-
MSI the localisation of probe (MPH) and metabolite (RA) was detected only on 
the epidermal layer of Labskin, suggesting an enzymatic activity of 
carboxylesterase 1 at this level. The results were compared with LC-MS/MS 
analysis performed on the extract of isolated epidermis and dermis of treated 
Labskin. LC-MS/MS data supported MALDI-MSI findings, displaying a peak 
belonging to RA only on the extract of isolated epidermis of Labskin. However, 
more technical and biological repeats are necessary to validate the reliability 
and the reproducibility of the experiment. More probes of carboxylesterase 1 
can be investigated to validate the results. In addition an optimisation step is 
required for both MALDI-MSI and LC-MS/MS techniques to enhance the signal 
intensity, and; finally, a comparison of the metabolic enzyme distribution found 
in Labskin to those found in human skin is required in order to assess the 
pharmacokinetic similarities between these two models. 
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Appendix I 
Table of contents  
1) Cell films  
 
Table displaying the results of the concentration of terbinafine hydrochloride 
(ng) per mm2. Firstly, the time requested for spraying two layers of each 
standard solution was tracked. The flow rate was set at 4 µL/min for spraying all 
standard solutions. By knowing the flow rate and the total time employed for 
spraying, the total volume (µL) applied was calculated for each standard 
solution. The area sprayed was calculated for each standard solution by 
multiplying the coordinates selected for the spraying (x and y). The amount of 
terbinafine (ng) within the volume sprayed was divided by the area sprayed for 
each standard solution and the amount of drug in ng/mm2 was calculated. 
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2) On-tissue application of standards by spraying 
 
Table displaying the results of the concentration of terbinafine hydrochloride 
(ng) per mm2. Firstly, the time requested for spraying two layers of each 
standard solution was tracked. The flow rate was set at 5 µL/min for spraying all 
standard solutions. By knowing the flow rate and the total time employed for 
spraying, the total volume (µL) applied was calculated for each standard 
solution. The area sprayed was calculated for each standard solution by 
multiplying the coordinates selected for the spraying (x and y). The amount of 
terbinafine (ng) within the volume sprayed was divided by the area sprayed for 
each standard solution and the amount of drug in ng/mm2 was calculated. 
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3) On-tissue application of standards by microspotting  
 
Table displaying the results of the concentration of terbinafine hydrochloride 
(ng) per mm2. Firstly, the amount of drug in each spot (3.4 nL) was calculated. 
To determine the spot size, ROI of the terbinafine fragment ion (m/z 141) was 
drawn around the spot at highest concentration (4000 ng/µL) and the area 
(mm2) was extracted by using msIQuant. The area of the spot was 0.09263 
mm2. Assuming the droplet size spot of the Portrait 630 is reproducible, the 
concentration of terbinafine from each spot was divided by the spot area 
(0.09263 mm2) and the concentration of drug was found in ng/mm2. 
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Appendix II 
 
Degradation of the Internal Standard on Tissue 
In Chapter 4 the degradation of the internal standard terbinafine-d7 
hydrochloride in solution has been reported. In this Appendix data from an 
investigation of the rate of degradation of the internal standard terbinafine-d7 
hydrochloride on tissue is reported.  
Materials  
Alpha cyano-4-hydroxycinnamic acid (α-CHCA), phosphorus red, terbinafine 
hydrochloride standard (TBF HCl, MW 327.89) were purchased from Sigma-
Aldrich (Gillingham, UK). The internal standard terbinafine-d7 hydrochloride 
(TBF-d7 HCl, MW 334.93) was obtained by Clearsynth (Maharashtra, India).   
 
Labskin living skin equivalent (LSE) samples were provided by Innovenn (UK) 
Ltd (York, England).  
 
Methods 
For this experiment, 9 microspots of a solution of terbinafine hydrochloride (100 
ng/µL) with terbinafine-d7 hydrochloride (100 ng/µL) in MeOH/H2O (50:50) were 
deposited on the dermis of 6 sections (12 µm thick) of blank Labskin using an 
acoustic robotic spotter (Portrait 630, Labcyte Inc., Sunnyvale, CA). The 
number of cycles for each spot was set to 20 for a total volume of 3.4 nL. Five 
extra spots were applied outside the tissue to give a "drying time" between each 
cycle. The microspotting of all sections was performed at the same time.  
 
The organic matrix CHCA was applied onto all six blank sections by sublimation 
as described in Chapter 2.4.2.1.2 and the sections were kept in the fridge at + 4 
ºC. 
  
235 
 
Instrumentation 
The sections were imaged using a Waters MALDI HDMS Synapt G2 mass 
spectrometer (Waters Coorporation, Manchester, U.K.) equipped with a 
neodynium: yttrium aluminium garnet (Nd:YAG) laser operated at 1 KHz, as 
reported in Chapter 4.6.1. Although all sections were prepared at the same 
time, they were imaged on different days in order to assess the degradation of 
the internal standard on the tissue over time. The ion mobility function of the 
instrument was not enabled in order to use the msIQuant software. 
 
Results  
By plotting the terbinafine-d7 hydrochloride source generated fragment ion peak 
([C11D7H2]
+; m/z 148)  it was possible to visualise each spot applied onto the 
dermis of blank Labskin sections. MsIQuant software was used to define 
regions of interest (ROIs) with equal area (4 pixels) for each spot and from them 
the average intensity for the signal of the terbinafine (m/z 141) and the 
terbinafine-d7 was extracted (Appendix Figure 1). 
 
Appendix II Figure 1.  MALDI-MSI at 60 µm X 60 µm spatial resolution of a 
constant concentration of terbinafine-d7 hydrochloride fragment ion in green 
([C11D7H2]
+; fragment ion; m/z 148) microspotted directly on the dermis of an 
untreated section of Labskin. Volume of each spot = 3.4 nL. 
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To assess the degradation of the internal standard on tissue, the average 
intensity ratio of the unlabelled drug (m/z 141) to its internal standard (m/z 148) 
was extracted from each microspot deposited onto the dermis of six Labskin 
sections and compared (Appendix Figure 2).  
 
 
Appendix II Figure 2. Distribution of the intensity ratio of terbinafine to its 
internal standard (m/z 141/148) extracted from each microspot of the solution 
(terbinafine (100 ng/µL) mixed with terbinafine-d7 (100 ng/µL) in MeOH/H2O 
(1:1)) deposited onto the dermis of six control Labskin sections. The sections 
were microspotted at the same time and imaged on different days. 
 
When the internal standard was kept onto the tissue over time, an increased 
amount of the unlabelled drug, due to hydrogen-deuterium exchange effect, 
was not observed. This was demonstrated by the comparison of the average 
intensity ratio (m/z 141/148) that was found to be similar in all sections. These 
results were in contrast with the data reported in Chapter 4, in which a 
significant loss of the deuterium from the internal standard kept in an aqueous 
solution over time was reported.  
The difference in the degree of internal standard degradation, in solution and on 
tissue, could be attributed to the different environment in which the internal 
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standard is kept. As reported by Chavez-Eng et al. the presence of water 
containing solvents favours the deuterium-hydrogen exchange. The authors 
reported the loss of deuterium from the internal standard of rofecoxib (13CD3-
rofecoxib) dissolved in acetonitrile (ACN) due to the trace of water usually 
present in ACN solvent (Chavez-Eng, Constanzer and Matuszewski, 2002).  
In this case, it is thought that the increased stability of the internal standard 
located on the tissue over time is due to a reduction of the solvent component.  
 
Conclusions 
In this Appendix the evaluation of an isotope exchange on tissue has been 
investigated. The results presented here showed the absence of a deuterium-
hydrogen exchange occurring from the internal standard terbinafine-d7 
hydrochloride on tissue over time. The stability of the internal standard on tissue 
could be explained by the absence of the solvent that is reported to increase the 
efficiency of deuterium-hydrogen exchange process. 
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Appendix III 
 
Appendix III Figure 1. MALDI-MSP spectra acquired in negative mode of 
methylparaben standard (100 μg/mL) mixed with the matrix NEDC. The 
methylparaben peak [M-H]- at m/z 151.04 was not detected using the Synapt 
G2 mass spectrometer instrument (A), whereas it was detected (indicated with 
a star) at low intensity when the Bruker mass spectrometer was used (B). 
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Appendix III Figure 2. MALDI-MS spectra acquired in negative mode of 4-
hydroxybenzoic acid standard (100 μg/mL) mixed with the matrix NEDC. The 4-
hydroxybenzoic acid peak [M-H]- at m/z 137.02 was not detected using the 
Synapt G2 mass spectrometer instrument (A), whereas it was detected 
(indicated with a star) at high intensity when the Bruker mass spectrometer was 
used (B). 
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Appendix IV 
 Scientific Publications 
Russo, C., Lewis, E. E. L., et al. (2018) ‘Mass Spectrometry Imaging of 3D 
Tissue Models.’, Proteomics, 1700462, p. e1700462. doi: 
10.1002/pmic.201700462. 
Russo, C., Brickelbank, N., et al. (2018) ‘Quantitative Investigation of 
Terbinafine Hydrochloride Absorption into a Living Skin Equivalent Model by 
MALDI-MSI’, Analytical Chemistry. American Chemical Society, 90(16), pp. 
10031–10038. doi: 10.1021/acs.analchem.8b02648. 
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 Conference Presentations 
Oral presentations 
Method development for quantitative investigation of Terbinafine hydrochloride 
in a 3D skin model by MALDI-MSI. 38th BMSS Annual Meeting, Manchester, 
UK, 2017. 
 
Method development for quantitative investigation of Terbinafine hydrochloride 
in a 3D skin model by MALDI-MSI. Drug Metabolism Discussion Group, 
Cambridge, UK, 2017. 
 
Tissue specific Regions Of Interests (ROIs).How to generate them? / How to act 
when internal   standard contain unlabeled counterpart?. ASMS Imaging MS 
Workshop. 66th ASMS Conference on Mass Spectrometry and Allied Topics, 
San Diego, CA, USA, 2017. 
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Poster presentations 
Optimisation of imaging the distribution of terbinafine hydrochloride in a 3D skin 
model. BMSS  Mass Spectrometry Imaging Symposium, Sheffield, 2016 (1st 
Poster Prize). 
 
Optimisation of Matrix Condition for the Analysis of the Antifungal Agent 
(Terbinafine hydrochloride) in a Living Skin Equivalent Model. 64th ASMS 
Conference on Mass Spectrometry and Allied Topics, San Antonio, TX, USA, 
2016. 
 
Optimisation of imaging the distribution of terbinafine hydrochloride in a 3D skin 
model. 37th BMSS Annual Meeting, Eastbourne, UK, 2016. 
 
Optimisation of imaging the distribution of Terbinafine hydrochloride in a 3D skin 
model. OurCon IV: Imaging Mass Spectrometry Conference, Ustron, Poland, 
2016. 
 
Method development for quantitative investigation of Terbinafine hydrochloride 
in a 3D skin model by MALDI-MSI. 65th ASMS Conference on Mass 
Spectrometry and Allied Topics, Indianapolis, IN, USA, 2017. 
 
Quantitative Determination of Terbinafine Hydrochloride in a 3D Skin Model by 
MALDI-MSI. OurCon V: Imaging Mass Spectrometry Conference, Doorn, The 
Netherlands, 2017. 
 
Quantitative Determination of Terbinafine Hydrochloride in a 3D Skin Model by 
MALDI-MSI. BMRC/MERI Christmas poster event, Sheffield Hallam University, 
Sheffield, UK, 2017 (1st Poster Prize). 
 
Detection of drug absorption in living skin equivalent models by using MALDI-
MSI. BMSS Mass Spectrometry Imaging Symposium, Sheffield Hallam 
University, Sheffield, UK, 2018 (1st Poster Prize). 
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Detection of drug absorption in living skin equivalent models by using MALDI-
MSI. 66th ASMS Conference on Mass Spectrometry and Allied Topics, San 
Diego, CA, USA, 2018. 
 
A quantitative method for the detection of drug absorption in living skin 
equivalent models using MALDI-MSI. 38th BMSS Annual Meeting, Cambridge, 
UK, 2018. 
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